WO2024083705A1 - Furoindazole derivatives for the treatment of pain - Google Patents
Furoindazole derivatives for the treatment of pain Download PDFInfo
- Publication number
- WO2024083705A1 WO2024083705A1 PCT/EP2023/078602 EP2023078602W WO2024083705A1 WO 2024083705 A1 WO2024083705 A1 WO 2024083705A1 EP 2023078602 W EP2023078602 W EP 2023078602W WO 2024083705 A1 WO2024083705 A1 WO 2024083705A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- furo
- carboxamide
- dihydro
- indazole
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 38
- 230000036407 pain Effects 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims abstract description 36
- LHTSYIHIIZNLCQ-UHFFFAOYSA-N 1h-furo[2,3-g]indazole Chemical class O1C=CC2=C1C=CC1=C2NN=C1 LHTSYIHIIZNLCQ-UHFFFAOYSA-N 0.000 title abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 238000011321 prophylaxis Methods 0.000 claims abstract description 27
- 208000004296 neuralgia Diseases 0.000 claims abstract description 23
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 15
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 14
- 208000027753 pain disease Diseases 0.000 claims abstract description 10
- 238000002512 chemotherapy Methods 0.000 claims abstract description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 9
- 206010006002 Bone pain Diseases 0.000 claims abstract description 8
- 206010011796 Cystitis interstitial Diseases 0.000 claims abstract description 8
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 8
- 201000005569 Gout Diseases 0.000 claims abstract description 8
- 208000005615 Interstitial Cystitis Diseases 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 238000001356 surgical procedure Methods 0.000 claims abstract description 8
- 206010044652 trigeminal neuralgia Diseases 0.000 claims abstract description 8
- -1 C1-C4-alkyl Chemical group 0.000 claims description 210
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 203
- 150000001875 compounds Chemical class 0.000 claims description 127
- 229910052739 hydrogen Inorganic materials 0.000 claims description 63
- 239000001257 hydrogen Substances 0.000 claims description 63
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 52
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 51
- 229910052805 deuterium Inorganic materials 0.000 claims description 50
- ZWZKHJQCLZIUIT-UHFFFAOYSA-N 1h-indazole-7-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1NN=C2 ZWZKHJQCLZIUIT-UHFFFAOYSA-N 0.000 claims description 49
- 125000001072 heteroaryl group Chemical group 0.000 claims description 48
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 47
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 37
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 30
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 27
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 17
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical group 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 150000001204 N-oxides Chemical class 0.000 claims description 13
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000003003 spiro group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- WRSXUNSJGJUKHE-UHFFFAOYSA-N indazole Chemical compound C1=CC=C[C]2C=NN=C21 WRSXUNSJGJUKHE-UHFFFAOYSA-N 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- GZHARABRHFLORI-UHFFFAOYSA-N FC(F)(F)N1N=C2C3=C(CCC2=C1)OC(=C3)C(=O)N Chemical compound FC(F)(F)N1N=C2C3=C(CCC2=C1)OC(=C3)C(=O)N GZHARABRHFLORI-UHFFFAOYSA-N 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 3
- DJDQNPKTGQGCPY-CJNGLKHVSA-N C1(CC1)C=1N=CC(=NC=1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F Chemical compound C1(CC1)C=1N=CC(=NC=1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F DJDQNPKTGQGCPY-CJNGLKHVSA-N 0.000 claims description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 2
- SXXUSAQZRJMFBK-HNNXBMFYSA-N 2-(cyclopropylmethyl)-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 SXXUSAQZRJMFBK-HNNXBMFYSA-N 0.000 claims description 2
- QNAFDBFVWAYUHU-HNNXBMFYSA-N 2-(cyclopropylmethyl)-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound C1(CC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NC[C@H]1OCCC1 QNAFDBFVWAYUHU-HNNXBMFYSA-N 0.000 claims description 2
- CPVYKCYSOGNNRR-OAHLLOKOSA-N 2-(cyclopropylmethyl)-N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCOC1 CPVYKCYSOGNNRR-OAHLLOKOSA-N 0.000 claims description 2
- AONNKSBGLLBFPY-OAHLLOKOSA-N 2-(cyclopropylmethyl)-N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methylspiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound C1(CC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NC[C@H]1OCCOC1 AONNKSBGLLBFPY-OAHLLOKOSA-N 0.000 claims description 2
- AONNKSBGLLBFPY-HNNXBMFYSA-N 2-(cyclopropylmethyl)-N-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methylspiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound C1(CC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NC[C@@H]1OCCOC1 AONNKSBGLLBFPY-HNNXBMFYSA-N 0.000 claims description 2
- MCEPGYGBZPFBMS-KRWDZBQOSA-N 2-[(1-ethylpiperidin-4-yl)methyl]-N-[[(2S)-oxolan-2-yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C(C)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 MCEPGYGBZPFBMS-KRWDZBQOSA-N 0.000 claims description 2
- XFHYNGFTLPJVCS-IBGZPJMESA-N 2-[(2,6-dimethylpyridin-3-yl)methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=NC(=CC=C1CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1)C XFHYNGFTLPJVCS-IBGZPJMESA-N 0.000 claims description 2
- CJWJVNSYJZEAGR-IBGZPJMESA-N 2-[(2,6-dimethylpyridin-4-yl)methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=NC(=CC(=C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1)C CJWJVNSYJZEAGR-IBGZPJMESA-N 0.000 claims description 2
- RUGLNXQJEDOSAG-LJQANCHMSA-N 2-[(2,6-dimethylpyridin-4-yl)methyl]-N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=NC(=CC(=C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCOC1)C RUGLNXQJEDOSAG-LJQANCHMSA-N 0.000 claims description 2
- WYTSJIFMOIBFTC-INIZCTEOSA-N 2-[(3-chloro-5-ethoxypyridin-2-yl)methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound ClC=1C(=NC=C(C=1)OCC)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 WYTSJIFMOIBFTC-INIZCTEOSA-N 0.000 claims description 2
- YSBBFMBUBYHAGK-HNNXBMFYSA-N 2-[(3-chloro-5-fluoropyridin-2-yl)methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound ClC=1C(=NC=C(C=1)F)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 YSBBFMBUBYHAGK-HNNXBMFYSA-N 0.000 claims description 2
- KTQFMZUPDZIXSW-HNNXBMFYSA-N 2-[(3-chloropyridin-2-yl)methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound ClC=1C(=NC=CC=1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 KTQFMZUPDZIXSW-HNNXBMFYSA-N 0.000 claims description 2
- RJXZBSHTSFNKBG-OAHLLOKOSA-N 2-[(3-chloropyridin-2-yl)methyl]-N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound ClC=1C(=NC=CC=1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCOC1 RJXZBSHTSFNKBG-OAHLLOKOSA-N 0.000 claims description 2
- JQUGXSHYHUARNP-AWEZNQCLSA-N 2-[(3-fluorooxetan-3-yl)methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound FC1(COC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 JQUGXSHYHUARNP-AWEZNQCLSA-N 0.000 claims description 2
- QDJXLLDVOZCOPC-HNNXBMFYSA-N 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)C1=NC(=NO1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 QDJXLLDVOZCOPC-HNNXBMFYSA-N 0.000 claims description 2
- IRSGQVGUFMRRDC-OAHLLOKOSA-N 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)C1=NC(=NO1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCOC1 IRSGQVGUFMRRDC-OAHLLOKOSA-N 0.000 claims description 2
- VMHQCEOKVCGTRB-IBGZPJMESA-N 2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C(C)C1=CC=C(C=N1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 VMHQCEOKVCGTRB-IBGZPJMESA-N 0.000 claims description 2
- KKXFTMGCZSJSDI-INIZCTEOSA-N 2-[(6-methylpyridin-3-yl)methyl]-N-[[(2S)-oxolan-2-yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=CC=C(C=N1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 KKXFTMGCZSJSDI-INIZCTEOSA-N 0.000 claims description 2
- RPDVJAYJMIXPQX-JKSUJKDBSA-N 2-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 RPDVJAYJMIXPQX-JKSUJKDBSA-N 0.000 claims description 2
- MTLDDKFXIBCQOM-PREGVCBESA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methyl-N-[(4-methyloxolan-2-yl)methyl]spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(CC4)C2=C1)OC(=C3C)C(=O)NCC1OCC(C1)C MTLDDKFXIBCQOM-PREGVCBESA-N 0.000 claims description 2
- RPDVJAYJMIXPQX-HOTGVXAUSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 RPDVJAYJMIXPQX-HOTGVXAUSA-N 0.000 claims description 2
- WVGCABADKDXJMC-HOTGVXAUSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methyl-N-[[(2S)-oxolan-2-yl]methyl]spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NC[C@H]1OCCC1 WVGCABADKDXJMC-HOTGVXAUSA-N 0.000 claims description 2
- GUJXDAIKVOKGBE-ZDUSSCGKSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-(1,3-oxazol-4-ylmethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCC=1N=COC=1 GUJXDAIKVOKGBE-ZDUSSCGKSA-N 0.000 claims description 2
- HBZFTAJKVFWGBA-LBPRGKRZSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-(1,3-thiazol-2-ylmethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCC=1SC=CN=1 HBZFTAJKVFWGBA-LBPRGKRZSA-N 0.000 claims description 2
- IGKULTQMAKWDTP-HNNXBMFYSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-(2-pyrazin-2-ylethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCCC1=NC=CN=C1 IGKULTQMAKWDTP-HNNXBMFYSA-N 0.000 claims description 2
- YNDHKPPVOQTGBX-INIZCTEOSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-(2-pyridin-2-ylethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCCC1=NC=CC=C1 YNDHKPPVOQTGBX-INIZCTEOSA-N 0.000 claims description 2
- NHIVWSFDZDINAE-INIZCTEOSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-(2-pyridin-3-ylethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCCC=1C=NC=CC=1 NHIVWSFDZDINAE-INIZCTEOSA-N 0.000 claims description 2
- NTNWWZQFZQAASB-AWEZNQCLSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-(pyrazin-2-ylmethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCC1=NC=CN=C1 NTNWWZQFZQAASB-AWEZNQCLSA-N 0.000 claims description 2
- BRWUWXWLMVISJJ-HNNXBMFYSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[(1-methylpyrazol-3-yl)methyl]-8-(trifluoromethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclobutane]-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NCC1=NN(C=C1)C BRWUWXWLMVISJJ-HNNXBMFYSA-N 0.000 claims description 2
- UWYYRBRFXLYQSE-HNNXBMFYSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[(5-methylpyrazin-2-yl)methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCC1=NC=C(N=C1)C UWYYRBRFXLYQSE-HNNXBMFYSA-N 0.000 claims description 2
- DWFXFQWKEPBIRV-INIZCTEOSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[(6-methylpyridin-2-yl)methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCC1=NC(=CC=C1)C DWFXFQWKEPBIRV-INIZCTEOSA-N 0.000 claims description 2
- NVYFILDQTBXZFT-ZDUSSCGKSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[2-(1,3-thiazol-2-yl)ethyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCCC=1SC=CN=1 NVYFILDQTBXZFT-ZDUSSCGKSA-N 0.000 claims description 2
- FEAJAIHAAITGAM-AWEZNQCLSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[2-(1H-imidazol-5-yl)ethyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCCC=1N=CNC=1 FEAJAIHAAITGAM-AWEZNQCLSA-N 0.000 claims description 2
- YWVPJQDTSLKANC-HNNXBMFYSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[2-(3-methylpyrazol-1-yl)ethyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCCN1N=C(C=C1)C YWVPJQDTSLKANC-HNNXBMFYSA-N 0.000 claims description 2
- VNOOICOUYUDLOQ-KRWDZBQOSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[2-(4-methylpyridin-2-yl)ethyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCCC1=NC=CC(=C1)C VNOOICOUYUDLOQ-KRWDZBQOSA-N 0.000 claims description 2
- ZEHZJHUNKSKTEK-KBPBESRZSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[[(2S)-oxolan-2-yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 ZEHZJHUNKSKTEK-KBPBESRZSA-N 0.000 claims description 2
- KXNMGHRYIMFELH-SJORKVTESA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[[(6R)-2,5-dioxaspiro[3.4]octan-6-yl]methyl]-8-methylspiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NC[C@@H]1OC2(COC2)CC1 KXNMGHRYIMFELH-SJORKVTESA-N 0.000 claims description 2
- GGNZSOCEWIGQFA-KRWDZBQOSA-N 2-[[1-(2-methoxyacetyl)piperidin-4-yl]methyl]-N-[[(2S)-oxolan-2-yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound COCC(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 GGNZSOCEWIGQFA-KRWDZBQOSA-N 0.000 claims description 2
- NXSICWKMAONPJT-GOSISDBHSA-N 2-[[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl]-N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 NXSICWKMAONPJT-GOSISDBHSA-N 0.000 claims description 2
- VMQSHZYRYUKWIM-LJQANCHMSA-N 2-[[1-(cyclopropylmethyl)piperidin-4-yl]methyl]-N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)CN1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 VMQSHZYRYUKWIM-LJQANCHMSA-N 0.000 claims description 2
- WFUFHWQTAJLBRT-IBGZPJMESA-N 2-[[1-(cyclopropylmethyl)piperidin-4-yl]methyl]-N-[[(2S)-oxolan-2-yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)CN1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 WFUFHWQTAJLBRT-IBGZPJMESA-N 0.000 claims description 2
- JKMKUGPZIJOOPX-UHFFFAOYSA-N 3-[[[8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carbonyl]amino]methyl]-1,2-oxazole-4-carboxylic acid Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NOC=C1C(=O)O JKMKUGPZIJOOPX-UHFFFAOYSA-N 0.000 claims description 2
- ZVXIFDJSKWSWPY-CYBMUJFWSA-N 7-N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-N,2-N,8-trimethylspiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-2,7-dicarboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)C(=O)N(C)C)CC3)O1)C ZVXIFDJSKWSWPY-CYBMUJFWSA-N 0.000 claims description 2
- JLASWANQHMMVMZ-KBPBESRZSA-N 8-(difluoromethyl)-2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound FC(C1=C(OC=2CCC3=CN(N=C3C=21)C[C@@H]1OCCOC1)C(=O)NC[C@H]1OCCC1)F JLASWANQHMMVMZ-KBPBESRZSA-N 0.000 claims description 2
- UKIFZGJTMOMRAW-KGLIPLIRSA-N 8-(difluoromethyl)-N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-[[(2S)-1,4-dioxan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound FC(C1=C(OC=2CCC3=CN(N=C3C=21)C[C@@H]1OCCOC1)C(=O)NC[C@H]1OCCOC1)F UKIFZGJTMOMRAW-KGLIPLIRSA-N 0.000 claims description 2
- KZSHWKVDVFDQLI-IRXDYDNUSA-N 8-cyclopropyl-2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)C1=C(OC=2CCC3=CN(N=C3C=21)C[C@@H]1OCCOC1)C(=O)NC[C@H]1OCCC1 KZSHWKVDVFDQLI-IRXDYDNUSA-N 0.000 claims description 2
- GZBBXERJZQVWEV-UHFFFAOYSA-N 8-cyclopropyl-N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)C1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC=1OC=CN=1 GZBBXERJZQVWEV-UHFFFAOYSA-N 0.000 claims description 2
- CUWNZFKQZYFABI-UHFFFAOYSA-N 8-cyclopropyl-N-[(1-methylpyrazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)C1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NN(C=C1)C CUWNZFKQZYFABI-UHFFFAOYSA-N 0.000 claims description 2
- DPXGAAXRKADIDX-GOSISDBHSA-N 8-cyclopropyl-N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)C1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1OCCOC1 DPXGAAXRKADIDX-GOSISDBHSA-N 0.000 claims description 2
- MLGKLFRWALSIOH-SFHVURJKSA-N 8-cyclopropyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)C1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1OCCC1 MLGKLFRWALSIOH-SFHVURJKSA-N 0.000 claims description 2
- BWUKOVBTVFFFMI-AWEZNQCLSA-N 8-methyl-2-(1,3-oxazol-2-ylmethyl)-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC=1OC=CN=1)C(=O)NC[C@H]1OCCC1 BWUKOVBTVFFFMI-AWEZNQCLSA-N 0.000 claims description 2
- CNFUJSXOYUBFQF-KRWDZBQOSA-N 8-methyl-2-(oxan-4-ylmethyl)-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1CCOCC1)C(=O)NC[C@H]1OCCC1 CNFUJSXOYUBFQF-KRWDZBQOSA-N 0.000 claims description 2
- FCXOTBCJOQSMIR-HNNXBMFYSA-N 8-methyl-2-(oxetan-3-ylmethyl)-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1COC1)C(=O)NC[C@H]1OCCC1 FCXOTBCJOQSMIR-HNNXBMFYSA-N 0.000 claims description 2
- OPXSKWLPJHCYEQ-UHFFFAOYSA-N 8-methyl-2-(pyridin-2-ylmethyl)-N-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCCN1CCN(CC1)C1=CC(=CC=C1)C(F)(F)F OPXSKWLPJHCYEQ-UHFFFAOYSA-N 0.000 claims description 2
- GAMVDMLNDHMRHB-UHFFFAOYSA-N 8-methyl-2-(pyridin-2-ylmethyl)-N-[2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]ethyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCCN1CCN(CC1)C1=NC=C(C=C1)C(F)(F)F GAMVDMLNDHMRHB-UHFFFAOYSA-N 0.000 claims description 2
- TTWTXTCYGBFZJL-SFHVURJKSA-N 8-methyl-2-[(2-methylpyridin-3-yl)methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC=1C(=NC=CC=1)C)C(=O)NC[C@H]1OCCC1 TTWTXTCYGBFZJL-SFHVURJKSA-N 0.000 claims description 2
- HLMSMLOGFLFFGP-SFHVURJKSA-N 8-methyl-2-[(2-methylpyridin-4-yl)methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=CC(=NC=C1)C)C(=O)NC[C@H]1OCCC1 HLMSMLOGFLFFGP-SFHVURJKSA-N 0.000 claims description 2
- UPSSLDYDOCKPPS-HNNXBMFYSA-N 8-methyl-2-[(3-methyloxetan-3-yl)methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1(COC1)C)C(=O)NC[C@H]1OCCC1 UPSSLDYDOCKPPS-HNNXBMFYSA-N 0.000 claims description 2
- XOIDMMGUVKWWOP-KRWDZBQOSA-N 8-methyl-2-[(3-methylpyridin-2-yl)methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1C)C(=O)NC[C@H]1OCCC1 XOIDMMGUVKWWOP-KRWDZBQOSA-N 0.000 claims description 2
- VHBLOJWIHMEUFG-SFHVURJKSA-N 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=C(C=C1)C)C(=O)NC[C@H]1OCCC1 VHBLOJWIHMEUFG-SFHVURJKSA-N 0.000 claims description 2
- XHPCXALYYAGUIF-IBGZPJMESA-N 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-N-[[(2S)-oxolan-2-yl]methyl]spiro[5H-furo[2,3-g]indazole-4,1'-cyclobutane]-7-carboxamide Chemical compound CC1=C(OC=2CC3(C4=CN(N=C4C=21)CC1=NC=C(C=C1)C)CCC3)C(=O)NC[C@H]1OCCC1 XHPCXALYYAGUIF-IBGZPJMESA-N 0.000 claims description 2
- KNLGCXSLCJYYKP-UHFFFAOYSA-N 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-(1,3-oxazol-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC(=CC=C1)C)C(=O)NCC=1OC=CN=1 KNLGCXSLCJYYKP-UHFFFAOYSA-N 0.000 claims description 2
- XEOZJCHDFHTAFZ-UHFFFAOYSA-N 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-(2-pyrrolidin-1-ylethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC(=CC=C1)C)C(=O)NCCN1CCCC1 XEOZJCHDFHTAFZ-UHFFFAOYSA-N 0.000 claims description 2
- GRRZTDLXRWZXNU-SFHVURJKSA-N 8-methyl-2-[(6-methylpyridin-3-yl)methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC=1C=NC(=CC=1)C)C(=O)NC[C@H]1OCCC1 GRRZTDLXRWZXNU-SFHVURJKSA-N 0.000 claims description 2
- NKVKWWQCHIXDCR-SFHVURJKSA-N 8-methyl-2-[(6-methylpyridin-3-yl)methyl]-N-[[(2S)-oxolan-2-yl]methyl]spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound CC1=C(OC=2CC3(C4=CN(N=C4C=21)CC=1C=NC(=CC=1)C)CC3)C(=O)NC[C@H]1OCCC1 NKVKWWQCHIXDCR-SFHVURJKSA-N 0.000 claims description 2
- GIMWAJYLZQGRGL-DLBZAZTESA-N 8-methyl-2-[[(2R)-4-methylmorpholin-2-yl]methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)C[C@H]1CN(CCO1)C)C(=O)NC[C@H]1OCCC1 GIMWAJYLZQGRGL-DLBZAZTESA-N 0.000 claims description 2
- DLTSIZAZVZAIRB-LSDHHAIUSA-N 8-methyl-2-[[(2R)-oxetan-2-yl]methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)C[C@@H]1OCC1)C(=O)NC[C@H]1OCCC1 DLTSIZAZVZAIRB-LSDHHAIUSA-N 0.000 claims description 2
- DLTSIZAZVZAIRB-GJZGRUSLSA-N 8-methyl-2-[[(2S)-oxetan-2-yl]methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)C[C@H]1OCC1)C(=O)NC[C@H]1OCCC1 DLTSIZAZVZAIRB-GJZGRUSLSA-N 0.000 claims description 2
- QJWSWBRVNQLOIT-HOTGVXAUSA-N 8-methyl-N,2-bis[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)C[C@H]1OCCC1)C(=O)NC[C@H]1OCCC1 QJWSWBRVNQLOIT-HOTGVXAUSA-N 0.000 claims description 2
- XYTAKRQZEYYZPI-UHFFFAOYSA-N 8-methyl-N-(1,2,4-oxadiazol-3-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NOC=N1 XYTAKRQZEYYZPI-UHFFFAOYSA-N 0.000 claims description 2
- MRSCAYWVQGIFSS-UHFFFAOYSA-N 8-methyl-N-(1,2-oxazol-3-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NOC=C1 MRSCAYWVQGIFSS-UHFFFAOYSA-N 0.000 claims description 2
- UFTQAUHUOJNSFU-UHFFFAOYSA-N 8-methyl-N-(1,2-oxazol-4-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC=1C=NOC=1 UFTQAUHUOJNSFU-UHFFFAOYSA-N 0.000 claims description 2
- RKSLSJZALOIWPZ-UHFFFAOYSA-N 8-methyl-N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC=1OC=CN=1 RKSLSJZALOIWPZ-UHFFFAOYSA-N 0.000 claims description 2
- AIVBRSWEEMHJMJ-UHFFFAOYSA-N 8-methyl-N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound CC1=C(OC=2CC3(C4=CN(N=C4C=21)CC1=NC=CC=C1)CC3)C(=O)NCC=1OC=CN=1 AIVBRSWEEMHJMJ-UHFFFAOYSA-N 0.000 claims description 2
- ULDQVWGELAMUFJ-UHFFFAOYSA-N 8-methyl-N-(1-methylpyrazol-3-yl)-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC1=NN(C=C1)C ULDQVWGELAMUFJ-UHFFFAOYSA-N 0.000 claims description 2
- PPDSPRDBHXTACW-UHFFFAOYSA-N 8-methyl-N-(oxetan-3-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1COC1 PPDSPRDBHXTACW-UHFFFAOYSA-N 0.000 claims description 2
- BASSCDRJGLSVAU-UHFFFAOYSA-N 8-methyl-N-[(1-methylpyrazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NN(C=C1)C BASSCDRJGLSVAU-UHFFFAOYSA-N 0.000 claims description 2
- HHRCCRRIZLVGSM-UHFFFAOYSA-N 8-methyl-N-[(1-methylpyrazol-3-yl)methyl]-2-[(6-methylpyridin-2-yl)methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC(=CC=C1)C)C(=O)NCC1=NN(C=C1)C HHRCCRRIZLVGSM-UHFFFAOYSA-N 0.000 claims description 2
- PBRYKHMPCGKDKT-UHFFFAOYSA-N 8-methyl-N-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NON=C1C PBRYKHMPCGKDKT-UHFFFAOYSA-N 0.000 claims description 2
- AOIJRISPMYMNDG-UHFFFAOYSA-N 8-methyl-N-[(4-methyl-1,2-oxazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NOC=C1C AOIJRISPMYMNDG-UHFFFAOYSA-N 0.000 claims description 2
- RSXOWAYYQDPOIE-UHFFFAOYSA-N 8-methyl-N-[(5-methyl-1,2-oxazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NOC(=C1)C RSXOWAYYQDPOIE-UHFFFAOYSA-N 0.000 claims description 2
- NASFEEMGLOBQLN-UHFFFAOYSA-N 8-methyl-N-[(5-propan-2-yl-1,2-oxazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C(C)(C)C1=CC(=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C NASFEEMGLOBQLN-UHFFFAOYSA-N 0.000 claims description 2
- BVBXPJQHZYXCMK-UHFFFAOYSA-N 8-methyl-N-[2-(4-methylpiperazin-1-yl)ethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCCN1CCN(CC1)C BVBXPJQHZYXCMK-UHFFFAOYSA-N 0.000 claims description 2
- HJDYUEUHPOCIAH-SFHVURJKSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(2-pyridin-3-ylpropan-2-yl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)C(C)(C)C=1C=NC=CC=1)C(=O)NC[C@H]1OCCC1 HJDYUEUHPOCIAH-SFHVURJKSA-N 0.000 claims description 2
- VKFJBJXZCRKIQO-KRWDZBQOSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(pyridin-2-ylmethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound CC1=C(OC=2CC3(C4=CN(N=C4C=21)CC1=NC=CC=C1)CC3)C(=O)NC[C@H]1OCCC1 VKFJBJXZCRKIQO-KRWDZBQOSA-N 0.000 claims description 2
- KZKAYMJQHCODIW-KRWDZBQOSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(pyridin-3-ylmethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound CC1=C(OC=2CC3(C4=CN(N=C4C=21)CC=1C=NC=CC=1)CC3)C(=O)NC[C@H]1OCCC1 KZKAYMJQHCODIW-KRWDZBQOSA-N 0.000 claims description 2
- YQQYGXMVXZJFDG-KRWDZBQOSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(pyridin-4-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=CC=NC=C1)C(=O)NC[C@H]1OCCC1 YQQYGXMVXZJFDG-KRWDZBQOSA-N 0.000 claims description 2
- NQLRPBOJKBQUNR-SFHVURJKSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(pyridin-4-ylmethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclobutane]-7-carboxamide Chemical compound CC1=C(OC=2CC3(C4=CN(N=C4C=21)CC1=CC=NC=C1)CCC3)C(=O)NC[C@H]1OCCC1 NQLRPBOJKBQUNR-SFHVURJKSA-N 0.000 claims description 2
- ZRLWABBNHRMYIY-HNNXBMFYSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(pyrimidin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=N1)C(=O)NC[C@H]1OCCC1 ZRLWABBNHRMYIY-HNNXBMFYSA-N 0.000 claims description 2
- NGWLWWQGRYNVAE-INIZCTEOSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(pyrimidin-5-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC=1C=NC=NC=1)C(=O)NC[C@H]1OCCC1 NGWLWWQGRYNVAE-INIZCTEOSA-N 0.000 claims description 2
- QJWSWBRVNQLOIT-JKSUJKDBSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-[[(2R)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)C[C@@H]1OCCC1)C(=O)NC[C@H]1OCCC1 QJWSWBRVNQLOIT-JKSUJKDBSA-N 0.000 claims description 2
- JHACMQNCNDEOHE-ZBFHGGJFSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-[[(3R)-oxolan-3-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)C[C@@H]1COCC1)C(=O)NC[C@H]1OCCC1 JHACMQNCNDEOHE-ZBFHGGJFSA-N 0.000 claims description 2
- HNOUJTFPPDJMJG-SFTDATJTSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-[[6-[[(2S)-oxolan-2-yl]methylcarbamoyl]pyridin-3-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC=1C=NC(=CC=1)C(NC[C@H]1OCCC1)=O)C(=O)NC[C@H]1OCCC1 HNOUJTFPPDJMJG-SFTDATJTSA-N 0.000 claims description 2
- MLPSRIJEZCIUJS-OAHLLOKOSA-N 8-methyl-N-[[(3R)-oxolan-3-yl]methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@@H]1COCC1 MLPSRIJEZCIUJS-OAHLLOKOSA-N 0.000 claims description 2
- MLPSRIJEZCIUJS-HNNXBMFYSA-N 8-methyl-N-[[(3S)-oxolan-3-yl]methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1COCC1 MLPSRIJEZCIUJS-HNNXBMFYSA-N 0.000 claims description 2
- QKTMJWHYUDWENA-UHFFFAOYSA-N 8-methyl-N-[[5-(morpholin-4-ylmethyl)-1,2-oxazol-3-yl]methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NOC(=C1)CN1CCOCC1 QKTMJWHYUDWENA-UHFFFAOYSA-N 0.000 claims description 2
- KJQSJVAWTGBIQU-SFHVURJKSA-N C(#N)C=1C=CC(=NC=1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound C(#N)C=1C=CC(=NC=1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 KJQSJVAWTGBIQU-SFHVURJKSA-N 0.000 claims description 2
- WHSXFMLLCNGJSK-INIZCTEOSA-N C(C)(=O)N1CC(C1)(F)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound C(C)(=O)N1CC(C1)(F)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 WHSXFMLLCNGJSK-INIZCTEOSA-N 0.000 claims description 2
- RDQCYTFJNGVCEG-KRWDZBQOSA-N C(C)(=O)N1CC(C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound C(C)(=O)N1CC(C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 RDQCYTFJNGVCEG-KRWDZBQOSA-N 0.000 claims description 2
- WIOGSNZZFCHUGB-KRWDZBQOSA-N C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 WIOGSNZZFCHUGB-KRWDZBQOSA-N 0.000 claims description 2
- BVSDOZBFKXQCEE-QGZVFWFLSA-N C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 Chemical compound C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 BVSDOZBFKXQCEE-QGZVFWFLSA-N 0.000 claims description 2
- YOQMMNQDFXJRJC-YOEHRIQHSA-N C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 YOQMMNQDFXJRJC-YOEHRIQHSA-N 0.000 claims description 2
- MXTFWGFSNAXAAJ-WMLDXEAASA-N C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 Chemical compound C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 MXTFWGFSNAXAAJ-WMLDXEAASA-N 0.000 claims description 2
- YOQMMNQDFXJRJC-PBHICJAKSA-N C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 YOQMMNQDFXJRJC-PBHICJAKSA-N 0.000 claims description 2
- MXTFWGFSNAXAAJ-RHSMWYFYSA-N C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 Chemical compound C(C)(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 MXTFWGFSNAXAAJ-RHSMWYFYSA-N 0.000 claims description 2
- VOFCVYNAMWDHLD-NRFANRHFSA-N C(C1=CC=CC=C1)(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound C(C1=CC=CC=C1)(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 VOFCVYNAMWDHLD-NRFANRHFSA-N 0.000 claims description 2
- FKZDTUIENRRHHF-OAQYLSRUSA-N C(C1=CC=CC=C1)(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 Chemical compound C(C1=CC=CC=C1)(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 FKZDTUIENRRHHF-OAQYLSRUSA-N 0.000 claims description 2
- CYLRDSPGLDYQOY-YJBOKZPZSA-N C1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound C1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 CYLRDSPGLDYQOY-YJBOKZPZSA-N 0.000 claims description 2
- IUNYYMVDSWWASX-MAUKXSAKSA-N C1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 Chemical compound C1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 IUNYYMVDSWWASX-MAUKXSAKSA-N 0.000 claims description 2
- CYLRDSPGLDYQOY-QAPCUYQASA-N C1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound C1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 CYLRDSPGLDYQOY-QAPCUYQASA-N 0.000 claims description 2
- IUNYYMVDSWWASX-CRAIPNDOSA-N C1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 Chemical compound C1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 IUNYYMVDSWWASX-CRAIPNDOSA-N 0.000 claims description 2
- QHPDWQMDEAFCTN-UHFFFAOYSA-N C1(CC1)C1=C(C=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C Chemical compound C1(CC1)C1=C(C=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C QHPDWQMDEAFCTN-UHFFFAOYSA-N 0.000 claims description 2
- UUCWZNUUWWKUCF-SJORKVTESA-N C1(CC1)C1=C(OC=2CCC3=CN(N=C3C=21)C[C@@H]1OCCOC1)C(=O)NC[C@H]1OCCOC1 Chemical compound C1(CC1)C1=C(OC=2CCC3=CN(N=C3C=21)C[C@@H]1OCCOC1)C(=O)NC[C@H]1OCCOC1 UUCWZNUUWWKUCF-SJORKVTESA-N 0.000 claims description 2
- DEOXPAKRKTVYCG-UHFFFAOYSA-N C1(CC1)C1=CC(=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC(=CC=C2)C)O1)C Chemical compound C1(CC1)C1=CC(=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC(=CC=C2)C)O1)C DEOXPAKRKTVYCG-UHFFFAOYSA-N 0.000 claims description 2
- OYJOMYHZMIZZFT-SFHVURJKSA-N C1(CC1)C1=CC(=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OC=3C(=NC=CC=3)OC2)O1)C Chemical compound C1(CC1)C1=CC(=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OC=3C(=NC=CC=3)OC2)O1)C OYJOMYHZMIZZFT-SFHVURJKSA-N 0.000 claims description 2
- OYJOMYHZMIZZFT-GOSISDBHSA-N C1(CC1)C1=CC(=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@H]2OC=3C(=NC=CC=3)OC2)O1)C Chemical compound C1(CC1)C1=CC(=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@H]2OC=3C(=NC=CC=3)OC2)O1)C OYJOMYHZMIZZFT-GOSISDBHSA-N 0.000 claims description 2
- WBXFGOVXGVXXJC-INIZCTEOSA-N C1(CC1)C=1N=CC(=NC=1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F Chemical compound C1(CC1)C=1N=CC(=NC=1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F WBXFGOVXGVXXJC-INIZCTEOSA-N 0.000 claims description 2
- DJDQNPKTGQGCPY-BBRMVZONSA-N C1(CC1)C=1N=CC(=NC=1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F Chemical compound C1(CC1)C=1N=CC(=NC=1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F DJDQNPKTGQGCPY-BBRMVZONSA-N 0.000 claims description 2
- NNVITFREVBGZHR-CYBMUJFWSA-N C1(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 Chemical compound C1(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCOC1 NNVITFREVBGZHR-CYBMUJFWSA-N 0.000 claims description 2
- XBDSDPYGYSKJCC-KRWDZBQOSA-N CC1(C2=CN(N=C2C2=C(C1)OC(=C2C)C(=O)NC[C@H]1OCCC1)CC1=NC=CC=C1)C Chemical compound CC1(C2=CN(N=C2C2=C(C1)OC(=C2C)C(=O)NC[C@H]1OCCC1)CC1=NC=CC=C1)C XBDSDPYGYSKJCC-KRWDZBQOSA-N 0.000 claims description 2
- JUOQMBLZQSNUKZ-CABCVRRESA-N CC1(CC[C@@H](O1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F)C Chemical compound CC1(CC[C@@H](O1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F)C JUOQMBLZQSNUKZ-CABCVRRESA-N 0.000 claims description 2
- JUOQMBLZQSNUKZ-GJZGRUSLSA-N CC1(CC[C@H](O1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F)C Chemical compound CC1(CC[C@H](O1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F)C JUOQMBLZQSNUKZ-GJZGRUSLSA-N 0.000 claims description 2
- STDSQPBAWDYEEI-UHFFFAOYSA-N CC1=C(OC=2CC3(C4=CN(N=C4C=21)CC1=NC=CC=C1)CC3)C(=O)NCC1=NN(C=C1)C Chemical compound CC1=C(OC=2CC3(C4=CN(N=C4C=21)CC1=NC=CC=C1)CC3)C(=O)NCC1=NN(C=C1)C STDSQPBAWDYEEI-UHFFFAOYSA-N 0.000 claims description 2
- NMVMCDXFDDQPNQ-TULHMLFLSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)C([2H])([2H])C1=CC=CC=C1)C(=O)NC[C@H]1OCCC1 Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)C([2H])([2H])C1=CC=CC=C1)C(=O)NC[C@H]1OCCC1 NMVMCDXFDDQPNQ-TULHMLFLSA-N 0.000 claims description 2
- HVBYOAWYMYSETA-GOSISDBHSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC(=CC=C1)C)C(=O)NC[C@@H]1OCCC1 Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC(=CC=C1)C)C(=O)NC[C@@H]1OCCC1 HVBYOAWYMYSETA-GOSISDBHSA-N 0.000 claims description 2
- HVBYOAWYMYSETA-SFHVURJKSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC(=CC=C1)C)C(=O)NC[C@H]1OCCC1 Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC(=CC=C1)C)C(=O)NC[C@H]1OCCC1 HVBYOAWYMYSETA-SFHVURJKSA-N 0.000 claims description 2
- WTLVBDOBNQYCAX-UHFFFAOYSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=CC=C(C=C1)C Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=CC=C(C=C1)C WTLVBDOBNQYCAX-UHFFFAOYSA-N 0.000 claims description 2
- XUZZCCIOCDWBMM-UHFFFAOYSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NOC(=C1)C(F)(F)F Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NOC(=C1)C(F)(F)F XUZZCCIOCDWBMM-UHFFFAOYSA-N 0.000 claims description 2
- YPGHHEUAXXQWEX-MRXNPFEDSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@@H]1OC(CC1)=O Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@@H]1OC(CC1)=O YPGHHEUAXXQWEX-MRXNPFEDSA-N 0.000 claims description 2
- FXACRENKCRYBSY-MRXNPFEDSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@@H]1OCC1 Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@@H]1OCC1 FXACRENKCRYBSY-MRXNPFEDSA-N 0.000 claims description 2
- QYWFCRVCCPCLAQ-SFHVURJKSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1CN(CCO1)C Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1CN(CCO1)C QYWFCRVCCPCLAQ-SFHVURJKSA-N 0.000 claims description 2
- YPGHHEUAXXQWEX-INIZCTEOSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1OC(CC1)=O Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1OC(CC1)=O YPGHHEUAXXQWEX-INIZCTEOSA-N 0.000 claims description 2
- FXACRENKCRYBSY-INIZCTEOSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1OCC1 Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1OCC1 FXACRENKCRYBSY-INIZCTEOSA-N 0.000 claims description 2
- UVYRBTNDTAPHQZ-KRWDZBQOSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1OCCC1 Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@H]1OCCC1 UVYRBTNDTAPHQZ-KRWDZBQOSA-N 0.000 claims description 2
- PKKIZRKGWUCLQM-QFIPXVFZSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1CN(C1)C(=O)OCC1=CC=CC=C1)C(NC[C@H]1OCCC1)=O Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1CN(C1)C(=O)OCC1=CC=CC=C1)C(NC[C@H]1OCCC1)=O PKKIZRKGWUCLQM-QFIPXVFZSA-N 0.000 claims description 2
- SZVJRPZNNSGAOS-FQEVSTJZSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CCN1CCN(CC1)C(=O)OC(C)(C)C)C(NC[C@H]1OCCC1)=O Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CCN1CCN(CC1)C(=O)OC(C)(C)C)C(NC[C@H]1OCCC1)=O SZVJRPZNNSGAOS-FQEVSTJZSA-N 0.000 claims description 2
- KYKMTCBGQUDJFV-KRWDZBQOSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CCN1CCNCC1)C(=O)NC[C@H]1OCCC1 Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CCN1CCNCC1)C(=O)NC[C@H]1OCCC1 KYKMTCBGQUDJFV-KRWDZBQOSA-N 0.000 claims description 2
- JHACMQNCNDEOHE-HOCLYGCPSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)C[C@H]1COCC1)C(=O)NC[C@H]1OCCC1 Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)C[C@H]1COCC1)C(=O)NC[C@H]1OCCC1 JHACMQNCNDEOHE-HOCLYGCPSA-N 0.000 claims description 2
- FBNZSSBEDDNBSS-INIZCTEOSA-N CC1=CC=C(C=N1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound CC1=CC=C(C=N1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 FBNZSSBEDDNBSS-INIZCTEOSA-N 0.000 claims description 2
- OOKNEPOJESXDBP-INIZCTEOSA-N CC=1C=CC(=NC=1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound CC=1C=CC(=NC=1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 OOKNEPOJESXDBP-INIZCTEOSA-N 0.000 claims description 2
- QISGNDZNKDWSPN-KRWDZBQOSA-N CC=1C=CC(=NC=1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound CC=1C=CC(=NC=1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 QISGNDZNKDWSPN-KRWDZBQOSA-N 0.000 claims description 2
- KDFLVADPNOJIDR-INIZCTEOSA-N CN1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound CN1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 KDFLVADPNOJIDR-INIZCTEOSA-N 0.000 claims description 2
- WGKQTDXNQPOLJF-UHFFFAOYSA-N CN1N=C(C=C1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=C(C=C2)C)CCC3)O1)C(F)(F)F Chemical compound CN1N=C(C=C1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=C(C=C2)C)CCC3)O1)C(F)(F)F WGKQTDXNQPOLJF-UHFFFAOYSA-N 0.000 claims description 2
- LFGZATNSLCHZEZ-UHFFFAOYSA-N CN1N=C(C=C1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CCC3)O1)C(F)(F)F Chemical compound CN1N=C(C=C1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CCC3)O1)C(F)(F)F LFGZATNSLCHZEZ-UHFFFAOYSA-N 0.000 claims description 2
- ANEATXCFHGZOOO-RDJZCZTQSA-N C[C@@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCN(CC1)C(C(CC)=O)=O Chemical compound C[C@@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCN(CC1)C(C(CC)=O)=O ANEATXCFHGZOOO-RDJZCZTQSA-N 0.000 claims description 2
- GNIYPLVGLXCXJK-ZFWWWQNUSA-N C[C@@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCOCC1 Chemical compound C[C@@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCOCC1 GNIYPLVGLXCXJK-ZFWWWQNUSA-N 0.000 claims description 2
- YXYVSPORTOXVKU-AEFFLSMTSA-N C[C@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCN(CC1)C(=O)C1(CC1)C Chemical compound C[C@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCN(CC1)C(=O)C1(CC1)C YXYVSPORTOXVKU-AEFFLSMTSA-N 0.000 claims description 2
- ANEATXCFHGZOOO-WBVHZDCISA-N C[C@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCN(CC1)C(C(CC)=O)=O Chemical compound C[C@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCN(CC1)C(C(CC)=O)=O ANEATXCFHGZOOO-WBVHZDCISA-N 0.000 claims description 2
- GNIYPLVGLXCXJK-HIFRSBDPSA-N C[C@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCOCC1 Chemical compound C[C@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCOCC1 GNIYPLVGLXCXJK-HIFRSBDPSA-N 0.000 claims description 2
- LBUKRFBUPKDJKD-AAEUAGOBSA-N ClC=1N=CC(=NC=1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F Chemical compound ClC=1N=CC(=NC=1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F LBUKRFBUPKDJKD-AAEUAGOBSA-N 0.000 claims description 2
- LBUKRFBUPKDJKD-YPMHNXCESA-N ClC=1N=CC(=NC=1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F Chemical compound ClC=1N=CC(=NC=1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F LBUKRFBUPKDJKD-YPMHNXCESA-N 0.000 claims description 2
- AOXOEKZUXYTERQ-HNNXBMFYSA-N FC1(CN(C1)C(=O)OC)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(NC[C@H]1OCCC1)=O Chemical compound FC1(CN(C1)C(=O)OC)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(NC[C@H]1OCCC1)=O AOXOEKZUXYTERQ-HNNXBMFYSA-N 0.000 claims description 2
- CKZDPCAOWNNLQM-NRFANRHFSA-N FC1(CN(C1)C(=O)OCC1=CC=CC=C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(NC[C@H]1OCCC1)=O Chemical compound FC1(CN(C1)C(=O)OCC1=CC=CC=C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(NC[C@H]1OCCC1)=O CKZDPCAOWNNLQM-NRFANRHFSA-N 0.000 claims description 2
- VPQLSWWZYYMHEP-HNNXBMFYSA-N FC1(CN(C1)S(=O)(=O)C)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound FC1(CN(C1)S(=O)(=O)C)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 VPQLSWWZYYMHEP-HNNXBMFYSA-N 0.000 claims description 2
- CFLHHHXQIHDBRC-STQMWFEESA-N FC1(C[C@H](OC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F)F Chemical compound FC1(C[C@H](OC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F)F CFLHHHXQIHDBRC-STQMWFEESA-N 0.000 claims description 2
- WRRDBTVDKCEXJW-KRWDZBQOSA-N FC1=CC(=NC=C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound FC1=CC(=NC=C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 WRRDBTVDKCEXJW-KRWDZBQOSA-N 0.000 claims description 2
- LLHYBIHEGCMZGM-KRWDZBQOSA-N FC=1C=C(C=NC=1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound FC=1C=C(C=NC=1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 LLHYBIHEGCMZGM-KRWDZBQOSA-N 0.000 claims description 2
- VKKKYXHUGRNZHW-HZPDHXFCSA-N N,2-bis[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@H]2OCCOC2)O1)C VKKKYXHUGRNZHW-HZPDHXFCSA-N 0.000 claims description 2
- NIRWVOXSTNUKNA-IRXDYDNUSA-N N,2-bis[[(2S)-1,4-dioxan-2-yl]methyl]-8-methylspiro[5H-furo[2,3-g]indazole-4,1'-cyclobutane]-7-carboxamide Chemical compound O1[C@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)C[C@@H]2OCCOC2)CCC3)O1)C NIRWVOXSTNUKNA-IRXDYDNUSA-N 0.000 claims description 2
- ARCYMQBBWRRXKH-UHFFFAOYSA-N N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1C(=NC=C1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C(F)(F)F ARCYMQBBWRRXKH-UHFFFAOYSA-N 0.000 claims description 2
- RLNXUUYGQPIVEQ-UHFFFAOYSA-N N-(2-hydroxy-2-methylpropyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound OC(CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C)(C)C RLNXUUYGQPIVEQ-UHFFFAOYSA-N 0.000 claims description 2
- GELTWUIEMNUPHT-UHFFFAOYSA-N N-(2-methoxyethyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound COCCNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C GELTWUIEMNUPHT-UHFFFAOYSA-N 0.000 claims description 2
- OFFMAJNVSVSGKD-UHFFFAOYSA-N N-(4-cyanophenyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C(#N)C1=CC=C(C=C1)NC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C OFFMAJNVSVSGKD-UHFFFAOYSA-N 0.000 claims description 2
- LTOBYZKCPOADBD-UHFFFAOYSA-N N-[(1-methylpyrazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CN1N=C(C=C1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C(F)(F)F LTOBYZKCPOADBD-UHFFFAOYSA-N 0.000 claims description 2
- OPUVASRNJWNGFN-UHFFFAOYSA-N N-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=NOC(=C1CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C)C OPUVASRNJWNGFN-UHFFFAOYSA-N 0.000 claims description 2
- IBCLALINQUKDQS-UHFFFAOYSA-N N-[(3-fluorooxetan-3-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound FC1(COC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C IBCLALINQUKDQS-UHFFFAOYSA-N 0.000 claims description 2
- SNPVJWXDVNXBNO-UHFFFAOYSA-N N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)C1=CC(=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C SNPVJWXDVNXBNO-UHFFFAOYSA-N 0.000 claims description 2
- HUHVZQMJIUHXAX-UHFFFAOYSA-N N-[2-(3,3-dimethyl-2-oxoazetidin-1-yl)ethyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1(C(N(C1)CCNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C)=O)C HUHVZQMJIUHXAX-UHFFFAOYSA-N 0.000 claims description 2
- NAPBGENAMRGRPI-UHFFFAOYSA-N N-[2-(azetidin-1-yl)ethyl]-8-methyl-2-[(6-methylpyridin-2-yl)methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound N1(CCC1)CCNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC(=CC=C2)C)O1)C NAPBGENAMRGRPI-UHFFFAOYSA-N 0.000 claims description 2
- AHSBEAGQGGPFHA-OAHLLOKOSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C(F)(F)F AHSBEAGQGGPFHA-OAHLLOKOSA-N 0.000 claims description 2
- DQQGDPRLTYBNLY-OAHLLOKOSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CC3)O1)C(F)(F)F DQQGDPRLTYBNLY-OAHLLOKOSA-N 0.000 claims description 2
- XNTZNONXUSHYHR-CQSZACIVSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-[(3-fluorooxetan-3-yl)methyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2(COC2)F)O1)C XNTZNONXUSHYHR-CQSZACIVSA-N 0.000 claims description 2
- YPQVECLDRSCYGV-LJQANCHMSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC=2C=NC(=CC=2)CC)O1)C YPQVECLDRSCYGV-LJQANCHMSA-N 0.000 claims description 2
- JPWGZISXJLSKMF-KGLIPLIRSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-[[(2S)-1,4-dioxan-2-yl]methyl]-4,4-dimethyl-8-(trifluoromethyl)-5H-furo[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC(C3=CN(N=C23)C[C@@H]2OCCOC2)(C)C)O1)C(F)(F)F JPWGZISXJLSKMF-KGLIPLIRSA-N 0.000 claims description 2
- VKKKYXHUGRNZHW-CVEARBPZSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C VKKKYXHUGRNZHW-CVEARBPZSA-N 0.000 claims description 2
- NIRWVOXSTNUKNA-SJORKVTESA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methylspiro[5H-furo[2,3-g]indazole-4,1'-cyclobutane]-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)C[C@@H]2OCCOC2)CCC3)O1)C NIRWVOXSTNUKNA-SJORKVTESA-N 0.000 claims description 2
- WRBDLHWOILLSJK-QGZVFWFLSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-[[1-(2-methoxyacetyl)piperidin-4-yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2CCN(CC2)C(COC)=O)O1)C(F)(F)F WRBDLHWOILLSJK-QGZVFWFLSA-N 0.000 claims description 2
- IZOGMKHJCNLYLH-NHCUHLMSSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-[[6-[[(2R)-1,4-dioxan-2-yl]methylcarbamoyl]pyridin-3-yl]methyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC=2C=NC(=CC=2)C(NC[C@H]2OCCOC2)=O)O1)C IZOGMKHJCNLYLH-NHCUHLMSSA-N 0.000 claims description 2
- CERVKVNXCWWXQM-OAHLLOKOSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(oxetan-3-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2COC2)O1)C CERVKVNXCWWXQM-OAHLLOKOSA-N 0.000 claims description 2
- QNEKCEUKPVPGLT-MRXNPFEDSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(pyridazin-3-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC=2N=NC=CC=2)O1)C QNEKCEUKPVPGLT-MRXNPFEDSA-N 0.000 claims description 2
- TVZOMPJPOXOGQN-GOSISDBHSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(pyridin-2-ylmethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclobutane]-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CCC3)O1)C TVZOMPJPOXOGQN-GOSISDBHSA-N 0.000 claims description 2
- PCHZXAFNNLHTQQ-QGZVFWFLSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(pyridin-2-ylmethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CC3)O1)C PCHZXAFNNLHTQQ-QGZVFWFLSA-N 0.000 claims description 2
- MASZVCVSIOSZDL-QGZVFWFLSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(pyridin-4-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=CC=NC=C2)O1)C MASZVCVSIOSZDL-QGZVFWFLSA-N 0.000 claims description 2
- DLDDEKWLXMAZLJ-OAHLLOKOSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(pyrimidin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=N2)O1)C DLDDEKWLXMAZLJ-OAHLLOKOSA-N 0.000 claims description 2
- AWSNNJZIEGBWEN-MRXNPFEDSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(pyrimidin-5-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC=2C=NC=NC=2)O1)C AWSNNJZIEGBWEN-MRXNPFEDSA-N 0.000 claims description 2
- LOCDFPFVLZJZBX-GOSISDBHSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[(2-methylpyridin-4-yl)methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=CC(=NC=C2)C)O1)C LOCDFPFVLZJZBX-GOSISDBHSA-N 0.000 claims description 2
- CGRAKGXRTJMROS-OAHLLOKOSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[(3-methyloxetan-3-yl)methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2(COC2)C)O1)C CGRAKGXRTJMROS-OAHLLOKOSA-N 0.000 claims description 2
- JUHOOBPKWMJPBP-QGZVFWFLSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[(3-methylpyridin-2-yl)methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2C)O1)C JUHOOBPKWMJPBP-QGZVFWFLSA-N 0.000 claims description 2
- ZOVVIDXJHWMELN-GOSISDBHSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[(6-methylpyridin-3-yl)methyl]spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC=2C=NC(=CC=2)C)CC3)O1)C ZOVVIDXJHWMELN-GOSISDBHSA-N 0.000 claims description 2
- BDQCDVJRQRAWRL-IAGOWNOFSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[[(2R)-4-methylmorpholin-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@H]2CN(CCO2)C)O1)C BDQCDVJRQRAWRL-IAGOWNOFSA-N 0.000 claims description 2
- LDSFTJPNCYZTPH-HUUCEWRRSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[[(2R)-oxetan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCC2)O1)C LDSFTJPNCYZTPH-HUUCEWRRSA-N 0.000 claims description 2
- BDQCDVJRQRAWRL-SJORKVTESA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[[(2S)-4-methylmorpholin-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2CN(CCO2)C)O1)C BDQCDVJRQRAWRL-SJORKVTESA-N 0.000 claims description 2
- LDSFTJPNCYZTPH-LSDHHAIUSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[[(2S)-oxetan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@H]2OCC2)O1)C LDSFTJPNCYZTPH-LSDHHAIUSA-N 0.000 claims description 2
- JOTXFOUOMHRPID-JKSUJKDBSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@H]2OCCC2)O1)C JOTXFOUOMHRPID-JKSUJKDBSA-N 0.000 claims description 2
- CFLHHHXQIHDBRC-OLZOCXBDSA-N N-[[(2R)-4,4-difluorooxolan-2-yl]methyl]-2-[[(2S)-1,4-dioxan-2-yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound FC1(C[C@@H](OC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F)F CFLHHHXQIHDBRC-OLZOCXBDSA-N 0.000 claims description 2
- DCFUIFSJOBDHGV-KRWDZBQOSA-N N-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C DCFUIFSJOBDHGV-KRWDZBQOSA-N 0.000 claims description 2
- TVZOMPJPOXOGQN-SFHVURJKSA-N N-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(pyridin-2-ylmethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclobutane]-7-carboxamide Chemical compound O1[C@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CCC3)O1)C TVZOMPJPOXOGQN-SFHVURJKSA-N 0.000 claims description 2
- HJXPRROZSVKUAI-HNNXBMFYSA-N N-[[(2S)-oxolan-2-yl]methyl]-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound N1=C(C=CC=C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 HJXPRROZSVKUAI-HNNXBMFYSA-N 0.000 claims description 2
- JINBBWSEUAUDJP-HNNXBMFYSA-N N-[[(2S)-oxolan-2-yl]methyl]-2-(pyridin-4-ylmethyl)-8-(trifluoromethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound N1=CC=C(C=C1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 JINBBWSEUAUDJP-HNNXBMFYSA-N 0.000 claims description 2
- RHHNPNJGBGKIBQ-UHFFFAOYSA-N N-[[5-(2-chlorophenyl)-1,2-oxazol-3-yl]methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound ClC1=C(C=CC=C1)C1=CC(=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C RHHNPNJGBGKIBQ-UHFFFAOYSA-N 0.000 claims description 2
- OJZXTRBHRNKXSI-UHFFFAOYSA-N N-[[5-(3-methoxyphenyl)-1,2-oxazol-3-yl]methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound COC=1C=C(C=CC=1)C1=CC(=NO1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C OJZXTRBHRNKXSI-UHFFFAOYSA-N 0.000 claims description 2
- CLSIVSJJWYFMQM-INIZCTEOSA-N N1=C(C=CC=C1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound N1=C(C=CC=C1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 CLSIVSJJWYFMQM-INIZCTEOSA-N 0.000 claims description 2
- RNRNRWCOPCLGAX-INIZCTEOSA-N N1=C(C=CC=C1)CN1N=C2C3=C(CCC2=C1)OC(=C3)C(=O)NC[C@H]1OCCC1 Chemical compound N1=C(C=CC=C1)CN1N=C2C3=C(CCC2=C1)OC(=C3)C(=O)NC[C@H]1OCCC1 RNRNRWCOPCLGAX-INIZCTEOSA-N 0.000 claims description 2
- VCVJSABZAFHSKY-INIZCTEOSA-N N1=CC=C(C=C1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound N1=CC=C(C=C1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 VCVJSABZAFHSKY-INIZCTEOSA-N 0.000 claims description 2
- LJRGEHVEWSJQSY-HNNXBMFYSA-N N1CC(C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound N1CC(C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 LJRGEHVEWSJQSY-HNNXBMFYSA-N 0.000 claims description 2
- WTIVYNPQUNVYMW-OAHLLOKOSA-N N1CC(C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCOC1 Chemical compound N1CC(C1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCOC1 WTIVYNPQUNVYMW-OAHLLOKOSA-N 0.000 claims description 2
- VXWASMFLSVTQTO-ZDUSSCGKSA-N NCCN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound NCCN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 VXWASMFLSVTQTO-ZDUSSCGKSA-N 0.000 claims description 2
- VRWXUWPATSWEOQ-CYBMUJFWSA-N NCCN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCOC1 Chemical compound NCCN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCOC1 VRWXUWPATSWEOQ-CYBMUJFWSA-N 0.000 claims description 2
- GOIUBJXBWYICOQ-QGZVFWFLSA-N NC[C@@H]1N(CCC1)C(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C Chemical compound NC[C@@H]1N(CCC1)C(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C GOIUBJXBWYICOQ-QGZVFWFLSA-N 0.000 claims description 2
- GOIUBJXBWYICOQ-KRWDZBQOSA-N NC[C@H]1N(CCC1)C(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C Chemical compound NC[C@H]1N(CCC1)C(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C GOIUBJXBWYICOQ-KRWDZBQOSA-N 0.000 claims description 2
- IDGXAYWYSKWGCS-UHFFFAOYSA-N O1C(=NC=C1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CCC3)O1)C(F)(F)F Chemical compound O1C(=NC=C1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CCC3)O1)C(F)(F)F IDGXAYWYSKWGCS-UHFFFAOYSA-N 0.000 claims description 2
- APYQRYNHRPGIJR-HNNXBMFYSA-N O1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound O1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 APYQRYNHRPGIJR-HNNXBMFYSA-N 0.000 claims description 2
- OPXHGQHUIDLJSW-HNNXBMFYSA-N O1[C@@H](CCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CC3)O1)C(F)(F)F Chemical compound O1[C@@H](CCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CC3)O1)C(F)(F)F OPXHGQHUIDLJSW-HNNXBMFYSA-N 0.000 claims description 2
- SHCUABWPCLZCFY-MRXNPFEDSA-N O1[C@@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NCC1=NOC=C1 Chemical compound O1[C@@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NCC1=NOC=C1 SHCUABWPCLZCFY-MRXNPFEDSA-N 0.000 claims description 2
- LQTLXVITJRNPIN-LJQANCHMSA-N O1[C@@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NCCN1CCN(CC1)C Chemical compound O1[C@@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NCCN1CCN(CC1)C LQTLXVITJRNPIN-LJQANCHMSA-N 0.000 claims description 2
- BWGPLNSOKBBSBU-DLBZAZTESA-N O1[C@@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound O1[C@@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 BWGPLNSOKBBSBU-DLBZAZTESA-N 0.000 claims description 2
- RTYZKPXEYBEHDK-LJQANCHMSA-N O1[C@@H](COC2=NC=CC=C21)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC(=CC=C2)C)O1)C Chemical compound O1[C@@H](COC2=NC=CC=C21)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC(=CC=C2)C)O1)C RTYZKPXEYBEHDK-LJQANCHMSA-N 0.000 claims description 2
- DKFPGMQLGZWZFZ-GOSISDBHSA-N O1[C@@H](COC2=NC=CC=C21)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C Chemical compound O1[C@@H](COC2=NC=CC=C21)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C DKFPGMQLGZWZFZ-GOSISDBHSA-N 0.000 claims description 2
- OJQDPENOIQOKOR-UONOGXRCSA-N O1[C@@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@@H]1OCCOC1 Chemical compound O1[C@@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@@H]1OCCOC1 OJQDPENOIQOKOR-UONOGXRCSA-N 0.000 claims description 2
- KEKZKRRKURPYNF-OAHLLOKOSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=CC=NC=C2)CC3)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=CC=NC=C2)CC3)O1)C(F)(F)F KEKZKRRKURPYNF-OAHLLOKOSA-N 0.000 claims description 2
- YIKLRLSHRJFSDW-MRXNPFEDSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=CC=NC=C2)CCC3)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=CC=NC=C2)CCC3)O1)C(F)(F)F YIKLRLSHRJFSDW-MRXNPFEDSA-N 0.000 claims description 2
- GIQDHNNSVISAOA-MRXNPFEDSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=C(C=C2)C)CC3)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=C(C=C2)C)CC3)O1)C(F)(F)F GIQDHNNSVISAOA-MRXNPFEDSA-N 0.000 claims description 2
- WYDNGVWOZBOBHQ-MRXNPFEDSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CCC3)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC2=NC=CC=C2)CCC3)O1)C(F)(F)F WYDNGVWOZBOBHQ-MRXNPFEDSA-N 0.000 claims description 2
- GAXIZAJGBVSZGZ-CVEARBPZSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)C[C@@H]2OCCOC2)CC3)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)C[C@@H]2OCCOC2)CC3)O1)C GAXIZAJGBVSZGZ-CVEARBPZSA-N 0.000 claims description 2
- QUCLBNJRUUCSSV-CABCVRRESA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)C[C@@H]2OCCOC2)CCC3)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)C[C@@H]2OCCOC2)CCC3)O1)C(F)(F)F QUCLBNJRUUCSSV-CABCVRRESA-N 0.000 claims description 2
- WBXTVNVVILATFB-NXMKPBRASA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C([2H])([2H])C2=CC=CC=C2)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C([2H])([2H])C2=CC=CC=C2)O1)C WBXTVNVVILATFB-NXMKPBRASA-N 0.000 claims description 2
- IFOPIGCYFZMWHO-GOSISDBHSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=C(C=C2)C)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=C(C=C2)C)O1)C IFOPIGCYFZMWHO-GOSISDBHSA-N 0.000 claims description 2
- DCFUIFSJOBDHGV-QGZVFWFLSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C DCFUIFSJOBDHGV-QGZVFWFLSA-N 0.000 claims description 2
- RASFNGPKVZCPBQ-QGZVFWFLSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2CCN(CC2)CC)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2CCN(CC2)CC)O1)C(F)(F)F RASFNGPKVZCPBQ-QGZVFWFLSA-N 0.000 claims description 2
- NFINJLUMOGVLCW-OAHLLOKOSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2CCOCC2)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2CCOCC2)O1)C(F)(F)F NFINJLUMOGVLCW-OAHLLOKOSA-N 0.000 claims description 2
- HNOYPWXGUSOIGM-GOSISDBHSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2CN(C2)C(=O)OC(C)(C)C)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2CN(C2)C(=O)OC(C)(C)C)O1)C HNOYPWXGUSOIGM-GOSISDBHSA-N 0.000 claims description 2
- OBIJCJGOOOHUOL-GOSISDBHSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC=2C(=NC=CC=2)C)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC=2C(=NC=CC=2)C)O1)C OBIJCJGOOOHUOL-GOSISDBHSA-N 0.000 claims description 2
- PBIWXIQPSNKSDD-HXUWFJFHSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CCN2CCN(CC2)C(=O)OC(C)(C)C)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CCN2CCN(CC2)C(=O)OC(C)(C)C)O1)C PBIWXIQPSNKSDD-HXUWFJFHSA-N 0.000 claims description 2
- LHCMMPGUSPYHJV-QGZVFWFLSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CCN2CCNCC2)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CCN2CCNCC2)O1)C LHCMMPGUSPYHJV-QGZVFWFLSA-N 0.000 claims description 2
- WUEZCFYVJFWPSB-GDBMZVCRSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2COCC2)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2COCC2)O1)C WUEZCFYVJFWPSB-GDBMZVCRSA-N 0.000 claims description 2
- OJQDPENOIQOKOR-KGLIPLIRSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F OJQDPENOIQOKOR-KGLIPLIRSA-N 0.000 claims description 2
- WUEZCFYVJFWPSB-GOEBONIOSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@H]2COCC2)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@H]2COCC2)O1)C WUEZCFYVJFWPSB-GOEBONIOSA-N 0.000 claims description 2
- OJQDPENOIQOKOR-ZIAGYGMSSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@H]2OCCOC2)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@H]2OCCOC2)O1)C(F)(F)F OJQDPENOIQOKOR-ZIAGYGMSSA-N 0.000 claims description 2
- NLHVFALCHLAAQY-FUHWJXTLSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)CC2CCN(CC2)C(=O)C2(CC2)C)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)CC2CCN(CC2)C(=O)C2(CC2)C)C)O1)C(F)(F)F NLHVFALCHLAAQY-FUHWJXTLSA-N 0.000 claims description 2
- CCTLHXIWYXMDBW-DOTOQJQBSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)CC2CCN(CC2)C(=O)C2(CC2)O)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)CC2CCN(CC2)C(=O)C2(CC2)O)C)O1)C(F)(F)F CCTLHXIWYXMDBW-DOTOQJQBSA-N 0.000 claims description 2
- LURWVFHGWAGWTP-DOTOQJQBSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)CC2CCN(CC2)C(C(CC)=O)=O)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)CC2CCN(CC2)C(C(CC)=O)=O)C)O1)C(F)(F)F LURWVFHGWAGWTP-DOTOQJQBSA-N 0.000 claims description 2
- IRLDEIGLJMQFQZ-DZGCQCFKSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)CC2CCOCC2)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)CC2CCOCC2)C)O1)C(F)(F)F IRLDEIGLJMQFQZ-DZGCQCFKSA-N 0.000 claims description 2
- KJFYYVHOKFLAOT-MJBXVCDLSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F KJFYYVHOKFLAOT-MJBXVCDLSA-N 0.000 claims description 2
- NLHVFALCHLAAQY-SJLPKXTDSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)CC2CCN(CC2)C(=O)C2(CC2)C)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)CC2CCN(CC2)C(=O)C2(CC2)C)C)O1)C(F)(F)F NLHVFALCHLAAQY-SJLPKXTDSA-N 0.000 claims description 2
- LURWVFHGWAGWTP-NVXWUHKLSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)CC2CCN(CC2)C(C(CC)=O)=O)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)CC2CCN(CC2)C(C(CC)=O)=O)C)O1)C(F)(F)F LURWVFHGWAGWTP-NVXWUHKLSA-N 0.000 claims description 2
- IRLDEIGLJMQFQZ-UKRRQHHQSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)CC2CCOCC2)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)CC2CCOCC2)C)O1)C(F)(F)F IRLDEIGLJMQFQZ-UKRRQHHQSA-N 0.000 claims description 2
- SBMKFFZYCXBICV-IJEWVQPXSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C(F)(F)F)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C(F)(F)F)O1)C SBMKFFZYCXBICV-IJEWVQPXSA-N 0.000 claims description 2
- KJFYYVHOKFLAOT-MCIONIFRSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C)O1)C(F)(F)F KJFYYVHOKFLAOT-MCIONIFRSA-N 0.000 claims description 2
- SCHYGBQOCLJFBU-FQEVSTJZSA-N O1[C@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NCC1=CC=C(C=C1)C Chemical compound O1[C@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NCC1=CC=C(C=C1)C SCHYGBQOCLJFBU-FQEVSTJZSA-N 0.000 claims description 2
- SHCUABWPCLZCFY-INIZCTEOSA-N O1[C@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NCC1=NOC=C1 Chemical compound O1[C@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NCC1=NOC=C1 SHCUABWPCLZCFY-INIZCTEOSA-N 0.000 claims description 2
- LQTLXVITJRNPIN-IBGZPJMESA-N O1[C@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NCCN1CCN(CC1)C Chemical compound O1[C@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NCCN1CCN(CC1)C LQTLXVITJRNPIN-IBGZPJMESA-N 0.000 claims description 2
- BWGPLNSOKBBSBU-IRXDYDNUSA-N O1[C@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound O1[C@H](COC2=NC=CC=C21)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 BWGPLNSOKBBSBU-IRXDYDNUSA-N 0.000 claims description 2
- RTYZKPXEYBEHDK-IBGZPJMESA-N O1[C@H](COC2=NC=CC=C21)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC(=CC=C2)C)O1)C Chemical compound O1[C@H](COC2=NC=CC=C21)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC(=CC=C2)C)O1)C RTYZKPXEYBEHDK-IBGZPJMESA-N 0.000 claims description 2
- DKFPGMQLGZWZFZ-SFHVURJKSA-N O1[C@H](COC2=NC=CC=C21)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C Chemical compound O1[C@H](COC2=NC=CC=C21)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2=NC=CC=C2)O1)C DKFPGMQLGZWZFZ-SFHVURJKSA-N 0.000 claims description 2
- JTWUQNFFTDVZMR-KBPBESRZSA-N O1[C@H](COCC1)CN1N=C2C3=C(CC(C2=C1)(C)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC(C2=C1)(C)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 JTWUQNFFTDVZMR-KBPBESRZSA-N 0.000 claims description 2
- DCCOWJJPTNMWLJ-KBPBESRZSA-N O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 DCCOWJJPTNMWLJ-KBPBESRZSA-N 0.000 claims description 2
- NACUURXSWDIRNJ-INIZCTEOSA-N O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NCC1=NN(C=C1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NCC1=NN(C=C1)C NACUURXSWDIRNJ-INIZCTEOSA-N 0.000 claims description 2
- CJKDEFBQZRIVPB-ZDUSSCGKSA-N O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NCC=1OC=CN=1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NCC=1OC=CN=1 CJKDEFBQZRIVPB-ZDUSSCGKSA-N 0.000 claims description 2
- XTCVVOIXCDTOQY-GJZGRUSLSA-N O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 XTCVVOIXCDTOQY-GJZGRUSLSA-N 0.000 claims description 2
- YOMVTQVDCHLHGK-IRXDYDNUSA-N O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CCC4)OC(=C3C)C(=O)NC[C@H]1OCCC1 YOMVTQVDCHLHGK-IRXDYDNUSA-N 0.000 claims description 2
- JRFSRUQTLSPMHH-YUELXQCFSA-N O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@@H]1O[C@@H](CC1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@@H]1O[C@@H](CC1)C JRFSRUQTLSPMHH-YUELXQCFSA-N 0.000 claims description 2
- JRFSRUQTLSPMHH-CFVMTHIKSA-N O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@@H]1O[C@H](CC1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@@H]1O[C@H](CC1)C JRFSRUQTLSPMHH-CFVMTHIKSA-N 0.000 claims description 2
- JRFSRUQTLSPMHH-QEJZJMRPSA-N O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1O[C@H](CC1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1O[C@H](CC1)C JRFSRUQTLSPMHH-QEJZJMRPSA-N 0.000 claims description 2
- QAUOBCYBEDYLHG-DZKIICNBSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C(F)(F)F)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C(F)(F)F)OC(=C3C)C(=O)NC[C@H]1OCCC1 QAUOBCYBEDYLHG-DZKIICNBSA-N 0.000 claims description 2
- UDYMDTWVNQCAAL-RYUDHWBXSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=CN=CS1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=CN=CS1 UDYMDTWVNQCAAL-RYUDHWBXSA-N 0.000 claims description 2
- PTQDMJUHGKYUEJ-BBRMVZONSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC(=CC=C1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC(=CC=C1)C PTQDMJUHGKYUEJ-BBRMVZONSA-N 0.000 claims description 2
- KSRKITRSHITXOX-KBPBESRZSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=C(C=N1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=C(C=N1)C KSRKITRSHITXOX-KBPBESRZSA-N 0.000 claims description 2
- BEWKEOVDLFJSEO-WFASDCNBSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=C(N=C1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=C(N=C1)C BEWKEOVDLFJSEO-WFASDCNBSA-N 0.000 claims description 2
- TUCDMQSMPPUOFB-STQMWFEESA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=CC=N1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=CC=N1 TUCDMQSMPPUOFB-STQMWFEESA-N 0.000 claims description 2
- REZXPSIRPBAJOO-JSGCOSHPSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=CN=C1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=CN=C1 REZXPSIRPBAJOO-JSGCOSHPSA-N 0.000 claims description 2
- FEGAIZKERGMPQV-JSGCOSHPSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NN(C=C1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NN(C=C1)C FEGAIZKERGMPQV-JSGCOSHPSA-N 0.000 claims description 2
- XCCSSWKLZSVBBY-WFASDCNBSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1C=NC(=NC=1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1C=NC(=NC=1)C XCCSSWKLZSVBBY-WFASDCNBSA-N 0.000 claims description 2
- HNSPFKWXOAGNDF-JSGCOSHPSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1N=CN(C=1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1N=CN(C=1)C HNSPFKWXOAGNDF-JSGCOSHPSA-N 0.000 claims description 2
- SGSZJENAPPIZIU-AAEUAGOBSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1N=COC=1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1N=COC=1 SGSZJENAPPIZIU-AAEUAGOBSA-N 0.000 claims description 2
- FJKJWODQSWGAKR-RYUDHWBXSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1OC=CN=1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1OC=CN=1 FJKJWODQSWGAKR-RYUDHWBXSA-N 0.000 claims description 2
- HRXSRKMQXGSYPV-RYUDHWBXSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1SC=CN=1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1SC=CN=1 HRXSRKMQXGSYPV-RYUDHWBXSA-N 0.000 claims description 2
- SBJUCHAIIXKPRS-IHRRRGAJSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 SBJUCHAIIXKPRS-IHRRRGAJSA-N 0.000 claims description 2
- QAUOBCYBEDYLHG-OFQRWUPVSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C(F)(F)F)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C(F)(F)F)OC(=C3C)C(=O)NC[C@H]1OCCC1 QAUOBCYBEDYLHG-OFQRWUPVSA-N 0.000 claims description 2
- UDYMDTWVNQCAAL-NEPJUHHUSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=CN=CS1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=CN=CS1 UDYMDTWVNQCAAL-NEPJUHHUSA-N 0.000 claims description 2
- KSRKITRSHITXOX-KGLIPLIRSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=C(C=N1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=C(C=N1)C KSRKITRSHITXOX-KGLIPLIRSA-N 0.000 claims description 2
- BEWKEOVDLFJSEO-DOMZBBRYSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=C(N=C1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=C(N=C1)C BEWKEOVDLFJSEO-DOMZBBRYSA-N 0.000 claims description 2
- TUCDMQSMPPUOFB-OLZOCXBDSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=CC=N1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=CC=N1 TUCDMQSMPPUOFB-OLZOCXBDSA-N 0.000 claims description 2
- REZXPSIRPBAJOO-OCCSQVGLSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=CN=C1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC=CN=C1 REZXPSIRPBAJOO-OCCSQVGLSA-N 0.000 claims description 2
- FEGAIZKERGMPQV-OCCSQVGLSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NN(C=C1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NN(C=C1)C FEGAIZKERGMPQV-OCCSQVGLSA-N 0.000 claims description 2
- XCCSSWKLZSVBBY-DOMZBBRYSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1C=NC(=NC=1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1C=NC(=NC=1)C XCCSSWKLZSVBBY-DOMZBBRYSA-N 0.000 claims description 2
- DHPKCIGQURTVTR-YPMHNXCESA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1C=NC(=NC=1)C(F)(F)F Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1C=NC(=NC=1)C(F)(F)F DHPKCIGQURTVTR-YPMHNXCESA-N 0.000 claims description 2
- HNSPFKWXOAGNDF-OCCSQVGLSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1N=CN(C=1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1N=CN(C=1)C HNSPFKWXOAGNDF-OCCSQVGLSA-N 0.000 claims description 2
- SGSZJENAPPIZIU-YPMHNXCESA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1N=COC=1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1N=COC=1 SGSZJENAPPIZIU-YPMHNXCESA-N 0.000 claims description 2
- FJKJWODQSWGAKR-NEPJUHHUSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1OC=CN=1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1OC=CN=1 FJKJWODQSWGAKR-NEPJUHHUSA-N 0.000 claims description 2
- HRXSRKMQXGSYPV-NEPJUHHUSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1SC=CN=1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1SC=CN=1 HRXSRKMQXGSYPV-NEPJUHHUSA-N 0.000 claims description 2
- SBJUCHAIIXKPRS-RDBSUJKOSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 SBJUCHAIIXKPRS-RDBSUJKOSA-N 0.000 claims description 2
- OJQDPENOIQOKOR-KBPBESRZSA-N O1[C@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F Chemical compound O1[C@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCOC2)O1)C(F)(F)F OJQDPENOIQOKOR-KBPBESRZSA-N 0.000 claims description 2
- NDXWZSRGKCJINU-RDJZCZTQSA-N OC1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound OC1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 NDXWZSRGKCJINU-RDJZCZTQSA-N 0.000 claims description 2
- NDXWZSRGKCJINU-WBVHZDCISA-N OC1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 Chemical compound OC1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 NDXWZSRGKCJINU-WBVHZDCISA-N 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- HEPJXTIXWXGVQJ-SFHVURJKSA-N tert-butyl 3-[[8-methyl-7-[[(2S)-oxolan-2-yl]methylcarbamoyl]-4,5-dihydrofuro[2,3-g]indazol-2-yl]methyl]azetidine-1-carboxylate Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1CN(C1)C(=O)OC(C)(C)C)C(NC[C@H]1OCCC1)=O HEPJXTIXWXGVQJ-SFHVURJKSA-N 0.000 claims description 2
- SCZPHRHPQWCGQO-MRXNPFEDSA-N tert-butyl N-[2-[7-[[(2R)-1,4-dioxan-2-yl]methylcarbamoyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazol-2-yl]ethyl]carbamate Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CCNC(OC(C)(C)C)=O)O1)C SCZPHRHPQWCGQO-MRXNPFEDSA-N 0.000 claims description 2
- AVTXTYFUEQOTKW-INIZCTEOSA-N tert-butyl N-[2-[8-methyl-7-[[(2S)-oxolan-2-yl]methylcarbamoyl]-4,5-dihydrofuro[2,3-g]indazol-2-yl]ethyl]carbamate Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CCNC(OC(C)(C)C)=O)C(NC[C@H]1OCCC1)=O AVTXTYFUEQOTKW-INIZCTEOSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 18
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- HXCBLPXNIOLOTM-AWEZNQCLSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methyl-N-(1,3-oxazol-2-ylmethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NCC=1OC=CN=1 HXCBLPXNIOLOTM-AWEZNQCLSA-N 0.000 claims 1
- GIMWAJYLZQGRGL-IRXDYDNUSA-N 8-methyl-2-[[(2S)-4-methylmorpholin-2-yl]methyl]-N-[[(2S)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)C[C@@H]1CN(CCO1)C)C(=O)NC[C@H]1OCCC1 GIMWAJYLZQGRGL-IRXDYDNUSA-N 0.000 claims 1
- GQRVXZPJBAHKME-UHFFFAOYSA-N 8-methyl-N-(1H-pyrazol-5-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC1=NNC=C1 GQRVXZPJBAHKME-UHFFFAOYSA-N 0.000 claims 1
- VVNYJAYXWQCWLI-QGZVFWFLSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(pyridin-3-ylmethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC=2C=NC=CC=2)CC3)O1)C VVNYJAYXWQCWLI-QGZVFWFLSA-N 0.000 claims 1
- RXUYVTTWLNNTSW-GOSISDBHSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[(6-methylpyridin-3-yl)methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC=2C=NC(=CC=2)C)O1)C RXUYVTTWLNNTSW-GOSISDBHSA-N 0.000 claims 1
- DBVOMVQKDFNCPX-UHFFFAOYSA-N N=1NC=C2C3(CC4=C(C=12)C=C(O4)C(=O)N)CC3 Chemical compound N=1NC=C2C3(CC4=C(C=12)C=C(O4)C(=O)N)CC3 DBVOMVQKDFNCPX-UHFFFAOYSA-N 0.000 claims 1
- GZBHWXFKYGVEOX-MRXNPFEDSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2CCN(CC2)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC2CCN(CC2)C)O1)C(F)(F)F GZBHWXFKYGVEOX-MRXNPFEDSA-N 0.000 claims 1
- CCTLHXIWYXMDBW-NVXWUHKLSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)CC2CCN(CC2)C(=O)C2(CC2)O)C)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@H](C3=CN(N=C23)CC2CCN(CC2)C(=O)C2(CC2)O)C)O1)C(F)(F)F CCTLHXIWYXMDBW-NVXWUHKLSA-N 0.000 claims 1
- KXNMGHRYIMFELH-IRXDYDNUSA-N O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NC[C@H]1OC2(COC2)CC1 Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NC[C@H]1OC2(COC2)CC1 KXNMGHRYIMFELH-IRXDYDNUSA-N 0.000 claims 1
- JRFSRUQTLSPMHH-SNPRPXQTSA-N O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1O[C@@H](CC1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1O[C@@H](CC1)C JRFSRUQTLSPMHH-SNPRPXQTSA-N 0.000 claims 1
- DHPKCIGQURTVTR-AAEUAGOBSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1C=NC(=NC=1)C(F)(F)F Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC=1C=NC(=NC=1)C(F)(F)F DHPKCIGQURTVTR-AAEUAGOBSA-N 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 12
- 208000024720 Fabry Disease Diseases 0.000 abstract description 7
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 description 47
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 description 47
- 230000000694 effects Effects 0.000 description 20
- 239000005557 antagonist Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000000155 isotopic effect Effects 0.000 description 10
- 239000002207 metabolite Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 7
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000556 agonist Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 5
- 229960001756 oxaliplatin Drugs 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 150000001975 deuterium Chemical group 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000005462 in vivo assay Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- GMUQLMNYOILZNL-UHFFFAOYSA-N N=1NC=C2C=CC3=C(C=12)C=C(O3)C(=O)N Chemical compound N=1NC=C2C=CC3=C(C=12)C=C(O3)C(=O)N GMUQLMNYOILZNL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- CUGDYSSBTWBKII-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CUGDYSSBTWBKII-LXGUWJNJSA-N 0.000 description 1
- IKXCHOUDIPZROZ-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(ethylamino)hexane-1,2,3,4,5-pentol Chemical compound CCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IKXCHOUDIPZROZ-LXGUWJNJSA-N 0.000 description 1
- FWIVDMJALNEADT-SFTDATJTSA-N (2s)-n-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1s)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide Chemical compound C1=CC([C@H](N[C@@H](CC(C)(F)C)C(=O)NC2(CC2)C#N)C(F)(F)F)=CC=C1C1=CC=C(S(C)(=O)=O)C=C1 FWIVDMJALNEADT-SFTDATJTSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- JLEPZAUPTZFVIM-RHIZIOMBSA-N (3s,5s,9r,10s,13r,17r)-3-hydroxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,4,5,6,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthrene-14-carbaldehyde Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CCC33C=O)C)C3=CC[C@H]21 JLEPZAUPTZFVIM-RHIZIOMBSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- PPLHDEFEINPSMR-ZDUSSCGKSA-N 2-N,2-N,8-trimethyl-7-N-[[(2S)-oxolan-2-yl]methyl]spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-2,7-dicarboxamide Chemical compound CN(C(=O)N1N=C2C3=C(CC4(C2=C1)CC4)OC(=C3C)C(=O)NC[C@H]1OCCC1)C PPLHDEFEINPSMR-ZDUSSCGKSA-N 0.000 description 1
- UZJZYEYQZYBSTJ-LJQANCHMSA-N 2-[(2,6-dimethylpyridin-3-yl)methyl]-N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=NC(=CC=C1CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCOC1)C UZJZYEYQZYBSTJ-LJQANCHMSA-N 0.000 description 1
- HWUZIBRRHBCICL-LBPRGKRZSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-(1,3-thiazol-5-ylmethyl)-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCC1=CN=CS1 HWUZIBRRHBCICL-LBPRGKRZSA-N 0.000 description 1
- AWZJZUBGJRJZLX-AWEZNQCLSA-N 2-[[(2S)-1,4-dioxan-2-yl]methyl]-N-[(1-methylimidazol-4-yl)methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NCC=1N=CN(C=1)C AWZJZUBGJRJZLX-AWEZNQCLSA-N 0.000 description 1
- URLZOAAWTHNCDI-SFHVURJKSA-N 2-[[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl]-N-[[(2S)-oxolan-2-yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C1(CC1)C(=O)N1CCC(CC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C(F)(F)F)C(=O)NC[C@H]1OCCC1 URLZOAAWTHNCDI-SFHVURJKSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WIFPJDJJFUSIFP-UHFFFAOYSA-N 4-aminobutane-1,2,3-triol Chemical compound NCC(O)C(O)CO WIFPJDJJFUSIFP-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 1
- PFSWASUQURIOOR-UHFFFAOYSA-N 6-(octylamino)-1h-pyrimidine-2,4-dione Chemical compound CCCCCCCCNC1=CC(=O)NC(=O)N1 PFSWASUQURIOOR-UHFFFAOYSA-N 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- OCIJPRHKGZPFFU-UHFFFAOYSA-N 8-methyl-2-(pyridin-2-ylmethyl)-N-(1,3-thiazol-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NCC=1SC=CN=1 OCIJPRHKGZPFFU-UHFFFAOYSA-N 0.000 description 1
- DPAKSUHFZBGZJU-UHFFFAOYSA-N 8-methyl-2-(pyridin-2-ylmethyl)-N-(1H-1,2,4-triazol-5-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC2=C1C3=NN(C=C3CC2)CC4=CC=CC=N4)C(=O)NCC5=NC=NN5 DPAKSUHFZBGZJU-UHFFFAOYSA-N 0.000 description 1
- VJVVHDCBEAIJNY-QGZVFWFLSA-N 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-N-[(3R)-oxolan-3-yl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=CN=C(C=C1)CN2C=C3CCC4=C(C3=N2)C(=C(O4)C(=O)N[C@@H]5CCOC5)C VJVVHDCBEAIJNY-QGZVFWFLSA-N 0.000 description 1
- MIANWONVXQGMPL-UHFFFAOYSA-N 8-methyl-N-(oxan-4-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC2=C1C3=NN(C=C3CC2)CC4=CC=CC=N4)C(=O)NCC5CCOCC5 MIANWONVXQGMPL-UHFFFAOYSA-N 0.000 description 1
- SBKIWEMQOUBTBW-INIZCTEOSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(pyridazin-3-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC=1N=NC=CC=1)C(=O)NC[C@H]1OCCC1 SBKIWEMQOUBTBW-INIZCTEOSA-N 0.000 description 1
- YYPRBQHPFJCNDZ-SFHVURJKSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(pyridin-2-ylmethyl)spiro[5H-furo[2,3-g]indazole-4,1'-cyclobutane]-7-carboxamide Chemical compound CC1=C(OC=2CC3(C4=CN(N=C4C=21)CC1=NC=CC=C1)CCC3)C(=O)NC[C@H]1OCCC1 YYPRBQHPFJCNDZ-SFHVURJKSA-N 0.000 description 1
- FIJIBWIYQPEYTD-KRWDZBQOSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-(pyridin-3-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC=1C=NC=CC=1)C(=O)NC[C@H]1OCCC1 FIJIBWIYQPEYTD-KRWDZBQOSA-N 0.000 description 1
- RQJLBNXIMKVFRG-KRWDZBQOSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-[[5-(trifluoromethyl)pyridin-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=C(C=C1)C(F)(F)F)C(=O)NC[C@H]1OCCC1 RQJLBNXIMKVFRG-KRWDZBQOSA-N 0.000 description 1
- NKIJGADOABDWQM-INIZCTEOSA-N 8-methyl-N-[[(2S)-oxolan-2-yl]methyl]-2-[[6-(trifluoromethyl)pyridin-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC(=CC=C1)C(F)(F)F)C(=O)NC[C@H]1OCCC1 NKIJGADOABDWQM-INIZCTEOSA-N 0.000 description 1
- ULVAEBJPGSSVBC-AUUYWEPGSA-N 8-methyl-N-[[(2S,3R)-3-methyloxolan-2-yl]methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound C[C@@H]1CCO[C@@H]1CNC(=O)C2=C(C3=C(O2)CCC4=CN(N=C43)CC5=CC=CC=N5)C ULVAEBJPGSSVBC-AUUYWEPGSA-N 0.000 description 1
- ORVCSSOGEGBCLY-UHFFFAOYSA-N 8-methyl-N-pyridin-3-yl-2-(pyridin-2-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=C(OC2=C1C3=NN(C=C3CC2)CC4=CC=CC=N4)C(=O)NC5=CN=CC=C5 ORVCSSOGEGBCLY-UHFFFAOYSA-N 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- NYSUXXHOMNIKAQ-UHFFFAOYSA-N C(CCCCCCC)C1=C(C(NC(N1)=O)=O)N Chemical compound C(CCCCCCC)C1=C(C(NC(N1)=O)=O)N NYSUXXHOMNIKAQ-UHFFFAOYSA-N 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- SCHYGBQOCLJFBU-HXUWFJFHSA-N CC1=C(C(NCC2=CC=C(C)C=C2)=O)OC2=C1C1=NN(C[C@H]3OC4=CC=CN=C4OC3)C=C1CC2 Chemical compound CC1=C(C(NCC2=CC=C(C)C=C2)=O)OC2=C1C1=NN(C[C@H]3OC4=CC=CN=C4OC3)C=C1CC2 SCHYGBQOCLJFBU-HXUWFJFHSA-N 0.000 description 1
- XCTIBUIKLYDJGJ-UHFFFAOYSA-N CC1=C(C(NCC2=NC=CC=C2)=O)OC2=C1C1=NN(CC3=NC=CC=C3)C=C1CC2 Chemical compound CC1=C(C(NCC2=NC=CC=C2)=O)OC2=C1C1=NN(CC3=NC=CC=C3)C=C1CC2 XCTIBUIKLYDJGJ-UHFFFAOYSA-N 0.000 description 1
- QYWFCRVCCPCLAQ-GOSISDBHSA-N CC1=C(C(NC[C@H]2OCCN(C)C2)=O)OC2=C1C1=NN(CC3=NC=CC=C3)C=C1CC2 Chemical compound CC1=C(C(NC[C@H]2OCCN(C)C2)=O)OC2=C1C1=NN(CC3=NC=CC=C3)C=C1CC2 QYWFCRVCCPCLAQ-GOSISDBHSA-N 0.000 description 1
- UVYRBTNDTAPHQZ-QGZVFWFLSA-N CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@@H]1OCCC1 Chemical compound CC1=C(OC=2CCC3=CN(N=C3C=21)CC1=NC=CC=C1)C(=O)NC[C@@H]1OCCC1 UVYRBTNDTAPHQZ-QGZVFWFLSA-N 0.000 description 1
- FZSULJCORGMSPH-UHFFFAOYSA-N CC1COC(CNC(C2=C(C)C(C3=NN(CC4=NC=CC=C4)C=C3CC3)=C3O2)=O)C1 Chemical compound CC1COC(CNC(C2=C(C)C(C3=NN(CC4=NC=CC=C4)C=C3CC3)=C3O2)=O)C1 FZSULJCORGMSPH-UHFFFAOYSA-N 0.000 description 1
- YXYVSPORTOXVKU-WMZOPIPTSA-N C[C@@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCN(CC1)C(=O)C1(CC1)C Chemical compound C[C@@H]1C2=CN(N=C2C2=C(C1)OC(=C2C(F)(F)F)C(=O)NC[C@H]1OCCC1)CC1CCN(CC1)C(=O)C1(CC1)C YXYVSPORTOXVKU-WMZOPIPTSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- UECHYISEJZTMKF-AWEZNQCLSA-N FC1(CNC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 Chemical compound FC1(CNC1)CN1N=C2C3=C(CCC2=C1)OC(=C3C)C(=O)NC[C@H]1OCCC1 UECHYISEJZTMKF-AWEZNQCLSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100033049 G-protein coupled receptor 42 Human genes 0.000 description 1
- 101710107771 G-protein coupled receptor 84 Proteins 0.000 description 1
- 102000048120 Galactokinases Human genes 0.000 description 1
- 108700023157 Galactokinases Proteins 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000871098 Homo sapiens G-protein coupled receptor 42 Proteins 0.000 description 1
- 101000735429 Homo sapiens Terminal nucleotidyltransferase 4B Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 101000835625 Mus musculus Tubulin-specific chaperone A Proteins 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- DDIODLNCAGKGOO-MRXNPFEDSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-2-[(6-methylpyridin-3-yl)methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound CC1=NC=C(C=C1)CN2C=C3CCC4=C(C3=N2)C(=C(O4)C(=O)NC[C@@H]5COCCO5)C(F)(F)F DDIODLNCAGKGOO-MRXNPFEDSA-N 0.000 description 1
- WOSDKOONPJFUHF-QGZVFWFLSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-(pyridin-3-ylmethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)CC=2C=NC=CC=2)O1)C WOSDKOONPJFUHF-QGZVFWFLSA-N 0.000 description 1
- JOTXFOUOMHRPID-HZPDHXFCSA-N N-[[(2R)-1,4-dioxan-2-yl]methyl]-8-methyl-2-[[(2R)-oxolan-2-yl]methyl]-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CCC3=CN(N=C23)C[C@@H]2OCCC2)O1)C JOTXFOUOMHRPID-HZPDHXFCSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- BFTRAASEIOMVFJ-MRXNPFEDSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC=2C=NC(=CC=2)C)CC3)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)CC=2C=NC(=CC=2)C)CC3)O1)C(F)(F)F BFTRAASEIOMVFJ-MRXNPFEDSA-N 0.000 description 1
- KMDJGAYHSCOZLS-KGLIPLIRSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)C[C@@H]2OCCOC2)CC3)O1)C(F)(F)F Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(CC3(C4=CN(N=C24)C[C@@H]2OCCOC2)CC3)O1)C(F)(F)F KMDJGAYHSCOZLS-KGLIPLIRSA-N 0.000 description 1
- SBMKFFZYCXBICV-YCPHGPKFSA-N O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C(F)(F)F)O1)C Chemical compound O1[C@@H](COCC1)CNC(=O)C1=C(C2=C(C[C@@H](C3=CN(N=C23)C[C@@H]2OCCOC2)C(F)(F)F)O1)C SBMKFFZYCXBICV-YCPHGPKFSA-N 0.000 description 1
- PTQDMJUHGKYUEJ-CJNGLKHVSA-N O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC(=CC=C1)C Chemical compound O1[C@H](COCC1)CN1N=C2C3=C(C[C@H](C2=C1)C)OC(=C3C(F)(F)F)C(=O)NCC1=NC(=CC=C1)C PTQDMJUHGKYUEJ-CJNGLKHVSA-N 0.000 description 1
- AJGJROVYVKUHID-UHFFFAOYSA-N OPNP Chemical compound OPNP AJGJROVYVKUHID-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 101710197776 Serine hydroxymethyltransferase 2 Proteins 0.000 description 1
- 102100034606 Serine hydroxymethyltransferase, mitochondrial Human genes 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100034938 Terminal nucleotidyltransferase 4B Human genes 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid group Chemical group C(CCCCCC)(=O)O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 102000052494 human GPR84 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000008534 mechanical pain sensitivity Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229950009755 odanacatib Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- QCRXMFTZTSTGJM-UHFFFAOYSA-N triacetyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(=O)OC(=O)CC(O)(C(=O)OC(C)=O)CC(=O)OC(C)=O QCRXMFTZTSTGJM-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Definitions
- the present invention covers the use of furoindazole compounds of general formula (I) as described and defined herein, for the treatment or prophylaxis of diseases in particular of inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome in humans and animals.
- inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain
- post-breast surgery pain cancer bone pain
- trigeminal neuralgia post-mastectomy pain
- fibromyalgia multiple sclerosis pain
- post-herpetic neuralgia Fabry disease
- gout gout
- the furoindazole compounds of general formula (I) are antagonists of the G-protein coupled receptor 84 (also known as GPR84).
- GPR84 G-protein coupled receptor 84
- MFFAs Medium-chain free fatty acids
- MCFFAs stimulate release of IL6 from fibroblasts (Smith and Tasi, Nat. Prod. Rep.2007 Oct, 24(5): 1041-72) and myristic acid increases IL6 and IL8 levels in human coronary arterial smooth muscle (HCASM) and endothelial (HCEC) cells (Soto-Vaca A. et al., J. Agric. Food Chem.2013 Oct 23, 61(42): 10074-9).
- GPR84 belongs to the group of Free Fatty Acid (FFA) receptors (Wang J. et al., J. Biol. Chem. 2006 Nov 10, 281(45): 34457-64).
- FFA receptors The group of FFA receptors consists of 4 GPCRs (FFA1-FFA2) and the new members GPR42 and GPR84.
- FFA receptors are involved in biological processes such as metabolic and immune function receptors (Wang J. et al., J. Biol. Chem.2006 Nov 10, 281(45): 34457-64).
- GPR84 has been described to be expressed primarily in various leukocyte populations and adipocytes (Wang J. et al., J. Biol. Chem.2006 Nov 10, 281(45): 34457-64; Lattin J.E. et al., Immunome Res. 2008 Apr 29, 4: 5; Nagasaki H.
- GPR84 promotes a comprehensive fibrotic and inflammatory cellular response, exerted by enhanced migration of macrophages and neutrophils, promoted pro-inflammatory M1 macrophage polarization and response and secretion of key inflammatory cytokines such as IL1beta and TNFalpha (Gagnon L. et al., Am. J. Pathol. 2018 May, 188(5): 1132-1148; Muredda L. et al., Arch. Physiol. Biochem. 2018 May, 124(2): 97-108; Huang Q. et al., Dev. Comp. Immunol.2014, 45(2): 252-258).
- IL1beta and TNFalpha key inflammatory cytokines
- GPR84 as microglia-associated protein is expressed in neuroinflammatory conditions and is described as a potential target for the treatment of multiple sclerosis (Bouchard C. et al., Glia 2007 Jun, 55(8): 790-800) and for endometriosis associated and inflammatory pain (Sacher F. et al.2018, Conference Abstract SRI 2018). Furthermore, inhibition of activity and/or the knockout of GPR84 are also effective in the treatment of neuropathic pain in several preclinical models (Roman et al. 2010, 7th Forum of European Neuroscience (FENS)).
- GPR84 for inflammatory kidney diseases has been shown in experiments using Gpr84-knockout mice or GPR84 antagonist in models of kidney fibrosis and models for inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases (Puengel et al.2018, 2018 International Liver Congress (ILC) of the European Association for the Study of the Liver (EASL); Thibodeau J.F. et al.2018, 51st Annual Meeting and Exposition of the American Society of Nephrology (ASN): Kidney Week 2018).
- inflammatory changes in adipose tissue enhance expression of GPR84 in adipocytes and modulation of GPR84 regulates adipocyte immune response capabilities (Muredda et al., Archives of Physiology and Biochemistry 2017 Aug, 124(2): 1-12) indicating the relevance of GPR84 in metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and polycystic ovary syndrome (PCOS) through normalization of adipose tissue inflammation.
- PCOS polycystic ovary syndrome
- GPR84 idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease
- lung diseases like asthma, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease
- GPR84 antagonists for example the patent applications WO2013092791 and WO2014095798 disclose dihydropyrimidinoisoquinolinones having activity as GPR84 antagonists. Such compounds find utility in several therapeutic applications including inflammatory conditions.
- the patent applications WO2015197550 and WO2016169911 disclose related dihydropyridoisoquinolinones as GPR84 antagonists.
- the patent application WO2018161831 discloses dibenzoannulen hydrogen phosphates as GPR84 antagonists.
- the patent application WO2009023773 discloses galactokinase inhibitors that were identified by a high throughput screening approach. Among the identified hits were two furoindazole compounds.
- the patent application US20090163545 discloses compounds for altering the lifespan of eukaryotic organisms that were identified by a cell-based phenotypic high throughput screening approach. Among the identified hits were two furoindazole compounds.
- the patent applications US6245796B1, WO2001083487 and WO2011071136 disclose aromatic tricyclic pyrrole or pyrazole derivatives as 5-HT2c ligands.
- the patent application WO2016085990 discloses compounds inhibiting serine hydroxy- methyltransferase 2 activity that were identified by a high throughput screening approach. Among the identified hits were nine furoindazole compounds.
- the patent application WO2019084271 discloses compounds inhibiting the non- canonical poly(A) RNA polymerase associated domain containing protein 5 (PAPD5) originating from diverse compound classes that were identified by a high throughput screening approach. Among the identified hits were eight furoindazole compounds.
- the compounds according to WO2021122415 have surprising and advantageous properties for the use in the treatment or prophylaxis of diseases, in particular of inflammatory-driven pain diseases such as neuropathic pain, more specifically for diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome.
- inflammatory-driven pain diseases such as neuropathic pain, more specifically for diseases like diabetic neuropathic pain, and chemotherapy induced pain
- post-breast surgery pain cancer bone pain
- trigeminal neuralgia post-mastectomy pain
- fibromyalgia multiple sclerosis pain
- post-herpetic neuralgia Fabry disease
- gout gout
- the present invention covers the use of compounds of general formula (I): in which: R 1 represents hydrogen, C 1 -C 4 -alkyl or C 1 -C 4 -haloalkyl; R 2 represents hydrogen, C 1 -C 4 -alkyl or C 1 -C 4 -haloalkyl; or R 1 and R 2 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl ring; R 3 represents C 3 -C 6 -cycloalkyl, 3- to 6-membered heterocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R 8 , or R 3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R 8 , and additionally R 7a and R 7b represent de
- substituted means that one or more hydrogen atoms on the designated atom or group are replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded. Combinations of substituents and/or variables are permissible.
- optionally substituted means that the number of substituents can be equal to or different from zero. Unless otherwise indicated, it is possible that optionally substituted groups are substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Commonly, it is possible for the number of optional substituents, when present, to be 1, 2, 3, 4, or 5, in particular 1, 2, or 3.
- the term “one or more”, e.g. in the definition of the substituents of the compounds of general formula (I) of the present invention, means 1, 2, 3, 4, or 5, particularly 1, 2, 3, or 4, more particularly 1, 2, or 3, even more particularly 1 or 2.
- an oxo substituent represents an oxygen atom, which is bound to a carbon atom via a double bond. Should a composite substituent be composed of more than one parts, e.g. (C 1 -C 4 -alkoxy)-(C 1 -C 4 -alkyl)-, it is possible for the position of a given part to be at any suitable position of said composite substituent, i.e.
- the C 1 -C 4 -alkoxy part can be attached to any carbon atom of the C 1 -C 4 -alkyl part of said (C 1 -C 4 -alkoxy)-(C 1 -C 4 -alkyl)- group.
- a hyphen at the beginning or at the end of such a composite substituent indicates the point of attachment of said composite substituent to the rest of the molecule.
- a ring comprising carbon atoms and optionally one or more heteroatoms, such as nitrogen, oxygen or sulphur atoms for example, be substituted with a substituent, it is possible for said substituent to be bound at any suitable position of said ring, be it bound to a suitable carbon atom and/or to a suitable heteroatom.
- halogen atom means a fluorine, chlorine, bromine or iodine atom, particularly a fluorine, chlorine or bromine atom.
- C 1 -C 4 -alkyl means a linear or branched, saturated, monovalent hydrocarbon group having 1, 2, 3, or 4 carbon atoms, e.g.
- said group has 1, 2, or 3 carbon atoms (“C 1 -C 3 -alkyl”), e.g. a methyl, ethyl, propyl, or isopropyl group, more particularly 1 or 2 carbon atoms (“C 1 -C 2 -alkyl”), e.g. a methyl or ethyl group.
- C 2 -C 4 -hydroxyalkyl means a linear or branched, saturated, monovalent hydrocarbon group in which the term “C 2 -C 4 -alkyl” is defined supra, and in which one hydrogen atom is replaced with a hydroxy group, e.g. a 1-hydroxyethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxypropan-2-yl, 2-hydroxypropan-2-yl, 3-hydroxy-2-methyl-propyl, 2-hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl group.
- a hydroxy group e.g. a 1-hydroxyethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxypropan-2-yl, 2-hydroxypropan-2-yl, 3-hydroxy-2-methyl-propyl, 2-hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl group.
- C 1 -C 4 -haloalkyl means a linear or branched, saturated, monovalent hydrocarbon group in which the term “C 1 -C 4 -alkyl” is as defined supra, and in which one or more of the hydrogen atoms are replaced, identically or differently, with a halogen atom. Particularly, said halogen atom is a fluorine atom.
- Said C 1 -C 4 -haloalkyl group is, for example, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl or 1,3-difluoropropan-2-yl.
- C 1 -C 4 -alkoxy means a linear or branched, saturated, monovalent group of formula (C 1 -C 4 -alkyl)-O-, in which the term “C 1 -C 4 -alkyl” is as defined supra, e.g.
- C 1 -C 4 -haloalkoxy means a linear or branched, saturated, monovalent C 1 -C 4 -alkoxy group, as defined supra, in which one or more of the hydrogen atoms is replaced, identically or differently, with a halogen atom.
- said halogen atom is a fluorine atom.
- Said C 1 -C 4 -haloalkoxy group is, for example, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy or pentafluoroethoxy.
- C 3 -C 6 -cycloalkyl means a saturated, monovalent, monocyclic hydrocarbon ring which contains 3, 4, 5, or 6 carbon atoms (“C 3 -C 6 -cycloalkyl”).
- Said C 3 -C 6 -cycloalkyl group is for example, e.g. a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl group.
- C 3 -C 6 -halocycloalkyl means a saturated, monovalent, monocyclic hydrocarbon ring in which the term “C 3 -C 6 -halocycloalkyl” is as defined supra, and in which one or more of the hydrogen atoms are replaced, identically or differently, with a halogen atom.
- said halogen atom is a fluorine atom.
- 4- to 6-membered heterocycloalkyl means a monocyclic, saturated heterocycle with 4, 5 or 6 ring atoms in total, which contains one or two identical or different ring heteroatoms from the series N, O and S, it being possible for said heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, a nitrogen atom.
- Said heterocycloalkyl group can be a 4-membered ring, such as azetidinyl, oxetanyl or thietanyl, for example; or a 5-membered ring, such as tetrahydrofuranyl, 1,3-dioxolanyl, thiolanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 1,1-dioxidothiolanyl, 1,2-oxazolidinyl, 1,3-oxazolidinyl or 1,3-thiazolidinyl, for example; or a 6-membered ring, such as tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, 1,3-dioxanyl, 1,4-dioxanyl or 1,2-
- “4- to 6-membered heterocycloalkyl” means a 4- to 6-membered heterocycloalkyl as defined supra containing one ring nitrogen or oxygen atom and optionally one further ring heteroatom from the series: N, O, S. More particularly, “5- or 6-membered heterocycloalkyl” means a monocyclic, saturated heterocycle with 5 or 6 ring atoms in total, containing one ring nitrogen or oxygen atom and optionally one further ring heteroatom from the series: N, O.
- heterocycloalkyl fused with phenyl or heteroaryl means a bicyclic heterocycle with 8, 9 or 10 ring atoms in total, in which the two rings share two adjacent ring atoms, and in which the “heterocycloalkyl” part contains one or two identical or different ring heteroatoms from the series: N, O and/or S
- heteroaryl means a monocyclic aromatic ring having 5 or 6 ring atoms (a “5- to 6-membered heteroaryl” group), which contains at least one ring heteroatom and optionally one, two or three further ring heteroatoms from the series N, O and/or S; it being possible for said fused heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, a nitrogen atom.
- heterospirocycloalkyl means a bicyclic, saturated heterocycle with 6, 7, 8, 9, 10 or 11 ring atoms in total, in which the two rings share one common ring carbon atom, which “heterospirocycloalkyl” contains one or two identical or different ring heteroatoms from the series: N, O, S; it being possible for said heterospirocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms, except the spiro carbon atom, or, if present, a nitrogen atom.
- Said heterospirocycloalkyl group is, for example, azaspiro[2.3]hexyl, azaspiro[3.3]heptyl, oxaazaspiro[3.3]heptyl, thiaazaspiro[3.3]heptyl, oxaspiro[3.3]heptyl, oxazaspiro[5.3]nonyl, oxazaspiro[4.3]octyl, azaspiro[4,5]decyl, oxazaspiro [5.5]undecyl, diazaspiro[3.3]heptyl, thiazaspiro[3.3]heptyl, thiazaspiro[4.3]octyl, azaspiro[5.5]undecyl, or one of the further homologous scaffolds such as spiro[3.4]-, spiro[4.4]-, spiro[2.4]-, spiro[2.5]-,
- heteroaryl means a monovalent, monocyclic, bicyclic or tricyclic aromatic ring having 5, 6, 8, 9, or 10 ring atoms (a “5- to 10-membered heteroaryl” group), particularly 5, 6, 9 or 10 ring atoms, which contains at least one ring heteroatom and optionally one, two or three further ring heteroatoms from the series: N, O and/or S, and which is bound via a ring carbon atom or optionally via a ring nitrogen atom (if allowed by valency).
- Said heteroaryl group can be a 5-membered heteroaryl group, such as, for example, thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl or tetrazolyl; or a 6-membered heteroaryl group, such as, for example, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl; or a tricyclic heteroaryl group, such as, for example, carbazolyl, acridinyl or phenazinyl; or a 9- membered heteroaryl group, such as, for example, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl,
- the heteroaryl groups include all possible isomeric forms thereof, e.g.: tautomers and positional isomers with respect to the point of linkage to the rest of the molecule.
- the term pyridinyl includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl; or the term thienyl includes thien-2-yl and thien-3-yl.
- the heteroaryl group is a pyridinyl group.
- C 1 -C 6 -alkyl in the context of the definition of “C 1 -C 6 -alkyl”, “C 1 -C 6 -haloalkyl”, “C 1 -C 6 -hydroxyalkyl”, “C 1 -C 6 -alkoxy” or “C 1 -C 6 -haloalkoxy” means an alkyl group having a finite number of carbon atoms of 1 to 6, i.e.1, 2, 3, 4, 5 or 6 carbon atoms.
- C 3 -C 8 as used in the present text, e.g.
- C 3 -C 8 -cycloalkyl in the context of the definition of “C 3 -C 8 -cycloalkyl”, means a cycloalkyl group having a finite number of carbon atoms of 3 to 8, i.e.3, 4, 5, 6, 7 or 8 carbon atoms. When a range of values is given, said range encompasses each value and sub-range within said range.
- C 1 -C 6 encompasses C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1 -C 6 , C 1 -C 5 , C 1 -C 4 , C 1 -C 3 , C 1 -C 2 , C 2 -C 6 , C 2 - C 5 , C 2 -C 4 , C 2 -C 3 , C 3 -C 6 , C 3 -C 5 , C 3 - C 4 , C 4 -C 6 , C 4 -C 5 , and C 5 -C 6 ;
- C 2 -C 6 encompasses C 2 , C 3 , C 4 , C 5 , C 6 , C 2 -C 6 , C 2 -C 5 , C 2 -C 4 , C 2 -C 3 , C 3 -C 6 , C 3 -C 5 , C 3 -C 4 , C 4 -C 6 , C 4 -C
- the term “leaving group” means an atom or a group of atoms that is displaced in a chemical reaction as stable species taking with it the bonding electrons.
- a leaving group is selected from the group comprising: halide, in particular fluoride, chloride, bromide or iodide, (methylsulfonyl)oxy, [(trifluoromethyl)sulfonyl]oxy, [(nonafluorobutyl)sulfonyl]oxy, (phenylsulfonyl)oxy, [(4-methylphenyl)sulfonyl]oxy, [(4-bromophenyl)sulfonyl]oxy, [(4-nitrophenyl)sulfonyl]oxy, [(2-nitrophenyl)sulfonyl]oxy, [(4-isopropylphenyl)sulfonyl]oxy, [(2,4,6-triisopropylphen
- the invention therefore includes the use of one or more isotopic variant(s) of the compounds of general formula (I), particularly deuterium-containing compounds of general formula (I).
- the term “Isotopic variant” of a compound or a reagent is defined as a compound exhibiting an unnatural proportion of one or more of the isotopes that constitute such a compound.
- the term “Isotopic variant of the compound of general formula (I)” is defined as a compound of general formula (I) exhibiting an unnatural proportion of one or more of the isotopes that constitute such a compound.
- the expression “unnatural proportion” means a proportion of such isotope which is higher than its natural abundance.
- isotopes to be applied in this context are described in “Isotopic Compositions of the Elements 1997”, Pure Appl. Chem., 70(1), 217-235, 1998.
- isotopes include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2 H (deuterium), 3 H (tritium), 11 C, 13 C, 14 C, 15 N, 17 O, 18 O, 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl, 82 Br, 123 I, 124 I, 125 I, 129 I and 131 I, respectively.
- the isotopic variant(s) of the compounds of general formula (I) preferably contain deuterium (“deuterium-containing compounds of general formula (I)”).
- deuterium-containing compounds of general formula (I) Isotopic variants of the compounds of general formula (I) in which one or more radioactive isotopes, such as 3 H or 14 C, are incorporated are useful e.g. in drug and/or substrate tissue distribution studies. These isotopes are particularly preferred for the ease of their incorporation and detectability.
- Positron emitting isotopes such as 18 F or 11 C may be incorporated into a compound of general formula (I). These isotopic variants of the compounds of general formula (I) are useful for in vivo imaging applications.
- Deuterium-containing and 13 C- containing compounds of general formula (I) can be used in mass spectrometry analyses in the context of preclinical or clinical studies.
- Isotopic variants of the compounds of general formula (I) can generally be prepared by methods known to a person skilled in the art, such as those described in the schemes and/or examples herein, by substituting a reagent for an isotopic variant of said reagent, preferably for a deuterium-containing reagent.
- a reagent for an isotopic variant of said reagent preferably for a deuterium-containing reagent.
- deuterium from D2O can be incorporated either directly into the compounds or into reagents that are useful for synthesizing such compounds.
- Deuterium gas is also a useful reagent for incorporating deuterium into molecules.
- Catalytic deuteration of olefinic bonds and acetylenic bonds is a rapid route for incorporation of deuterium.
- Metal catalysts i.e. Pd, Pt, and Rh
- Pd, Pt, and Rh metal catalysts in the presence of deuterium gas can be used to directly exchange deuterium for hydrogen in functional groups containing hydrocarbons.
- a variety of deuterated reagents and synthetic building blocks are commercially available from companies such as for example C/D/N Isotopes, Quebec, Canada; Cambridge Isotope Laboratories Inc., Andover, MA, USA; and CombiPhos Catalysts, Inc., Princeton, NJ, USA.
- deuterium-containing compound of general formula (I) is defined as a compound of general formula (I), in which one or more hydrogen atom(s) is/are replaced by one or more deuterium atom(s) and in which the abundance of deuterium at each deuterated position of the compound of general formula (I) is higher than the natural abundance of deuterium, which is about 0.015%. Particularly, in a deuterium-containing compound of general formula (I) the abundance of deuterium at each deuterated position of the compound of general formula (I) is higher than 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80%, preferably higher than 90%, 95%, 96% or 97%, even more preferably higher than 98% or 99% at said position(s).
- the abundance of deuterium at each deuterated position is independent of the abundance of deuterium at other deuterated position(s).
- the selective incorporation of one or more deuterium atom(s) into a compound of general formula (I) may alter the physicochemical properties (such as for example acidity [C. L. Perrin, et al., J. Am. Chem. Soc., 2007, 129, 4490], basicity [C. L. Perrin et al., J. Am. Chem. Soc., 2005, 127, 9641], lipophilicity [B. Testa et al., Int. J.
- deuterium substitution reduces or eliminates the formation of an undesired or toxic metabolite and enhances the formation of a desired metabolite (e.g. Nevirapine: A. M. Sharma et al., Chem. Res. Toxicol., 2013, 26, 410; Efavirenz: A. E. Mutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102).
- the major effect of deuteration is to reduce the rate of systemic clearance. As a result, the biological half-life of the compound is increased.
- the potential clinical benefits would include the ability to maintain similar systemic exposure with decreased peak levels and increased trough levels.
- Deuterated drugs showing this effect may have reduced dosing requirements (e.g. lower number of doses or lower dosage to achieve the desired effect) and/or may produce lower metabolite loads.
- a compound of general formula (I) may have multiple potential sites of attack for metabolism. To optimize the above-described effects on physicochemical properties and metabolic profile, deuterium-containing compounds of general formula (I) having a certain pattern of one or more deuterium-hydrogen exchange(s) can be selected.
- the deuterium atom(s) of deuterium-containing compound(s) of general formula (I) is/are attached to a carbon atom and/or is/are located at those positions of the compound of general formula (I), which are sites of attack for metabolizing enzymes such as e.g. cytochrome P450.
- metabolizing enzymes such as e.g. cytochrome P450.
- the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like, is used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate or the like.
- stable compound' or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
- the compounds intended for the use according to the present invention optionally contain one or more asymmetric centres, depending upon the location and nature of the various substituents desired. It is possible that one or more asymmetric carbon atoms are present in the (R) or (S) configuration, which can result in racemic mixtures in the case of a single asymmetric centre, and in diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, it is possible that asymmetry also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds. Preferred compounds are those which produce the more desirable biological activity.
- Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of the present invention are also included within the scope of the present invention.
- the purification and the separation of such materials can be accomplished by standard techniques known in the art.
- Preferred isomers are those which produce the more desirable biological activity.
- These separated, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention.
- the purification and the separation of such materials can be accomplished by standard techniques known in the art.
- the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers.
- Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid.
- Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation.
- the optically active bases or acids are then liberated from the separated diastereomeric salts.
- a different process for separation of optical isomers involves the use of chiral chromatography (e.g., HPLC columns using a chiral phase), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers.
- Suitable HPLC columns using a chiral phase are commercially available, such as those manufactured by Daicel, e.g., Chiracel OD and Chiracel OJ, for example, among many others, which are all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful.
- the optically active compounds of the present invention can likewise be obtained by chiral syntheses utilizing optically active starting materials. In order to distinguish different types of isomers from each other reference is made to IUPAC Rules Section E (Pure Appl Chem 45, 11-30, 1976).
- the compounds intended for the use according to the present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g.
- the compounds intended for the use according to the present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio.
- the compounds intended for the use according to the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised.
- the present invention includes all such possible N-oxides.
- the present invention also covers the use of useful forms of the compounds, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and/or co-precipitates.
- the compounds intended for the use according to the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example, as structural element of the crystal lattice of the compounds. It is possible for the amount of polar solvents, in particular water, to exist in a stoichiometric or non-stoichiometric ratio.
- polar solvents in particular water
- stoichiometric solvates e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible.
- the present invention includes all such hydrates or solvates.
- the compounds intended for the use according to the present invention may exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or to exist in the form of a salt.
- Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, which is customarily used in pharmacy, or which is used, for example, for isolating or purifying the compounds of the present invention.
- pharmaceutically acceptable salt refers to an inorganic or organic acid addition salt of a compound of the present invention.
- pharmaceutically acceptable salt refers to an inorganic or organic acid addition salt of a compound of the present invention.
- S. M. Berge, et al. “Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19.
- a suitable pharmaceutically acceptable salt of the compounds intended for the use according tothe present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, or “mineral acid”, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfamic, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphtho
- an alkali metal salt for example a sodium or potassium salt
- an alkaline earth metal salt for example a calcium, magnesium or strontium salt, or an aluminium or a zinc salt
- acid addition salts of the claimed compounds to be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
- alkali and alkaline earth metal salts of acidic compounds of the present invention are prepared by reacting the compounds of the present invention with the appropriate base via a variety of known methods.
- the present invention includes the use of all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio.
- the present invention includes all possible crystalline forms, or polymorphs, of the compounds intended for the use according to the present invention, either as single polymorph, or as a mixture of more than one polymorph, in any ratio.
- the compounds intended for the use according to the present invention also include prodrugs of the compounds.
- prodrugs here designates compounds which themselves can be biologically active or inactive but are converted (for example metabolically or hydrolytically) into compounds according to the invention during their residence time in the body.
- the present invention covers the use of compounds of general formula (I), supra, in which: R 1 represents hydrogen, C 1 -C 4 -alkyl or C 1 -C 4 -haloalkyl; R 2 represents hydrogen, C 1 -C 4 -alkyl or C 1 -C 4 -haloalkyl; or R 1 and R 2 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl ring; R 3 represents C 3 -C 6 -cycloalkyl, 3- to 6-membered heterocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R 8 , or R 3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R 8 , and additionally R 7a and R 7b represent
- the present invention covers the use of compounds of general formula (I), supra, in which: R 1 represents hydrogen, C 1 -C 4 -alkyl or C 1 -C 4 -haloalkyl; R 2 represents hydrogen or C 1 -C 4 -alkyl; or R 1 and R 2 together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl or heterocycloalkyl ring; R 3 represents C 3 -C 6 -cycloalkyl, 4- to 6-membered heterocycloalkyl, heterocycloalkyl fused with heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R 8 , or R 3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R 8 , and additionally R 7a and R 7b represent deuterium; R 4 represents hydrogen, C 1 -C 4 -alkyl or C 1 -C 4 -halo
- the present invention covers the use of compounds of general formula (I), supra, in which: R 1 represents hydrogen, methyl or trifluoromethyl; R 2 represents hydrogen or methyl; or R 1 and R 2 together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; R 3 represents cyclopropyl, 4- to 6-membered heterocycloalkyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R 8 , or R 3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R 8 , and additionally R 7a and R 7b represent deuterium; R 4 represents hydrogen, methyl, C 1 -haloalkyl or cyclopropyl; R 5 represents hydrogen; R 6 represents methoxy-ethyl
- the present invention covers the use of compounds of general formula (I), supra, in which: R 1 represents hydrogen or methyl; R 2 represents hydrogen or methyl; or R 1 and R 2 together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; R 3 represents cyclopropyl, 2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, oxetan-3-yl, oxolan-3-yl, oxolan-2-yl, 3-methyloxetan-3-yl, 3-fluorooxetan-3-yl, pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, oxan-4-yl, 1,4-dioxan-2-yl, 6-methylpyridin-3-yl, 5- methylpyridin-2-yl, 3-methylpyridin
- R 3 represents phenyl, and additionally R 7a and R 7b represent deuterium;
- R 4 represents methyl, difluoromethyl, trifluoromethyl, or cyclopropyl;
- R 5 represents hydrogen;
- R 6 represents (oxolan-2-yl)methyl, (1,3-oxazol-4-yl)methyl, (1,2-oxazol-3-yl)methyl, (4-methyloxolan-2-yl)methyl, (pyrimidin-2-yl)methyl, (pyrazin-2-yl)methyl, (5- methyloxolan-2-yl)methyl, (5-methyloxolan-2-yl)methyl, (1,4-dioxan-2-yl)methyl, (4-methylphenyl)methyl, (5-methylpyrimidin-2-yl)methyl, (5-methylpyrazin-2- yl)methyl, (5-chloropyrazin-2-yl)methyl, (5-cyclopropyl-pyrazin-2-yl)methyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2
- the invention refers to the use of one of the following compounds: 1 2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 2 8-methyl-N-[(4-methylphenyl)methyl]-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 3 8-methyl-2-(pyridin-2-ylmethyl)-N-[(2R/S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 3 8-methyl-2-(pyridin-2-ylmethyl)-N-[(2R)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,
- the invention refers to the use of (4R)-N-[(5-cyclopropylpyrazin-2- yl)methyl]-2- ⁇ [(2S)-1,4-dioxan-2-yl]methyl ⁇ -4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide for the treatment or prophylaxis of diseases, in particular of inflammatory-driven pain diseases such as neuropathic pain, more specifically for diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome.
- inflammatory-driven pain diseases such as neuropathic pain, more specifically for diseases like diabetic neuropathic pain, and chemotherapy induced pain
- the compounds of general formula (I) can be prepared according to the schemes 1, 2, 3, and 4 according to WO2021122415 page 40, 43, 45, and 47 which are incorporated herein as a reference and are part of the present application. Furthermore, the preparation of the compounds of general formula (I) according to WO2021122415, reported on page 39, line 21 to page 47, line 11 is also incorporated herein as a reference and is part of the present application. Compounds of general formula (I) demonstrate a valuable pharmacological spectrum of action which could not have been predicted.
- Compounds of the present invention have surprisingly been found to be effective antagonists of GPR84 and it is possible therefore that said compounds be used for the treatment or prophylaxis of diseases, in particular of inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome.
- Compounds of general formula (I) can be utilized to inhibit, antagonize, block, reduce, decrease GPR84 signal transduction, activity and cellular function.
- This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of general formula (I), or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof; which is effective to treat the disorder.
- a mammal in need thereof, including a human, an amount of a compound of general formula (I), or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof; which is effective to treat the disorder.
- inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome in humans and animals.
- treating or “treatment” as used in the present text is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of a disease or disorder, such as PCOS or IPF.
- the present invention covers the use of a compound of formula (I), described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the prophylaxis or treatment of diseases, in particular of inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post- mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome in humans and animals.
- diseases in particular of inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post- mastectomy pain, fibromy
- the compounds of general formula (I) can have systemic and/or local activity.
- they can be administered in a suitable manner, such as, for example, via the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, otic route or as an implant or stent.
- a suitable manner such as, for example, via the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, otic route or as an implant or stent.
- the compounds of general formula (I) can be administered in suitable administration forms.
- the compounds intended for the use according to the invention for oral administration, it is possible to formulate the compounds intended for the use according to the invention to dosage forms known in the art that deliver the compounds rapidly and/or in a modified manner, such as, for example, tablets (uncoated or coated tablets, for example with enteric or controlled release coatings that dissolve with a delay or are insoluble), orally-disintegrating tablets, films/wafers, films/lyophilizates, capsules (for example hard or soft gelatine capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. It is possible to incorporate the compounds intended for the use according to the invention in crystalline and/or amorphized and/or dissolved form into said dosage forms.
- Parenteral administration can be effected with avoidance of an absorption step (for example intravenous, intraarterial, intracardial, intraspinal or intralumbal) or with inclusion of absorption (for example intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal).
- absorption step for example intravenous, intraarterial, intracardial, intraspinal or intralumbal
- absorption for example intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal.
- Administration forms which are suitable for parenteral administration are, inter alia, preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilizates or sterile powders.
- Examples which are suitable for other administration routes are pharmaceutical forms for inhalation [inter alia powder inhalers, nebulizers], nasal drops, nasal solutions, nasal sprays; tablets/films/wafers/capsules for lingual, sublingual or buccal administration; suppositories; eye drops, eye ointments, eye baths, ocular inserts, ear drops, ear sprays, ear powders, ear-rinses, ear tampons; vaginal capsules, aqueous suspensions (lotions, mixturae agitandae), lipophilic suspensions, emulsions, ointments, creams, transdermal therapeutic systems (such as, for example, patches), milk, pastes, foams, dusting powders, implants or stents.
- inhalation inter alia powder inhalers, nebulizers
- nasal drops nasal solutions, nasal sprays
- tablets/films/wafers/capsules for lingual, sublingual or buccal
- compositions of general formula (I) can be incorporated into the stated administration forms. This can be effected in a manner known per se by mixing with pharmaceutically suitable excipients.
- Pharmaceutically suitable excipients include, inter alia, • fillers and carriers (for example cellulose, microcrystalline cellulose (such as, for example, Avicel ® ), lactose, mannitol, starch, calcium phosphate (such as, for example, Di-Cafos ® )), • ointment bases (for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols), • bases for suppositories (for example polyethylene glycols, cacao butter, hard fat), • solvents (for example water, ethanol, isopropanol, glycerol, propylene glycol, medium chain-length triglycerides fatty oils, liquid polyethylene glycols, paraffin
- the present invention furthermore relates to a pharmaceutical composition which comprise at least one compound according to the invention, conventionally together with one or more pharmaceutically suitable excipient(s), and to their use according to the present invention.
- a pharmaceutical composition which comprise at least one compound according to the invention, conventionally together with one or more pharmaceutically suitable excipient(s), and to their use according to the present invention.
- the synthesis of the compounds 1 to 323, the required intermediates for said synthesis and the methods for their identification were described in the patent application WO2021122415, Experimental section, page 58 to 479 which is incorporated herein as a reference and is part of the present application.
- the compounds 1 to 323 are numbered in accordance with the examples described in WO2021122415 and in case of stereoisomers one single example number was assigned.
- cAMP HTRF® Assay for identification of cellular GPR84 antagonists
- HTRF® Homogenous Time-Resolved Fluorescence
- CHO-K1 cells stably expressing human GPR84 receptor purchased from DiscoveRx, now Eurofins were used and treated with Forskolin (F6886, Sigma, Germany) to stimulate membrane adenylyl cyclases and thereby unspecific cAMP formation.
- Activation of the Gi-coupled GPR84 by a natural or small molecule agonist results in inhibition of cellular cAMP formation which can be released again by antagonists to this receptor.
- Detection and quantification of cellular cAMP levels in this HTRF assay is achieved by interaction between a fluorescent cAMP tracer (cAMP-d2) and an Eu-cryptate labelled anti-cAMP antibody. Following excitation at 337 nm this pairing allows for the generation of a fluorescence resonance energy transfer (FRET) between the partners and results in FRET induced emissions at 665 nm and 620 nm, the latter representing background signal by Eu- cryptate labelled anti-cAMP antibody.
- FRET fluorescence resonance energy transfer
- CHO-K1 cells expressing hGPR84 prepared by acCELLerate, Hamburg, Germany
- cell suspension (1.67E+06 cells/mL) in assay media (Ham’s F12 Nutrient Mix, Thermo Fisher Scientific, Waltham, USA; 5% fetal calf serum, Biomol, Hamburg, Germany) containing cAMP-d2 (dilution 1:20, supplied with the kit #62AM5PEJ, Cisbio, Condolet, France) was prepared.
- 3 ⁇ L/well cell suspension including cAMP-d2 were added to a pre-dispensed assay plate (Greiner Bio-One, Kremsmuenster, Austria) containing 50nl/well test compound in 100% DMSO or 100% DMSO as control. This was followed by a 30 minutes incubation step at room temperature. The stimulation time was started by addition of 2 ⁇ L/well assay media containing 2.5xEC 80 agonist 6-OAU and 2.5xEC 9 0 Forskolin (negative control: 2.5xEC 90 Forskolin in assay media) and was continued for 30 minutes at room temperature.
- cAMP Eu-Cryptate antibody (dilution 1:20) (both supplied with the kit #62AM5PEJ, Cisbio, Condolet, France).
- cAMP Eu-Cryptate antibody both supplied with the kit #62AM5PEJ, Cisbio, Condolet, France.
- plates were incubated for 60 minutes at room temperature before measurement in an HTRF reader, e.g. a PHERAstar (BMG Labtech, Ortenberg, Germany).
- Example GPR84 IC 50 [ ⁇ M] Example GPR84 IC 50 [ ⁇ M] Table 6 (continued)
- Example GPR84 IC 50 [ ⁇ M] Example GPR84 IC 50 [ ⁇ M] 53 0.032 80 0.057 Table 6 (continued)
- Example GPR84 IC 50 [ ⁇ M] Example GPR84 IC 50 [ ⁇ M] 113 0.091 146 0.047 Table 6 (continued)
- Example GPR84 IC 50 [ ⁇ M] Example GPR84 IC 50 [ ⁇ M] 179 6.41 216 0.006 Table 6 (continued)
- Example GPR84 IC 50 [ ⁇ M] Example GPR84 IC 50 [ ⁇ M] 246 0.075 273 0.009 Table 6 (continued)
- Example GPR84 IC 50 [ ⁇ M] 306 0.027 The suitability of the compounds of general formula (I) for the treatment pain disorders can be demonstrated in the following animal models
- Example 3-2 Efficacy of GPR84 antagonist in the rat DHT-PCOS model
- In vivo assay 2 Effects of Example 3-2 in the CFA pain model The efficacy of Example 3-2 in vivo on inflammatory pain was measured in inflamed paws after administration of complete Freund’s adjuvant (CFA) (24 h) in the dynamic weight- bearing (DWB) model. The effects of repeated preventive treatment with Example 3-2 on pain following repeated oral administration (3x) in the mouse CFA model of inflammation were investigated using a preventive setting.
- Example 3-2 (20 or 60 mg/kg, 3x doses) was administered 2 h before injection of CFA and 6-8 h later at day 0. At 24 h after CFA application, the third dose of Example 3-2 was given 2 h before DWB testing. Statistical analysis was performed with one-way analysis of variance, followed by Bonferroni’s multiple comparison test against vehicle control groups using the GraphPad PRISM software, *p ⁇ 0.05.
- Table 8 Effects of GPR84 antagonist in the CFA pain model
- In vivo assay 3 Effects in the Oxaliplatin induced pain model
- the efficacy of example 320 in vivo on chemotherapy (Oxaliplatin; OPNP) induced pain was measured in a rat Oxaliplatin-induced 6 weeks neuropathic pain model.
- the GPR84 antagonist example 320 was administered with the first application at d1.
- Rats were habituated to the circumstances for 30 min before starting with behavioral test.
- von Frey test was conducted on all animals for baseline measurement.
- paw withdrawal thresholds was measured by applying the von Frey filaments (with ascending weights; 0.4, 0.6, 1.4, 2, 4, 6, 8, 15 g) on the center of the right hind paw.
- Von Frey tests were conducted prior to test article administration (baseline) and once per week, 1 hr, 2 hr and 4 hr post dosing until the end of the experiment.
- Statistical analysis was performed with one-way analysis of variance, followed by Dunnett multiple comparison test against vehicle control group using the GraphPad PRISM software, *p ⁇ 0.05.
- Table 9 Effects of GPR84 antagonist in Oxaliplatin induced pain model Example mg/kg/d Threshold to von Frey Stimulation (g) on day 28 E l 10
- In vivo assay 4 Effects in the Streptozotocin (STZ)-induced diabetic neuropathic pain model The efficacy of example 320 in vivo on diabetic neuropathic pain was studied in the Streptozotocin (STZ)-induced neuropathic pain model. Diabetes was induced in Sprague Dawley male rats by dosing of Streptozotocin (STZ, 60 mg/kg) on study day 0. The development of diabetes was confirmed by the measurement of blood glucose levels on study day 3.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention covers the use of furoindazole compounds of general formula (I): (I) in which R1, R2, R3, R4, R5, R6, R7a, and R7b are as defined herein, for the treatment or prophylaxis of diseases, in particular of inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post- mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome in humans and animals.
Description
USE OF FUROINDAZOLE DERIVATIVES The present invention covers the use of furoindazole compounds of general formula (I) as described and defined herein, for the treatment or prophylaxis of diseases in particular of inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome in humans and animals. BACKGROUND The furoindazole compounds of general formula (I) are antagonists of the G-protein coupled receptor 84 (also known as GPR84). The relevance of GPR84 for human disease has been described and studied in several publications. Medium-chain free fatty acids (MCFFAs) are fatty acids with tails of 6 to 12 carbons and can activate GPR84 (Wang J et al., J. Biol. Chem. 2006 Nov 10, 281(45): 34457-64). There are two sources of FAs for animal metabolism, exogenously-derived (dietary) FAs and endogenously-synthesized FAs. The biosynthesis of the latter is catalysed by FASN. MCFFAs stimulate release of IL6 from fibroblasts (Smith and Tasi, Nat. Prod. Rep.2007 Oct, 24(5): 1041-72) and myristic acid increases IL6 and IL8 levels in human coronary arterial smooth muscle (HCASM) and endothelial (HCEC) cells (Soto-Vaca A. et al., J. Agric. Food Chem.2013 Oct 23, 61(42): 10074-9). GPR84 belongs to the group of Free Fatty Acid (FFA) receptors (Wang J. et al., J. Biol. Chem. 2006 Nov 10, 281(45): 34457-64). The group of FFA receptors consists of 4 GPCRs (FFA1-FFA2) and the new members GPR42 and GPR84. FFA receptors are involved in biological processes such as metabolic and immune function receptors (Wang J. et al., J. Biol. Chem.2006 Nov 10, 281(45): 34457-64). In contrast to all other FFA receptors which have a broader expression pattern, GPR84 has been described to be expressed primarily in various leukocyte populations and adipocytes (Wang J. et al., J. Biol. Chem.2006 Nov 10, 281(45): 34457-64; Lattin J.E. et al., Immunome Res. 2008 Apr 29, 4: 5; Nagasaki H. et al., FEBS Lett. 2012 Feb 17, 586(4): 368-72).
Activation of GPR84 promotes a comprehensive fibrotic and inflammatory cellular response, exerted by enhanced migration of macrophages and neutrophils, promoted pro-inflammatory M1 macrophage polarization and response and secretion of key inflammatory cytokines such as IL1beta and TNFalpha (Gagnon L. et al., Am. J. Pathol. 2018 May, 188(5): 1132-1148; Muredda L. et al., Arch. Physiol. Biochem. 2018 May, 124(2): 97-108; Huang Q. et al., Dev. Comp. Immunol.2014, 45(2): 252-258). Based on the involvement of GPR84 in fibrotic and inflammatory cellular response several diseases have been suggested to be GPR84 dependent. GPR84 as microglia-associated protein is expressed in neuroinflammatory conditions and is described as a potential target for the treatment of multiple sclerosis (Bouchard C. et al., Glia 2007 Jun, 55(8): 790-800) and for endometriosis associated and inflammatory pain (Sacher F. et al.2018, Conference Abstract SRI 2018). Furthermore, inhibition of activity and/or the knockout of GPR84 are also effective in the treatment of neuropathic pain in several preclinical models (Roman et al. 2010, 7th Forum of European Neuroscience (FENS)). The relevance of GPR84 for inflammatory kidney diseases has been shown in experiments using Gpr84-knockout mice or GPR84 antagonist in models of kidney fibrosis and models for inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases (Puengel et al.2018, 2018 International Liver Congress (ILC) of the European Association for the Study of the Liver (EASL); Thibodeau J.F. et al.2018, 51st Annual Meeting and Exposition of the American Society of Nephrology (ASN): Kidney Week 2018). As described previously for macrophages and monocytes, inflammatory changes in adipose tissue enhance expression of GPR84 in adipocytes and modulation of GPR84 regulates adipocyte immune response capabilities (Muredda et al., Archives of Physiology and Biochemistry 2017 Aug, 124(2): 1-12) indicating the relevance of GPR84 in metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and polycystic ovary syndrome (PCOS) through normalization of adipose tissue inflammation. Regulation of neutrophil activity and general inflammation by GPR84 was also described to be relevant for lung diseases like asthma, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease (Nguyen et al.2018; Annual Congress Scientific Sessions of the American Heart Association (AHA 2018); Saniere L. et al.2019; 2019 International Conference of the American Thoracic Society (ATS)).
Few compounds are known as GPR84 antagonists, for example the patent applications WO2013092791 and WO2014095798 disclose dihydropyrimidinoisoquinolinones having activity as GPR84 antagonists. Such compounds find utility in several therapeutic applications including inflammatory conditions. The patent applications WO2015197550 and WO2016169911 disclose related dihydropyridoisoquinolinones as GPR84 antagonists. The patent application WO2018161831 discloses dibenzoannulen hydrogen phosphates as GPR84 antagonists. The patent application WO2009023773 discloses galactokinase inhibitors that were identified by a high throughput screening approach. Among the identified hits were two furoindazole compounds. The patent application US20090163545 discloses compounds for altering the lifespan of eukaryotic organisms that were identified by a cell-based phenotypic high throughput screening approach. Among the identified hits were two furoindazole compounds. The patent applications US6245796B1, WO2001083487 and WO2011071136 disclose aromatic tricyclic pyrrole or pyrazole derivatives as 5-HT2c ligands. The patent application WO2016085990 discloses compounds inhibiting serine hydroxy- methyltransferase 2 activity that were identified by a high throughput screening approach. Among the identified hits were nine furoindazole compounds. The patent application WO2019084271 discloses compounds inhibiting the non- canonical poly(A) RNA polymerase associated domain containing protein 5 (PAPD5) originating from diverse compound classes that were identified by a high throughput screening approach. Among the identified hits were eight furoindazole compounds. The patent application WO2021122415 discloses furoindazole compounds intended for the use according to the present invention. However, the state of the art does not describe the use of the furoindazole compounds of general formula (I) according to WO2021122415 as described and defined herein. It has now been found, and this constitutes the basis of the present invention, that the compounds according to WO2021122415 have surprising and advantageous properties for the use in the treatment or prophylaxis of diseases, in particular of inflammatory-driven pain diseases such as neuropathic pain, more specifically for diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer
bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome. DESCRIPTION In accordance with a first aspect, the present invention covers the use of compounds of general formula (I): in which:
R1 represents hydrogen, C1-C4-alkyl or C1-C4-haloalkyl; R2 represents hydrogen, C1-C4-alkyl or C1-C4-haloalkyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl ring; R3 represents C3-C6-cycloalkyl, 3- to 6-membered heterocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R8, or R3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R8, and additionally R7a and R7b represent deuterium; R4 represents hydrogen, C1-C4-alkyl, C1-C4-haloalkyl or C3-C6-cycloalkyl; R5, R6 represent, independently of each other, hydrogen, C1-C4-alkyl, C2-C4-hydroxyalkyl, (C1-C4-alkoxy)-( C2-C4-alkyl)-, C3-C6-cycloalkyl, C1-C4-haloalkyl, C3-C6-halocycloalkyl, 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, phenyl, heteroaryl, heterocycloalkyl fused with phenyl or heteroaryl, 3- to 6-membered heterocycloalkyl-(C1-C3-alkyl)-, heterospirocycloalkyl-(C1-C3-alkyl)-, (heterocycloalkyl fused with phenyl or
heteroaryl)-(C1-C3-alkyl)-, phenyl-(C1-C3-alkyl)- or heteroaryl-(C1-C3-alkyl)-, wherein said 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, phenyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R9, or R5 and R6 together with the nitrogen atom to which they are attached form a 3- to 6-membered nitrogen containing heterocyclic ring, optionally containing one additional heteroatom or heteroatom containing group selected from O, NH and S, and which may be optionally substituted, one or more times, independently of each other, with R9; R7a represents hydrogen, deuterium, or C1-C4-alkyl; R7b represents hydrogen, deuterium, or C1-C4-alkyl; R8 represents halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkyl-(C1-C3-alkyl)-, R13-(C=O)-, R10-O-(C=O)-, R11-NH-(C=O)-, or R12-(SO2)-; R9 represents halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, H2N-C1-C4-alkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, C3-C6-cycloalkyl, R10-O-(C=O)-, oxo, 5- to 6- membered heterocycloalkyl-, 5- to 6-membered heterocycloalkyl-(C1-C3-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C3-alkoxy, or C1-C3-haloalkoxy; R10 represents hydrogen, C1-C4-alkyl, or phenyl-CH2-; R11 represents hydrogen, C1-C4-alkyl, or 5- to 6-membered heterocycloalkyl-(C1-C3-alkyl)-; R12 represents C1-C4-alkyl or phenyl; R13 represents C1-C4-alkyl, C1-C4-haloalkyl, (C1-C4-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkyl-(C=O)-, C3-C6-cycloalkyl, or phenyl, wherein said C3-C6-cycloalkyl group is optionally substituted with C1-C4-alkyl or hydroxy and said phenyl group is optionally substituted, one or more times, independently of each other, with halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C3-alkoxy, or C1-C3-haloalkoxy; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, for the treatment or prophylaxis of diseases.
DEFINITIONS The term “substituted” means that one or more hydrogen atoms on the designated atom or group are replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded. Combinations of substituents and/or variables are permissible. The term “optionally substituted” means that the number of substituents can be equal to or different from zero. Unless otherwise indicated, it is possible that optionally substituted groups are substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Commonly, it is possible for the number of optional substituents, when present, to be 1, 2, 3, 4, or 5, in particular 1, 2, or 3. As used herein, the term “one or more”, e.g. in the definition of the substituents of the compounds of general formula (I) of the present invention, means 1, 2, 3, 4, or 5, particularly 1, 2, 3, or 4, more particularly 1, 2, or 3, even more particularly 1 or 2. As used herein, an oxo substituent represents an oxygen atom, which is bound to a carbon atom via a double bond. Should a composite substituent be composed of more than one parts, e.g. (C1-C4-alkoxy)-(C1-C4-alkyl)-, it is possible for the position of a given part to be at any suitable position of said composite substituent, i.e. the C1-C4-alkoxy part can be attached to any carbon atom of the C1-C4-alkyl part of said (C1-C4-alkoxy)-(C1-C4-alkyl)- group. A hyphen at the beginning or at the end of such a composite substituent indicates the point of attachment of said composite substituent to the rest of the molecule. Should a ring, comprising carbon atoms and optionally one or more heteroatoms, such as nitrogen, oxygen or sulphur atoms for example, be substituted with a substituent, it is possible for said substituent to be bound at any suitable position of said ring, be it bound to a suitable carbon atom and/or to a suitable heteroatom. The term “comprising” when used in the specification includes “consisting of”. If within the present text any item is referred to as “as mentioned herein”, it means that it may be mentioned anywhere in the present text. The terms as mentioned in the present text have the following meanings: The term “halogen atom” means a fluorine, chlorine, bromine or iodine atom, particularly a fluorine, chlorine or bromine atom.
The term C1-C4-alkyl means a linear or branched, saturated, monovalent hydrocarbon group having 1, 2, 3, or 4 carbon atoms, e.g. a methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, isobutyl, tert-butyl. Particularly, said group has 1, 2, or 3 carbon atoms (“C1-C3-alkyl”), e.g. a methyl, ethyl, propyl, or isopropyl group, more particularly 1 or 2 carbon atoms (“C1-C2-alkyl”), e.g. a methyl or ethyl group. The term “C2-C4-hydroxyalkyl” means a linear or branched, saturated, monovalent hydrocarbon group in which the term “C2-C4-alkyl” is defined supra, and in which one hydrogen atom is replaced with a hydroxy group, e.g. a 1-hydroxyethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxypropan-2-yl, 2-hydroxypropan-2-yl, 3-hydroxy-2-methyl-propyl, 2-hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl group. The term “C1-C4-haloalkyl” means a linear or branched, saturated, monovalent hydrocarbon group in which the term “C1-C4-alkyl” is as defined supra, and in which one or more of the hydrogen atoms are replaced, identically or differently, with a halogen atom. Particularly, said halogen atom is a fluorine atom. Said C1-C4-haloalkyl group is, for example, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl or 1,3-difluoropropan-2-yl. The term “C1-C4-alkoxy” means a linear or branched, saturated, monovalent group of formula (C1-C4-alkyl)-O-, in which the term “C1-C4-alkyl” is as defined supra, e.g. a methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, or tert-butoxy group. The term “C1-C4-haloalkoxy” means a linear or branched, saturated, monovalent C1-C4-alkoxy group, as defined supra, in which one or more of the hydrogen atoms is replaced, identically or differently, with a halogen atom. Particularly, said halogen atom is a fluorine atom. Said C1-C4-haloalkoxy group is, for example, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy or pentafluoroethoxy. The term “C3-C6-cycloalkyl” means a saturated, monovalent, monocyclic hydrocarbon ring which contains 3, 4, 5, or 6 carbon atoms (“C3-C6-cycloalkyl”). Said C3-C6-cycloalkyl group is for example, e.g. a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl group. The term “C3-C6-halocycloalkyl” means a saturated, monovalent, monocyclic hydrocarbon ring in which the term “C3-C6-halocycloalkyl” is as defined supra, and in which one or more of the hydrogen atoms are replaced, identically or differently, with a halogen atom. Particularly, said halogen atom is a fluorine atom.
The term 4- to 6-membered heterocycloalkyl means a monocyclic, saturated heterocycle with 4, 5 or 6 ring atoms in total, which contains one or two identical or different ring heteroatoms from the series N, O and S, it being possible for said heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, a nitrogen atom. Said heterocycloalkyl group, without being limited thereto, can be a 4-membered ring, such as azetidinyl, oxetanyl or thietanyl, for example; or a 5-membered ring, such as tetrahydrofuranyl, 1,3-dioxolanyl, thiolanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 1,1-dioxidothiolanyl, 1,2-oxazolidinyl, 1,3-oxazolidinyl or 1,3-thiazolidinyl, for example; or a 6-membered ring, such as tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, 1,3-dioxanyl, 1,4-dioxanyl or 1,2-oxazinanyl, for example. Particularly, “4- to 6-membered heterocycloalkyl” means a 4- to 6-membered heterocycloalkyl as defined supra containing one ring nitrogen or oxygen atom and optionally one further ring heteroatom from the series: N, O, S. More particularly, “5- or 6-membered heterocycloalkyl” means a monocyclic, saturated heterocycle with 5 or 6 ring atoms in total, containing one ring nitrogen or oxygen atom and optionally one further ring heteroatom from the series: N, O. The term “heterocycloalkyl fused with phenyl or heteroaryl” means a bicyclic heterocycle with 8, 9 or 10 ring atoms in total, in which the two rings share two adjacent ring atoms, and in which the “heterocycloalkyl” part contains one or two identical or different ring heteroatoms from the series: N, O and/or S, and the term “heteroaryl” means a monocyclic aromatic ring having 5 or 6 ring atoms (a “5- to 6-membered heteroaryl” group), which contains at least one ring heteroatom and optionally one, two or three further ring heteroatoms from the series N, O and/or S; it being possible for said fused heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, a nitrogen atom. The term “heterospirocycloalkyl” means a bicyclic, saturated heterocycle with 6, 7, 8, 9, 10 or 11 ring atoms in total, in which the two rings share one common ring carbon atom, which “heterospirocycloalkyl” contains one or two identical or different ring heteroatoms from the series: N, O, S; it being possible for said heterospirocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms, except the spiro carbon atom, or, if present, a nitrogen atom. Said heterospirocycloalkyl group is, for example, azaspiro[2.3]hexyl, azaspiro[3.3]heptyl, oxaazaspiro[3.3]heptyl, thiaazaspiro[3.3]heptyl, oxaspiro[3.3]heptyl,
oxazaspiro[5.3]nonyl, oxazaspiro[4.3]octyl, azaspiro[4,5]decyl, oxazaspiro [5.5]undecyl, diazaspiro[3.3]heptyl, thiazaspiro[3.3]heptyl, thiazaspiro[4.3]octyl, azaspiro[5.5]undecyl, or one of the further homologous scaffolds such as spiro[3.4]-, spiro[4.4]-, spiro[2.4]-, spiro[2.5]-, spiro[2.6]-, spiro[3.5]-, spiro[3.6]-, spiro[4.5]- and spiro[4.6]-. The term “heteroaryl” means a monovalent, monocyclic, bicyclic or tricyclic aromatic ring having 5, 6, 8, 9, or 10 ring atoms (a “5- to 10-membered heteroaryl” group), particularly 5, 6, 9 or 10 ring atoms, which contains at least one ring heteroatom and optionally one, two or three further ring heteroatoms from the series: N, O and/or S, and which is bound via a ring carbon atom or optionally via a ring nitrogen atom (if allowed by valency). Said heteroaryl group can be a 5-membered heteroaryl group, such as, for example, thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl or tetrazolyl; or a 6-membered heteroaryl group, such as, for example, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl; or a tricyclic heteroaryl group, such as, for example, carbazolyl, acridinyl or phenazinyl; or a 9- membered heteroaryl group, such as, for example, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzothiazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl, indolizinyl or purinyl; or a 10-membered heteroaryl group, such as, for example, quinolinyl, quinazolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinoxalinyl or pteridinyl. In general, and unless otherwise mentioned, the heteroaryl groups include all possible isomeric forms thereof, e.g.: tautomers and positional isomers with respect to the point of linkage to the rest of the molecule. Thus, for some illustrative non-restricting examples, the term pyridinyl includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl; or the term thienyl includes thien-2-yl and thien-3-yl. Particularly, the heteroaryl group is a pyridinyl group. The term “C1-C6”, as used in the present text, e.g. in the context of the definition of “C1-C6-alkyl”, “C1-C6-haloalkyl”, “C1-C6-hydroxyalkyl”, “C1-C6-alkoxy” or “C1-C6-haloalkoxy” means an alkyl group having a finite number of carbon atoms of 1 to 6, i.e.1, 2, 3, 4, 5 or 6 carbon atoms. Further, as used herein, the term “C3-C8”, as used in the present text, e.g. in the context of the definition of “C3-C8-cycloalkyl”, means a cycloalkyl group having a finite number of carbon atoms of 3 to 8, i.e.3, 4, 5, 6, 7 or 8 carbon atoms. When a range of values is given, said range encompasses each value and sub-range within said range.
For example: "C1-C6" encompasses C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2- C5, C2-C4, C2-C3, C3-C6, C3-C5, C3- C4, C4-C6, C4-C5, and C5-C6; " C2-C6" encompasses C2, C3, C4, C5, C6, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6; "C3-C10" encompasses C3, C4, C5, C6, C7, C8, C9, C10, C3- C10, C3-C9, C3-C8, C3- C7, C3-C6, C3-C5, C3-C4, C4-C10, C4-C9, C4-C8, C4-C7, C4-C6, C4-C5, C5-C10, C5- C9, C5-C8, C5-C7, C5-C6, C6-C10, C6-C9, C6- C8, C6-C7, C7-C10, C7-C9, C7-C8, C8-C10, C8-C9 and C9-C10; "C3-C8" encompasses C3, C4, C5, C6, C7, C8, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4, C4-C8, C4- C7, C4-C6, C4-C5, C5-C8, C5-C7, C5-C6, C6-C8, C6-C7 and C7-C8; "C3-C6" encompasses C3, C4, C5, C6, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6; "C4-C8" encompasses C4, C5, C6, C7, C8, C4-C8, C4-C7, C4-C6, C4-C5, C5-C8, C5-C7, C5-C6, C6-C8, C6-C7 and C7-C8; "C4-C7" encompasses C4, C5, C6, C7, C4-C7, C4-C6, C4-C5, C5-C7, C5-C6 and C6-C7; "C4-C6" encompasses C4, C5, C6, C4-C6, C4-C5 and C5-C6; "C5-C10" encompasses C5, C6, C7, C8, C9, C10, C5-C10, C5-C9, C5-C8, C5-C7, C5-C6, C6-C10, C6-C9, C6-C8, C6-C7, C7-C10, C7-C9, C7-C8, C8-C10, C8-C9 and C9-C10; "C6-C10" encompasses C6, C7, C8, C9, C10, C6-C10, C6-C9, C6-C8, C6-C7, C7-C10, C7-C9, C7- C8, C8-C10, C8-C9 and C9-C10. As used herein, the term “leaving group” means an atom or a group of atoms that is displaced in a chemical reaction as stable species taking with it the bonding electrons. In particular, such a leaving group is selected from the group comprising: halide, in particular fluoride, chloride, bromide or iodide, (methylsulfonyl)oxy, [(trifluoromethyl)sulfonyl]oxy, [(nonafluorobutyl)sulfonyl]oxy, (phenylsulfonyl)oxy, [(4-methylphenyl)sulfonyl]oxy, [(4-bromophenyl)sulfonyl]oxy, [(4-nitrophenyl)sulfonyl]oxy, [(2-nitrophenyl)sulfonyl]oxy, [(4-isopropylphenyl)sulfonyl]oxy, [(2,4,6-triisopropylphenyl)sulfonyl]oxy, [(2,4,6-trimethylphenyl)sulfonyl]oxy, [(4-tert-butylphenyl)sulfonyl]oxy and [(4-methoxyphenyl)sulfonyl]oxy. It is possible for the compounds of general formula (I) to exist as isotopic variants. The invention therefore includes the use of one or more isotopic variant(s) of the compounds
of general formula (I), particularly deuterium-containing compounds of general formula (I). The term “Isotopic variant” of a compound or a reagent is defined as a compound exhibiting an unnatural proportion of one or more of the isotopes that constitute such a compound. The term “Isotopic variant of the compound of general formula (I)” is defined as a compound of general formula (I) exhibiting an unnatural proportion of one or more of the isotopes that constitute such a compound. The expression “unnatural proportion” means a proportion of such isotope which is higher than its natural abundance. The natural abundances of isotopes to be applied in this context are described in “Isotopic Compositions of the Elements 1997”, Pure Appl. Chem., 70(1), 217-235, 1998. Examples of such isotopes include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2H (deuterium), 3H (tritium), 11C, 13C, 14C, 15N, 17O, 18O, 32P, 33P, 33S, 34S, 35S, 36S, 18F, 36Cl, 82Br, 123I, 124I, 125I, 129I and 131I, respectively. With respect to the treatment and/or prophylaxis of the disorders specified herein the isotopic variant(s) of the compounds of general formula (I) preferably contain deuterium (“deuterium-containing compounds of general formula (I)”). Isotopic variants of the compounds of general formula (I) in which one or more radioactive isotopes, such as 3H or 14C, are incorporated are useful e.g. in drug and/or substrate tissue distribution studies. These isotopes are particularly preferred for the ease of their incorporation and detectability. Positron emitting isotopes such as 18F or 11C may be incorporated into a compound of general formula (I). These isotopic variants of the compounds of general formula (I) are useful for in vivo imaging applications. Deuterium-containing and 13C- containing compounds of general formula (I) can be used in mass spectrometry analyses in the context of preclinical or clinical studies. Isotopic variants of the compounds of general formula (I) can generally be prepared by methods known to a person skilled in the art, such as those described in the schemes and/or examples herein, by substituting a reagent for an isotopic variant of said reagent, preferably for a deuterium-containing reagent. Depending on the desired sites of deuteration, in some cases deuterium from D2O can be incorporated either directly into the compounds or into reagents that are useful for synthesizing such compounds. Deuterium gas is also a useful reagent for incorporating deuterium into molecules. Catalytic deuteration of olefinic bonds and acetylenic bonds is a rapid route for
incorporation of deuterium. Metal catalysts (i.e. Pd, Pt, and Rh) in the presence of deuterium gas can be used to directly exchange deuterium for hydrogen in functional groups containing hydrocarbons. A variety of deuterated reagents and synthetic building blocks are commercially available from companies such as for example C/D/N Isotopes, Quebec, Canada; Cambridge Isotope Laboratories Inc., Andover, MA, USA; and CombiPhos Catalysts, Inc., Princeton, NJ, USA. The term “deuterium-containing compound of general formula (I)” is defined as a compound of general formula (I), in which one or more hydrogen atom(s) is/are replaced by one or more deuterium atom(s) and in which the abundance of deuterium at each deuterated position of the compound of general formula (I) is higher than the natural abundance of deuterium, which is about 0.015%. Particularly, in a deuterium-containing compound of general formula (I) the abundance of deuterium at each deuterated position of the compound of general formula (I) is higher than 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80%, preferably higher than 90%, 95%, 96% or 97%, even more preferably higher than 98% or 99% at said position(s). It is understood that the abundance of deuterium at each deuterated position is independent of the abundance of deuterium at other deuterated position(s). The selective incorporation of one or more deuterium atom(s) into a compound of general formula (I) may alter the physicochemical properties (such as for example acidity [C. L. Perrin, et al., J. Am. Chem. Soc., 2007, 129, 4490], basicity [C. L. Perrin et al., J. Am. Chem. Soc., 2005, 127, 9641], lipophilicity [B. Testa et al., Int. J. Pharm., 1984, 19(3), 271]) and/or the metabolic profile of the molecule and may result in changes in the ratio of parent compound to metabolites or in the amounts of metabolites formed. Such changes may result in certain therapeutic advantages and hence may be preferred in some circumstances. Reduced rates of metabolism and metabolic switching, where the ratio of metabolites is changed, have been reported (A. E. Mutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102). These changes in the exposure to parent drug and metabolites can have important consequences with respect to the pharmacodynamics, tolerability and efficacy of a deuterium-containing compound of general formula (I). In some cases, deuterium substitution reduces or eliminates the formation of an undesired or toxic metabolite and enhances the formation of a desired metabolite (e.g. Nevirapine: A. M. Sharma et al., Chem. Res. Toxicol., 2013, 26, 410; Efavirenz: A. E. Mutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102). In other cases, the major effect of deuteration is to reduce the rate of systemic clearance. As a result, the biological half-life of the compound is increased. The potential clinical benefits would include the ability to maintain similar systemic exposure with decreased peak levels and increased trough levels. This
could result in lower side effects and enhanced efficacy, depending on the particular compound’s pharmacokinetic/ pharmacodynamic relationship. ML-337 (C. J. Wenthur et al., J. Med. Chem., 2013, 56, 5208) and Odanacatib (K. Kassahun et al., WO2012/112363) are examples for this deuterium effect. Still other cases have been reported in which reduced rates of metabolism result in an increase in exposure of the drug without changing the rate of systemic clearance (e.g. Rofecoxib: F. Schneider et al., Arzneim. Forsch. / Drug. Res., 2006, 56, 295; Telaprevir: F. Maltais et al., J. Med. Chem., 2009, 52, 7993). Deuterated drugs showing this effect may have reduced dosing requirements (e.g. lower number of doses or lower dosage to achieve the desired effect) and/or may produce lower metabolite loads. A compound of general formula (I) may have multiple potential sites of attack for metabolism. To optimize the above-described effects on physicochemical properties and metabolic profile, deuterium-containing compounds of general formula (I) having a certain pattern of one or more deuterium-hydrogen exchange(s) can be selected. Particularly, the deuterium atom(s) of deuterium-containing compound(s) of general formula (I) is/are attached to a carbon atom and/or is/are located at those positions of the compound of general formula (I), which are sites of attack for metabolizing enzymes such as e.g. cytochrome P450. Where the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like, is used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate or the like. By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The compounds intended for the use according to the present invention optionally contain one or more asymmetric centres, depending upon the location and nature of the various substituents desired. It is possible that one or more asymmetric carbon atoms are present in the (R) or (S) configuration, which can result in racemic mixtures in the case of a single asymmetric centre, and in diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, it is possible that asymmetry also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds. Preferred compounds are those which produce the more desirable biological activity. Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of the present invention are also included
within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art. Preferred isomers are those which produce the more desirable biological activity. These separated, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., HPLC columns using a chiral phase), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable HPLC columns using a chiral phase are commercially available, such as those manufactured by Daicel, e.g., Chiracel OD and Chiracel OJ, for example, among many others, which are all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful. The optically active compounds of the present invention can likewise be obtained by chiral syntheses utilizing optically active starting materials. In order to distinguish different types of isomers from each other reference is made to IUPAC Rules Section E (Pure Appl Chem 45, 11-30, 1976). The compounds intended for the use according to the present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g. (R)- or (S)- isomers, in any ratio. Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention is achieved by any suitable state of the art method, such as hromatography, especially chiral chromatography, for example. Further, it is possible for the compounds to exist as tautomers. For example, any compound of the present invention which contains an indazole moiety can exist as a 1H tautomer, or a 2H tautomer, or even a mixture in any amount of the two tautomers, namely:
1H tautomer 2H tautomer
The compounds intended for the use according to the present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio.
Further, the compounds intended for the use according to the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised. The present invention includes all such possible N-oxides.
The present invention also covers the use of useful forms of the compounds, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and/or co-precipitates.
The compounds intended for the use according to the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example, as structural element of the crystal lattice of the compounds. It is possible for the amount of polar solvents, in particular water, to exist in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible. The present invention includes all such hydrates or solvates.
Further, it is possible for the compounds intended for the use according to the present invention to exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or to exist in the form of a salt. Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, which is customarily used in pharmacy, or which is used, for example, for isolating or purifying the compounds of the present invention.
The term “pharmaceutically acceptable salt" refers to an inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. “Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19.
A suitable pharmaceutically acceptable salt of the compounds intended for the use according tothe present invention may be, for example, an acid-addition salt of a
compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, or “mineral acid”, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfamic, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nicotinic, pamoic, pectinic, 3-phenylpropionic, pivalic, 2-hydroxyethanesulfonic, itaconic, trifluoromethanesulfonic, dodecylsulfuric, ethanesulfonic, benzenesulfonic, para- toluenesulfonic, methanesulfonic, 2-naphthalenesulfonic, naphthalinedisulfonic, camphorsulfonic acid, citric, tartaric, stearic, lactic, oxalic, malonic, succinic, malic, adipic, alginic, maleic, fumaric, D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic, or thiocyanic acid, for example. Further, another suitably pharmaceutically acceptable salt of a compound intended for the use according tothe present invention which is sufficiently acidic, is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium, magnesium or strontium salt, or an aluminium or a zinc salt, or an ammonium salt derived from ammonia or from an organic primary, secondary or tertiary amine having 1 to 20 carbon atoms, such as ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, diethylaminoethanol, tris(hydroxymethyl)aminomethane, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, 1,2-ethylenediamine, N-methylpiperidine, N-methyl-glucamine, N,N- dimethyl-glucamine, N-ethyl-glucamine, 1,6-hexanediamine, glucosamine, sarcosine, serinol, 2-amino-1,3-propanediol, 3-amino-1,2-propanediol, 4-amino-1,2,3-butanetriol, or a salt with a quarternary ammonium ion having 1 to 20 carbon atoms, such as tetramethylammonium, tetraethylammonium, tetra(n-propyl)ammonium, tetra(n- butyl)ammonium, N-benzyl-N,N,N-trimethylammonium, choline or benzalkonium. Those skilled in the art will further recognise that it is possible for acid addition salts of the claimed compounds to be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts of acidic compounds of the present invention are prepared by reacting the compounds of the present invention with the appropriate base via a variety of known methods.
The present invention includes the use of all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio. For the synthesis of intermediates and of examples of the compounds intended for the use according to the present invention, when a compound is mentioned as a salt form with the corresponding base or acid, the exact stoichiometric composition of said salt form, as obtained by the respective preparation and/or purification process, is, in most cases, unknown. Unless specified otherwise, suffixes to chemical names or structural formulae relating to salts, such as "hydrochloride", "trifluoroacetate", "sodium salt", or "x HCl", "x CF3COOH", "x Na+", for example, mean a salt form, the stoichiometry of which salt form not being specified. This applies analogously to cases in which synthesis intermediates or example compounds or salts thereof have been obtained, by the preparation and/or purification processes described, as solvates, such as hydrates, with (if defined) unknown stoichiometric composition. Furthermore, the present invention includes all possible crystalline forms, or polymorphs, of the compounds intended for the use according to the present invention, either as single polymorph, or as a mixture of more than one polymorph, in any ratio. Moreover, the compounds intended for the use according to the present invention also include prodrugs of the compounds. The term “prodrugs” here designates compounds which themselves can be biologically active or inactive but are converted (for example metabolically or hydrolytically) into compounds according to the invention during their residence time in the body. In accordance with a second embodiment of the first aspect, the present invention covers the use of compounds of general formula (I), supra, in which: R1 represents hydrogen, C1-C4-alkyl or C1-C4-haloalkyl; R2 represents hydrogen, C1-C4-alkyl or C1-C4-haloalkyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl ring; R3 represents C3-C6-cycloalkyl, 3- to 6-membered heterocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R8, or
R3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R8, and additionally R7a and R7b represent deuterium; R4 represents hydrogen, C1-C4-alkyl, C1-C4-haloalkyl or C3-C6-cycloalkyl; R5, R6 represent, independently of each other, hydrogen, C1-C4-alkyl, C2-C4- hydroxyalkyl, (C1-C4-alkoxy)-(C2-C4-alkyl)-, C3-C6-cycloalkyl, C1-C4-haloalkyl, C3-C6-halocycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, heteroaryl, heterocycloalkyl fused with phenyl or heteroaryl, 3- to 6-membered heterocycloalkyl-(C1-C3-alkyl)-, (heterocycloalkyl fused with phenyl or heteroaryl)-(C1-C3-alkyl)-, phenyl-(C1-C3-alkyl)- or heteroaryl-(C1-C3-alkyl)-, wherein said 3- to 6-membered heterocycloalkyl, phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with R9, or R5 and R6 together with the nitrogen atom to which they are attached form a 3- to 6-membered nitrogen containing heterocyclic ring, optionally containing one additional heteroatom or heteroatom containing group selected from O, NH and S, and which may be optionally substituted, one or more times, independently of each other, with R9; R7a represents hydrogen, deuterium, or C1-C4-alkyl; R7b represents hydrogen, deuterium, or C1-C4-alkyl; R8 represents halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, C3-C6-cycloalkyl, C1-C4-alkyl-(C=O)-, R10-O-(C=O)-, R11-NH-(C=O)-, or R12-(SO2)-; R9 represents halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, H2N-C1-C4-alkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, C3-C6-cycloalkyl, R10-O-(C=O)-, oxo, 5- to 6- membered heterocycloalkyl-, 5- to 6-membered heterocycloalkyl-(C1-C3-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C3-alkoxy, or C1-C3-haloalkoxy; R10 represents hydrogen, C1-C4-alkyl, or phenyl-CH2-; R11 represents hydrogen, C1-C4-alkyl, or 5- to 6-membered heterocycloalkyl-(C1-C3-alkyl)-;
R represents C1-C4-alkyl or phenyl; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, for the treatment or prophylaxis of diseases. In accordance with a third embodiment of the first aspect, the present invention covers the use of compounds of general formula (I), supra, in which: R1 represents hydrogen, C1-C4-alkyl or C1-C4-haloalkyl; R2 represents hydrogen or C1-C4-alkyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl or heterocycloalkyl ring; R3 represents C3-C6-cycloalkyl, 4- to 6-membered heterocycloalkyl, heterocycloalkyl fused with heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R8, or R3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R8, and additionally R7a and R7b represent deuterium; R4 represents hydrogen, C1-C4-alkyl, C1-C4-haloalkyl or C3-C6-cycloalkyl; R5, R6 represent, independently of each other, hydrogen, C2-C4-hydroxyalkyl, (C1-C4-alkoxy)-(C2-C4-alkyl)-, 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, phenyl, heteroaryl, 4- to 6-membered heterocycloalkyl- (C1-C3-alkyl)-, heterospirocycloalkyl-(C1-C3-alkyl)-, (heterocycloalkyl fused with heteroaryl)-(C1-C3-alkyl)-, or heteroaryl-(C1-C3-alkyl)-, wherein said 3- to 6- membered heterocycloalkyl, phenyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R9, or R5 and R6 together with the nitrogen atom to which they are attached form a 5-membered nitrogen containing heterocyclic ring, which may be optionally substituted, once with R9; R7a represents hydrogen, deuterium, or methyl; R7b represents hydrogen, deuterium, or methyl;
R8 represents halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C3-alkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkyl-(C1-C3-alkyl)-, R13-(C=O)-, R10-O-(C=O)-, R11-NH-(C=O)-, or R12-(SO2)-; R9 represents halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, H2N-C1-C4-alkyl, C3-C6-cycloalkyl, R10-O-(C=O)-, oxo, 6-membered heterocycloalkyl- (C1-C3-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, C1-C4-haloalkyl, or C1-C3-alkoxy; R10 represents hydrogen, C1-C4-alkyl, or phenyl-CH2-; R11 represents 5- to 6-membered heterocycloalkyl-(C1-C3-alkyl)-; R12 represents C1-C4-alkyl; R13 represents C1-C4-alkyl, (C1-C4-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkyl-(C=O)-, C3-C6-cycloalkyl, or phenyl, wherein said C3-C6-cycloalkyl group is optionally substituted with methyl or hydroxy; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, for the treatment or prophylaxis of diseases. In accordance with a fourth embodiment of the first aspect, the present invention covers the use of compounds of general formula (I), supra, in which: R1 represents hydrogen, methyl or trifluoromethyl; R2 represents hydrogen or methyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; R3 represents cyclopropyl, 4- to 6-membered heterocycloalkyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R8, or R3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R8, and additionally R7a and R7b represent deuterium; R4 represents hydrogen, methyl, C1-haloalkyl or cyclopropyl;
R5 represents hydrogen; R6 represents methoxy-ethyl, 5-membered heteroaryl, 4- to 6-membered heterocycloalkyl-( C1-C2-alkyl)-, heterospirocycloalkyl-methyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl, or 5- to 6-membered heteroaryl-(C1- C2-alkyl)-, wherein said 4- to 6-membered heterocycloalkyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R9; R7a represents hydrogen, deuterium, or methyl; R7b represents hydrogen, deuterium, or methyl; R8 represents fluoro, chloro, C1-C2-alkyl, trifluoromethyl, C1-C3-alkoxy, cyclopropyl, cyclopropylmethyl, R13-(C=O)-, R10-O-(C=O)-, R11-NH-(C=O)-, or R12-(SO2)-; R9 represents fluoro, chloro, C1-C3-alkyl, trifluoromethyl, cyclopropyl, or oxo; R10 represents C1-C4-alkyl, or phenyl-CH2-; R11 represents 5- to 6-membered heterocycloalkyl-methyl; R12 represents methyl; R13 represents methyl, methoxymethyl, ethyl-(C=O)-, cyclopropyl, or phenyl, wherein said cyclopropyl group is optionally substituted with methyl or hydroxy; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, for the treatment or prophylaxis of diseases. In accordance with a fifth embodiment of the first aspect, the present invention covers the use of compounds of general formula (I), supra, in which: R1 represents hydrogen or methyl; R2 represents hydrogen or methyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; R3 represents cyclopropyl, 2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, oxetan-3-yl, oxolan-3-yl, oxolan-2-yl, 3-methyloxetan-3-yl, 3-fluorooxetan-3-yl, pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, oxan-4-yl, 1,4-dioxan-2-yl, 6-methylpyridin-3-yl, 5- methylpyridin-2-yl, 3-methylpyridin-2-yl, 2-methylpyridin-4-yl, 6-methylpyridin-2-
yl, 3-chloropyridin-2-yl, 6-ethylpyridin-3-yl, 1 -acetylpiperidin-4-yl, 3-chloro-5- ethoxypyridin-2-yl, 1 -benzoylpiperidin-4-yl, or a group selected from:
R3 represents phenyl, and additionally R7a and R7b represent deuterium;
R4 represents methyl, difluoromethyl, trifluoromethyl, or cyclopropyl;
R5 represents hydrogen; R6 represents (oxolan-2-yl)methyl, (1,3-oxazol-4-yl)methyl, (1,2-oxazol-3-yl)methyl, (4-methyloxolan-2-yl)methyl, (pyrimidin-2-yl)methyl, (pyrazin-2-yl)methyl, (5- methyloxolan-2-yl)methyl, (5-methyloxolan-2-yl)methyl, (1,4-dioxan-2-yl)methyl, (4-methylphenyl)methyl, (5-methylpyrimidin-2-yl)methyl, (5-methylpyrazin-2- yl)methyl, (5-chloropyrazin-2-yl)methyl, (5-cyclopropyl-pyrazin-2-yl)methyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl, 1,3-oxazol-2-ylmethyl, 1,3-thiazol-2- ylmethyl, (1-methyl-1H-pyrazol-3-yl)methyl, (1-methyl-1H-imidazol-4-yl)methyl, (5-isopropyl-1,2-oxazol-3-yl)methyl, (5-cyclopropyl-1,2-oxazol-3-yl)methyl, (5,5- dimethyltetrahydrofuran-2-yl)methyl, (4,4-difluorotetrahydrofuran-2-yl)methyl, (6,6-dimethyl-1,4-dioxan-2-yl)methyl, 5-oxaspiro[2.4]heptan-6-ylmethyl, or 2,6- dioxaspiro[3.4]octan-7-ylmethyl; R7a represents hydrogen; R7b represents hydrogen; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, for the treatment or prophylaxis of diseases. More particularly the invention refers to the use of one of the following compounds: 1 2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 2 8-methyl-N-[(4-methylphenyl)methyl]-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 3 8-methyl-2-(pyridin-2-ylmethyl)-N-[(2R/S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 3 8-methyl-2-(pyridin-2-ylmethyl)-N-[(2R)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 3 8-methyl-2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide
4 8-methyl-N-[2-(4-methylpiperazin-1-yl)ethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 5 8-methyl-N-[(1,2,4-oxadiazol-3-yl)methyl]-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 6 8-methyl-N-(1,2-oxazol-3-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 7 N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8 8-methyl-N-[(5-methyl-1,2-oxazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 9 N-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-(pyridin-2- ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 9 N-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-(pyridin-2- ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 9 N-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-(pyridin-2- ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 10 N-(2-hydroxy-2-methylpropyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 11 8-methyl-N-{[5-(morpholin-4-ylmethyl)-1,2-oxazol-3-yl]methyl}-2-(pyridin-2- ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 12 8-methyl-2-(pyridin-2-ylmethyl)-N-(2-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin- 1-yl}ethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 13 8-methyl-2-(pyridin-2-ylmethyl)-N-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1- yl}ethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 14 N-{[5-(3-methoxyphenyl)-1,2-oxazol-3-yl]methyl}-8-methyl-2-(pyridin-2-ylmethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
15 8-methyl-N-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 16 N-[(5-cyclopropyl-1,2-oxazol-4-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 17 N-{[5-(2-chlorophenyl)-1,2-oxazol-3-yl]methyl}-8-methyl-2-(pyridin-2-ylmethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 18 N-[(5-isopropyl-1,2-oxazol-3-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 19 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 19 N-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 20 8-methyl-2-(pyridin-2-ylmethyl)-N-(4H-1,2,4-triazol-3-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 21 8-methyl-N,2-bis(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide 22 8-methyl-N-(1H-pyrazol-3-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 23 8-methyl-2-(pyridin-2-ylmethyl)-N-(1,3-thiazol-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 24 8-methyl-N-(1,2-oxazol-4-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 25 8-methyl-2-(pyridin-2-ylmethyl)-N-{[5-(trifluoromethyl)-1,2-oxazol-3-yl]methyl}- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 26 8-methyl-N-[(4-methyl-1,2-oxazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide
27 N-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 28 N-[2-(3,3-dimethyl-2-oxoazetidin-1-yl)ethyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 29 N-(2-methoxyethyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 30 [(2R/S)-2-(aminomethyl)pyrrolidin-1-yl][8-methyl-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-yl]methanone 30 [(2R)-2-(aminomethyl)pyrrolidin-1-yl][8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazol-7-yl]methanone 30 [(2S)-2-(aminomethyl)pyrrolidin-1-yl][8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazol-7-yl]methanone 31 3-[({[8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazol-7- yl]carbonyl}amino)methyl]-1,2-oxazole-4-carboxylic acid 32 8-methyl-N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 33 8-methyl-2-(pyridin-2-ylmethyl)-N-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 33 8-methyl-2-(pyridin-2-ylmethyl)-N-[(3R)-tetrahydrofuran-3-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 34 8-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 35 8-methyl-N-[(2R/S)-oxetan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 35 8-methyl-N-[(2R)-oxetan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide
35 8-methyl-N-[(2S)-oxetan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 36 8-methyl-N-(oxetan-3-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 37 N-[(3-fluorooxetan-3-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 38 8-methyl-N-{[(2R/S)-4-methylmorpholin-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 38 8-methyl-N-{[(2R)-4-methylmorpholin-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 38 8-methyl-N-{[(2S)-4-methylmorpholin-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 39 8-methyl-N-{[(2R/S)-5-oxotetrahydrofuran-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 39 8-methyl-N-{[(2R)-5-oxotetrahydrofuran-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 39 8-methyl-N-{[(2S)-5-oxotetrahydrofuran-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 40 8-methyl-N-(1-methyl-1H-pyrazol-3-yl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 41 8-methyl-N-(pyridin-3-yl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 42 8-methyl-N-(2-phenylethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 43 N-(4-cyanophenyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide
44 8-methyl-2-(pyridin-3-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 45 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyridin-3-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 46 8-methyl-2-(pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 47 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyridin-4-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 48 2-(cyclopropylmethyl)-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 49 2-(cyclopropylmethyl)-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 50 N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3- b]pyridin-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 50 N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-2-[(2R)-2,3-dihydro[1,4]dioxino[2,3- b]pyridin-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 50 N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-2-[(2S)-2,3-dihydro[1,4]dioxino[2,3- b]pyridin-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 51 2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2R/S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 51 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2R/S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 51 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2R/S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 52 2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
52 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 52 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 53 2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(4- methylbenzyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 53 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(4- methylbenzyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 53 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(4- methylbenzyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 54 2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[2-(4- methylpiperazin-1-yl)ethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 54 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[2-(4- methylpiperazin-1-yl)ethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 54 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[2-(4- methylpiperazin-1-yl)ethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 55 2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(1,2- oxazol-3-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 55 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(1,2-oxazol- 3-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 55 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(1,2-oxazol- 3-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 56 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-{[6-(trifluoromethyl)pyridin-2- yl]methyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 57 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-{[5-(trifluoromethyl)pyridin-2- yl]methyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
58 2-[(3-chloro-5-fluoropyridin-2-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 59 2-[(3-chloro-5-ethoxypyridin-2-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 60 2-[(3-chloropyridin-2-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 61 2-[(3-chloropyridin-2-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 62 8-methyl-2-[(3-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 63 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3-methylpyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 64 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 65 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(5-methylpyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 66 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[(2R/S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 66 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[(2R)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 66 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 67 N-[2-(azetidin-1-yl)ethyl]-8-methyl-2-[(6-methylpyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 68 N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-8-methyl-2-[(6-methylpyridin-2- yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
69 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[2-(pyrrolidin-1-yl)ethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 70 N-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-[(6- methylpyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 70 N-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-[(6- methylpyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 70 N-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-[(6- methylpyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 71 8-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-[(6-methylpyridin-2-yl)methyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 72 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-(1,3-oxazol-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 73 8-methyl-2-[(2-methylpyridin-3-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 74 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2-methylpyridin-3-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 75 8-methyl-2-[(6-methylpyridin-3-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 76 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(6-methylpyridin-3-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 77 2-[(2,6-dimethylpyridin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 78 2-[(2,6-dimethylpyridin-3-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 79 8-methyl-2-[(2-methylpyridin-4-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
80 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2-methylpyridin-4-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 81 2-[(2,6-dimethylpyridin-4-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 82 2-[(2,6-dimethylpyridin-4-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 83 8-methyl-2-(pyrimidin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 84 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyrimidin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 85 8-methyl-2-(pyrimidin-5-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 86 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyrimidin-5-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 87 2-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 88 N,2-bis[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxamide 89 2-[(2S)-1,4-dioxan-2-ylmethyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 90 N-[(2R)-1,4-dioxan-2-ylmethyl]-2-[(2S)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 91 8-methyl-2-(oxetan-3-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 92 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(oxetan-3-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide
93 8-methyl-2-[(3-methyloxetan-3-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 94 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3-methyloxetan-3-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 95 2-[(3-fluorooxetan-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 96 N-[(2R)-1,4-dioxan-2-ylmethyl]-2-[(3-fluorooxetan-3-yl)methyl]-8-methyl-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 97 8-methyl-2-[(2R)-oxetan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 98 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2R)-oxetan-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 99 8-methyl-2-[(2S)-oxetan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 100 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2S)-oxetan-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 101 8-methyl-2-{[(2R)-4-methylmorpholin-2-yl]methyl}-N-[(2S)-tetrahydrofuran-2- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 102 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-{[(2R)-4-methylmorpholin-2- yl]methyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 103 8-methyl-2-{[(2S)-4-methylmorpholin-2-yl]methyl}-N-[(2S)-tetrahydrofuran-2- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 104 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-{[(2S)-4-methylmorpholin-2- yl]methyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 105 8-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
106 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 107 8-methyl-N,2-bis[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 108 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 109 tert-butyl 3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5- dihydro-2H-furo[2,3-g]indazol-2-yl)methyl]azetidine-1-carboxylate 110 tert-butyl 3-[(7-{[(2R)-1,4-dioxan-2-ylmethyl]carbamoyl}-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazol-2-yl)methyl]azetidine-1-carboxylate 111 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-[(3R)-tetrahydrofuran-3- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 112 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3R)-tetrahydrofuran-3-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 113 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-[(3S)-tetrahydrofuran-3-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 114 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 115 2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 116 N-[(2R)-1,4-dioxan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 117 N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 118 N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide
119 8-cyclopropyl-2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 120 8-cyclopropyl-N-[(2R)-1,4-dioxan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 121 8-cyclopropyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 122 8-cyclopropyl-N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 123 8'-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 124 8'-methyl-N-(1,3-oxazol-2-ylmethyl)-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 125 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 126 N-[(2R)-1,4-dioxan-2-ylmethyl]-2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 127 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 128 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-(1,3-oxazol-2-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 129 2'-(cyclopropylmethyl)-8'-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 130 2'-(cyclopropylmethyl)-N-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 131 2'-(cyclopropylmethyl)-N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide
132 8'-methyl-2'-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 133 N-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 134 N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 135 8-methyl-2-[phenyl(2H2)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 136 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[phenyl(2H2)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 137 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran- 2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 138 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8- methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 139 tert-butyl [2-(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5- dihydro-2H-furo[2,3-g]indazol-2-yl)ethyl]carbamate 140 tert-butyl [2-(7-{[(2R)-1,4-dioxan-2-ylmethyl]carbamoyl}-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazol-2-yl)ethyl]carbamate 141 tert-butyl 4-[2-(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5- dihydro-2H-furo[2,3-g]indazol-2-yl)ethyl]piperazine-1-carboxylate 142 tert-butyl 4-[2-(7-{[(2R)-1,4-dioxan-2-ylmethyl]carbamoyl}-8-methyl-4,5-dihydro- 2H-furo[2,3-g]indazol-2-yl)ethyl]piperazine-1-carboxylate 143 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 2',5'-dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 144 N,2'-bis[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-2',5'-dihydrospiro[cyclobutane- 1,4'-furo[2,3-g]indazole]-7'-carboxamide
145 N-[(2R)-1,4-dioxan-2-ylmethyl]-2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 146 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-[(6-{[(2S)-tetrahydrofuran-2- ylmethyl]carbamoyl}pyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide 147 N-[(2R)-1,4-dioxan-2-ylmethyl]-2-[(6-{[(2R)-1,4-dioxan-2- ylmethyl]carbamoyl}pyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 148 4,4,8-trimethyl-2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 149 8'-methyl-2'-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 150 N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 151 8'-methyl-2'-(pyridin-3-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 152 N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-3-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 153 N2',N2',8'-trimethyl-N7'-[(2S)-tetrahydrofuran-2-ylmethyl]spiro[cyclopropane-1,4'- furo[2,3-g]indazole]-2',7'(5'H)-dicarboxamide 154 N7'-[(2R)-1,4-dioxan-2-ylmethyl]-N2',N2',8'-trimethylspiro[cyclopropane-1,4'- furo[2,3-g]indazole]-2',7'(5'H)-dicarboxamide 155 benzyl 3-fluoro-3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5- dihydro-2H-furo[2,3-g]indazol-2-yl)methyl]azetidine-1-carboxylate 156 benzyl 3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5-dihydro- 2H-furo[2,3-g]indazol-2-yl)methyl]azetidine-1-carboxylate 157 2-[(3-fluoroazetidin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
158 2-(azetidin-3-ylmethyl)-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 159 2-(azetidin-3-ylmethyl)-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 160 2-(2-aminoethyl)-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 161 2-(2-aminoethyl)-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 162 8-methyl-2-[2-(piperazin-1-yl)ethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 163 N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[2-(piperazin-1-yl)ethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 164 2-[(1-acetylazetidin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 165 2-[(1-acetyl-3-fluoroazetidin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 166 2-{[3-fluoro-1-(methylsulfonyl)azetidin-3-yl]methyl}-8-methyl-N-[(2S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 167 methyl 3-fluoro-3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5- dihydro-2H-furo[2,3-g]indazol-2-yl)methyl]azetidine-1-carboxylate 168 2'-[(2S)-1,4-dioxan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'- (trifluoromethyl)-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'- carboxamide 169 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'- (trifluoromethyl)-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'- carboxamide 170 N-{[(2±)-5,5-dimethyloxolan-2-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide
171 8-methyl-N-[(oxan-4-yl)methyl]-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 172 8-methyl-N-{[(2±)-oxan-2-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 173 8-methyl-N-{[(2±)-2-methyloxolan-2-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 174 N-{[(2±)-4,4-difluorooxolan-2-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 175 8-methyl-N-[(4-methyltetrahydrofuran-2-yl)methyl]-2-(2-pyridylmethyl)-4,5- dihydrofuro[2,3-g]indazole-7-carboxamide 176 8-methyl-N-{[(2±,5±)-5-methyloxolan-2-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 177 2,5-anhydro-1,3,4-trideoxy-3-methyl-1-({8-methyl-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carbonyl}amino)-D-threo-pentitol (Racemate) 178 8-methyl-N-{[(6±)-5-oxaspiro[2.4]heptan-6-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 179 N-{[(2±)-3,3-dimethyloxolan-2-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 180 N-{[(6±)-2,5-dioxaspiro[3.4]octan-6-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 181 N-{[(2±)-6,6-dimethyl-1,4-dioxan-2-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 182 2-[(4-fluoropyridin-2-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 183 2-[(5-fluoropyridin-3-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide
184 8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-2-[(pyridazin-3-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 185 N-{[(2R)-1,4-dioxan-2-yl]methyl}-8-methyl-2-[(pyridazin-3-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 186 2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 187 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 188 8-methyl-2-[(1,3-oxazol-2-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 189 8-methyl-2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 190 8-methyl-2-{[(2±)-oxan-2-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 191 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(6-methylpyridin-3-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 192 2-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 193 8-cyclopropyl-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 194 8-cyclopropyl-2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 195 N-{[(2±)-5,5-dimethyloxolan-2-yl]methyl}-2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'- methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 196 N-{[(2±)-6,6-dimethyl-1,4-dioxan-2-yl]methyl}-2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'- methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide
197 N-{[(2±)-4,4-difluorooxolan-2-yl]methyl}-2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'- methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 198 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'-methyl-N-{[(2±,5±)-5-methyloxolan-2- yl]methyl}-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'- carboxamide 199 2-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methyl-N-[(4-methyltetrahydrofuran-2- yl)methyl]spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide 200 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'-methyl-N-{[(6±)-5-oxaspiro[2.4]heptan-6- yl]methyl}-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'- carboxamide 201 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(6±)-2,5-dioxaspiro[3.4]octan-6-yl]methyl}- 8'-methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'- carboxamide 201 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(6R)-2,5-dioxaspiro[3.4]octan-6-yl]methyl}- 8'-methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'- carboxamide 201 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(6S)-2,5-dioxaspiro[3.4]octan-6-yl]methyl}- 8'-methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'- carboxamide 202 8'-Methyl-2'-(pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 203 8'-Methyl-2'-[(5-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 210 N-{[(2R)-1,4-dioxan-2-yl]methyl}-8'-methyl-2'-[(6-methylpyridin-3-yl)methyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 211 8'-methyl-2'-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide
212 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2'-[(6-methylpyridin-3-yl)methyl]-8'- (trifluoromethyl)-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'- carboxamide 213 2'-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8'-(trifluoromethyl)- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 214 2'-[(5-methylpyridin-2-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8'-(trifluoromethyl)- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 215 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2'-[(5-methylpyridin-2-yl)methyl]-8'- (trifluoromethyl)-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'- carboxamide 216 N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-4-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclopropan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 217 2'-(Pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluormethyl)- 2',5'-dihydrospiro[cyclopropan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 218 N-{[(2S)-oxolan-2-yl]methyl}-2'-[(pyridin-2-yl)methyl]-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 219 N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-2-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclopropan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 220 N,2-bis{[(2R)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 221 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 222 N-{[(2±)-4,4-difluorooxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 222 N-{[(2R)-4,4-difluorooxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 222 N-{[(2S)-4,4-difluorooxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
223 N-{[(2±)-5,5-dimethyloxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 223 N-{[(2R)-5,5-dimethyloxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 223 N-{[(2S)-5,5-dimethyloxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 224 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2±, 5±)-5-methyloxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 224 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2R, 5R)-5-methyloxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 224 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2S, 5R)-5-methyloxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 224 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2R, 5S)-5-methyloxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 224 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2S, 5S)-5-methyloxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 226 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-(1,3-thiazol-2-ylmethyl)-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide 227 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[(5-methylpyrazin-2-yl)methyl]-8- (trifluormethyl)-4,5-dihydro-2H-furo[2,3-g]indazol-7-carboxamide 228 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-(pyrazin-2-ylmethyl)-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide 230 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[(1-methyl-1H-imidazol-4-yl)methyl]-8- (trifluormethyl)-4,5-dihydro-2H-furo[2,3-g]indazol-7-carboxamide 231 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-(1,3-thiazol-5-ylmethyl)-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide
232 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(4-methylpyridin-2-yl)ethyl]-8-(trifluormethyl)- 4,5-dihydro-2H-furo[2,3-g]indazol-7-carboxamide 233 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(pyridin-2-yl)ethyl]-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide 234 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(3-methyl-1H-pyrazol-1-yl)ethyl]-8- (trifluormethyl)-4,5-dihydro-2H-furo[2,3-g]indazol-7-carboxamide 235 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(1H-imidazol-4-yl)ethyl]-8-(trifluormethyl)- 4,5-dihydro-2H-furo[2,3-g]indazol-7-carboxamide 236 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(pyridin-3-yl)ethyl]-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide 237 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(1,3-thiazol-2-yl)ethyl]-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide 238 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[(6-methylpyridin-2-yl)methyl]-8-(trifluormethyl)- 4,5-dihydro-2H-furo[2,3-g]indazol-7-carboxamide 239 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-(1,3-oxazol-4-ylmethyl)-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide 240 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-[2-(pyrazin-2-yl)ethyl]-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 242 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(oxan-4-yl)methyl]-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 243 2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 244 8-(difluoromethyl)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2- yl]methyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 245 8-(difluoromethyl)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
246 (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4,8-dimethyl-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 247 (4±)-4,8-dimethyl-N-{[(2S)-oxolan-2-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 248 (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4,8- dimethyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 249 (4±)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4,8-dimethyl-N-{[(2S)-oxolan-2-yl]methyl}- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 250 (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-[(pyridin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 251 (4±)-4-methyl-2-[(5-methyl-2-pyridyl)methyl]-N-[[(2S)-tetrahydrofuran-2- yl]methyl]-8-(trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide 252 (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-[(6-methylpyridin-3-yl)methyl]- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 253 (4±)-4-methyl-2-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 254 (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 254 (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 254 (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 255 (4±)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 255 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
255 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 256 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-oxazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 256 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-oxazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 257 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1-methyl-1H-pyrazol-3- yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 257 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1-methyl-1H-pyrazol-3- yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 258 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(5-methylpyrazin-2-yl)methyl]- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 258 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(5-methylpyrazin-2-yl)methyl]- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 259 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-thiazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 259 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-thiazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 260 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(pyrazin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 260 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(pyrazin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 261 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-oxazol-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 261 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-oxazol-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
262 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8-(trifluoromethyl)-N-{[2- (trifluoromethyl)pyrimidin-5-yl]methyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide 262 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8-(trifluoromethyl)-N-{[2- (trifluoromethyl)pyrimidin-5-yl]methyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide 263 (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-[(oxan-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 263 (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-[(oxan-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 264 (4R)-4-methyl-2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 264 (4S)-4-methyl-2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 265 (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl- 4-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 265 (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl- 4-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 265 (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl- 4-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 266 (4±)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 266 2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-(4R)-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 266 2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-(4S)-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 267 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4,4-dimethyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
268 2-{[(2S)-1,4-dioxan-2-yl]methyl}-4,4-dimethyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 269 N-[(2R)-1,4-dioxan-2-ylmethyl]-2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-(trifluormethyl)- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 270 2'-[(2S)-1,4-dioxan-2-ylmethyl]-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-8'- (trifluormethyl)-2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'- carboxamide 271 2'-[(2S)-1,4-dioxan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'- (trifluormethyl)-2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'- carboxamide 272 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-N-[(1,3-oxazol-2-yl)methyl]-8'-(trifluoromethyl)- 2',5'-dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 273 N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-2-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 274 2'-(Pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluormethyl)- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 275 N-(1,3-Oxazol-2-ylmethyl)-2'-(pyridin-2-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 276 N-[(1-Methyl-1H-pyrazol-3-yl)methyl]-2'-(pyridin-2-ylmethyl)-8'-(trifluormethyl)- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 277 2'-[(5-Methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'- (trifluormethyl)-2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'- carboxamide 278 N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-[(5-methylpyridin-2-yl)methyl]-8'- (trifluormethyl)-2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'- carboxamide 279 N-[(1-Methyl-1H-pyrazol-3-yl)methyl]-2'-[(5-methylpyridin-2-yl)methyl]-8'- (trifluormethyl)-2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'- carboxamide
280 2'-(Pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluormethyl)- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 281 N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-4-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 282 2-(cyclopropylmethyl)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 283 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[1-(methoxyacetyl)piperidin-4-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 284 2-{[1-(methoxyacetyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 285 2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-N-{[(2R)-1,4-dioxan-2- yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 286 2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 287 2-[(1-benzoylpiperidin-4-yl)methyl]-N-{[(2R)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 288 2-[(1-benzoylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 289 8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-2-[2-(pyridin-3-yl)propan-2-yl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 290 (4R)-2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-4-methyl-N-{[(2S)- oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide 290 (4S)-2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-4-methyl-N-{[(2S)- oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide
291 (4R)-2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-N-{[(2R)-1,4-dioxan-2- yl]methyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide 291 (4S)-2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-N-{[(2R)-1,4-dioxan-2- yl]methyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide 292 (4R)-2-[(1-acetylpiperidin-4-yl)methyl]-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 292 (4S)-2-[(1-acetylpiperidin-4-yl)methyl]-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 293 (4R)-2-{[1-(1-hydroxycyclopropane-1-carbonyl)piperidin-4-yl]methyl}-4-methyl-N- {[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxamide 293 (4S)-2-{[1-(1-hydroxycyclopropane-1-carbonyl)piperidin-4-yl]methyl}-4-methyl-N- {[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxamide 294 (4R)-2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 294 (4S)-2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 295 (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[1-(1-hydroxycyclopropane-1- carbonyl)piperidin-4-yl]methyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 295 (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[1-(1-hydroxycyclopropane-1- carbonyl)piperidin-4-yl]methyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 296 (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4- yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
296 (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4- yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 297 (4R)-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2- yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 297 (4S)-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2- yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 298 (4R)-4-methyl-2-{[1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl]methyl}-N- {[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxamide 298 (4S)-4-methyl-2-{[1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl]methyl}-N- {[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxamide 299 (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-{[1-(1-methylcyclopropane-1- carbonyl)piperidin-4-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 299 (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-{[1-(1-methylcyclopropane-1- carbonyl)piperidin-4-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 300 N,2-bis{[(2S)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 301 2-{[(2R)-1,4-dioxan-2-yl]methyl}-N-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 302 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(2-methylpyrimidin-5- yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 302 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(2-methylpyrimidin-5- yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 303 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(5-methylpyrimidin-2- yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
303 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(5-methylpyrimidin-2- yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 304 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(pyrimidin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 304 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(pyrimidin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 305 2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 306 2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2R)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 307 2-{[1-(cyclopropylmethyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 308 2-[(1-methylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 309 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(1-methylpiperidin-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 310 2-{[1-(cyclopropylmethyl)piperidin-4-yl]methyl}-N-{[(2R)-1,4-dioxan-2-yl]methyl}- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 311 2-[(1-ethylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 312 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(1-ethylpiperidin-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 313 2,5-anhydro-1,3,4-trideoxy-1-{[(4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carbonyl]amino}-4- methylpentitol 313 2,5-anhydro-1,3,4-trideoxy-1-{[(4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carbonyl]amino}-4- methylpentitol
314 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1-methyl-1H-imidazol-4- yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 314 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1-methyl-1H-imidazol-4- yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 315 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(6-methylpyridin-2-yl)methyl]- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 315 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(6-methylpyridin-2-yl)methyl]- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 316 (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-thiazol-5-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 316 (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-thiazol-5-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 317 8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-2-[(1±)-1-(pyridin-2-yl)ethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 317 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-N-[(3R)-oxolan-3-yl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 317 2-[(5-cyanopyridin-2-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 318 N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 319 N-[(5-cyclopropylpyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 320 (4R)-N-[(5-cyclopropylpyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4- methyl-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 321 (4S)-N-[(5-cyclopropylpyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4- methyl-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
322 (4R)-N-[(5-chloropyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 323 (4S)-N-[(5-chloropyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide The compounds 1 to 323 are numbered in accordance with the examples described in WO2021122415 and in case of stereoisomers one single example number was assigned. More particularly the invention refers to the use of (4R)-N-[(5-cyclopropylpyrazin-2- yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide for the treatment or prophylaxis of diseases, in particular of inflammatory-driven pain diseases such as neuropathic pain, more specifically for diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome. The compounds of general formula (I) can be prepared according to the schemes 1, 2, 3, and 4 according to WO2021122415 page 40, 43, 45, and 47 which are incorporated herein as a reference and are part of the present application. Furthermore, the preparation of the compounds of general formula (I) according to WO2021122415, reported on page 39, line 21 to page 47, line 11 is also incorporated herein as a reference and is part of the present application. Compounds of general formula (I) demonstrate a valuable pharmacological spectrum of action which could not have been predicted. Compounds of the present invention have surprisingly been found to be effective antagonists of GPR84 and it is possible therefore that said compounds be used for the treatment or prophylaxis of diseases, in particular of inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome. Compounds of general formula (I) can be utilized to inhibit, antagonize, block, reduce, decrease GPR84 signal transduction, activity and cellular function. This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of general formula (I), or a pharmaceutically acceptable salt, isomer,
polymorph, metabolite, hydrate, solvate or ester thereof; which is effective to treat the disorder. In particular of inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome in humans and animals. These disorders have been well characterized in humans, but also exist with a similar aetiology in other mammals and can be treated by administering pharmaceutical compositions of the present invention. The term “treating”, or “treatment” as used in the present text is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of a disease or disorder, such as PCOS or IPF. The present invention covers the use of a compound of formula (I), described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the prophylaxis or treatment of diseases, in particular of inflammatory-driven pain diseases such as neuropathic pain diseases like diabetic neuropathic pain, and chemotherapy induced pain, and post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post- mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome in humans and animals. It is possible for the compounds of general formula (I) to have systemic and/or local activity. For this purpose, they can be administered in a suitable manner, such as, for example, via the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, otic route or as an implant or stent. For these administration routes, it is possible for the compounds of general formula (I) to be administered in suitable administration forms. For oral administration, it is possible to formulate the compounds intended for the use according to the invention to dosage forms known in the art that deliver the compounds rapidly and/or in a modified manner, such as, for example, tablets (uncoated or coated tablets, for example with enteric or controlled release coatings that dissolve with a delay or are insoluble), orally-disintegrating tablets, films/wafers, films/lyophilizates, capsules (for example hard or soft gelatine capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. It is possible to incorporate the
compounds intended for the use according to the invention in crystalline and/or amorphized and/or dissolved form into said dosage forms. Parenteral administration can be effected with avoidance of an absorption step (for example intravenous, intraarterial, intracardial, intraspinal or intralumbal) or with inclusion of absorption (for example intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal). Administration forms which are suitable for parenteral administration are, inter alia, preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilizates or sterile powders. Examples which are suitable for other administration routes are pharmaceutical forms for inhalation [inter alia powder inhalers, nebulizers], nasal drops, nasal solutions, nasal sprays; tablets/films/wafers/capsules for lingual, sublingual or buccal administration; suppositories; eye drops, eye ointments, eye baths, ocular inserts, ear drops, ear sprays, ear powders, ear-rinses, ear tampons; vaginal capsules, aqueous suspensions (lotions, mixturae agitandae), lipophilic suspensions, emulsions, ointments, creams, transdermal therapeutic systems (such as, for example, patches), milk, pastes, foams, dusting powders, implants or stents. The compounds of general formula (I) can be incorporated into the stated administration forms. This can be effected in a manner known per se by mixing with pharmaceutically suitable excipients. Pharmaceutically suitable excipients include, inter alia, • fillers and carriers (for example cellulose, microcrystalline cellulose (such as, for example, Avicel®), lactose, mannitol, starch, calcium phosphate (such as, for example, Di-Cafos®)), • ointment bases (for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols), • bases for suppositories (for example polyethylene glycols, cacao butter, hard fat), • solvents (for example water, ethanol, isopropanol, glycerol, propylene glycol, medium chain-length triglycerides fatty oils, liquid polyethylene glycols, paraffins), • surfactants, emulsifiers, dispersants or wetters (for example sodium dodecyl sulfate), lecithin, phospholipids, fatty alcohols (such as, for example, Lanette®), sorbitan fatty acid esters (such as, for example, Span®), polyoxyethylene sorbitan fatty acid esters (such as, for example, Tween®), polyoxyethylene fatty acid glycerides (such as, for example, Cremophor®), polyoxethylene fatty acid esters,
polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers (such as, for example, Pluronic®), • buffers, acids and bases (for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine), • isotonicity agents (for example glucose, sodium chloride), • adsorbents (for example highly-disperse silicas), • viscosity-increasing agents, gel formers, thickeners and/or binders (for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, carboxymethylcellulose-sodium, starch, carbomers, polyacrylic acids (such as, for example, Carbopol®); alginates, gelatine), • disintegrants (for example modified starch, carboxymethylcellulose-sodium, sodium starch glycolate (such as, for example, Explotab®), cross- linked polyvinylpyrrolidone, croscarmellose-sodium (such as, for example, AcDiSol®)), • flow regulators, lubricants, glidants and mould release agents (for example magnesium stearate, stearic acid, talc, highly-disperse silicas (such as, for example, Aerosil®)), • coating materials (for example sugar, shellac) and film formers for films or diffusion membranes which dissolve rapidly or in a modified manner (for example polyvinylpyrrolidones (such as, for example, Kollidon®), polyvinyl alcohol, hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxypropylmethylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates such as, for example, Eudragit®)), • capsule materials (for example gelatine, hydroxypropylmethylcellulose), • synthetic polymers (for example polylactides, polyglycolides, polyacrylates, polymethacrylates (such as, for example, Eudragit®), polyvinylpyrrolidones (such as, for example, Kollidon®), polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and blockcopolymers), • plasticizers (for example polyethylene glycols, propylene glycol, glycerol, triacetine, triacetyl citrate, dibutyl phthalate), • penetration enhancers,
stabilisers (for example antioxidants such as, for example, ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate), • preservatives (for example parabens, sorbic acid, thiomersal, benzalkonium chloride, chlorhexidine acetate, sodium benzoate), • colourants (for example inorganic pigments such as, for example, iron oxides, titanium dioxide), • flavourings, sweeteners, flavour- and/or odour-masking agents. The present invention furthermore relates to a pharmaceutical composition which comprise at least one compound according to the invention, conventionally together with one or more pharmaceutically suitable excipient(s), and to their use according to the present invention. The synthesis of the compounds 1 to 323, the required intermediates for said synthesis and the methods for their identification were described in the patent application WO2021122415, Experimental section, page 58 to 479 which is incorporated herein as a reference and is part of the present application. The compounds 1 to 323 are numbered in accordance with the examples described in WO2021122415 and in case of stereoisomers one single example number was assigned. EXPERIMENTAL SECTION – BIOLOGICAL ASSAYS The in vitro activity of the compounds of the present invention can be demonstrated in the following assay: cAMP HTRF® Assay for identification of cellular GPR84 antagonists By using a Homogenous Time-Resolved Fluorescence (HTRF®) based assay (#62AM5PEJ, Cisbio, Condolet, France) the inhibition of the Gi-coupled GPR84 receptor can be detected. CHO-K1 cells stably expressing human GPR84 receptor (purchased from DiscoveRx, now Eurofins) were used and treated with Forskolin (F6886, Sigma, Germany) to stimulate membrane adenylyl cyclases and thereby unspecific cAMP formation. Activation of the Gi-coupled GPR84 by a natural or small molecule agonist (e.g. 6-n-octyl aminouracile, inhouse) results in inhibition of cellular cAMP formation which can be released again by antagonists to this receptor. Detection and quantification of cellular cAMP levels in this HTRF assay is achieved by interaction between a
fluorescent cAMP tracer (cAMP-d2) and an Eu-cryptate labelled anti-cAMP antibody. Following excitation at 337 nm this pairing allows for the generation of a fluorescence resonance energy transfer (FRET) between the partners and results in FRET induced emissions at 665 nm and 620 nm, the latter representing background signal by Eu- cryptate labelled anti-cAMP antibody. Maximal signal is obtained in the absence of any cellular cAMP (no competition for the binding of the tracer to the antibody). Given the combination of the Gi coupling properties of GPR84 and the competitive nature of the detection system agonist treatment should result in an increase in the HTRF signal due to lowered cAMP levels. Any signal decrease in the presence of Forskolin, agonist and compound is indicative of antagonist mediated abrogation of GPR84 signalling. For the assay, frozen aliquots of CHO-K1 cells expressing hGPR84 (prepared by acCELLerate, Hamburg, Germany) were thawed and a cell suspension (1.67E+06 cells/mL) in assay media (Ham’s F12 Nutrient Mix, Thermo Fisher Scientific, Waltham, USA; 5% fetal calf serum, Biomol, Hamburg, Germany) containing cAMP-d2 (dilution 1:20, supplied with the kit #62AM5PEJ, Cisbio, Condolet, France) was prepared. After recovery of cells for 20 minutes at 37 °C, 3 µL/well cell suspension including cAMP-d2 were added to a pre-dispensed assay plate (Greiner Bio-One, Kremsmuenster, Austria) containing 50nl/well test compound in 100% DMSO or 100% DMSO as control. This was followed by a 30 minutes incubation step at room temperature. The stimulation time was started by addition of 2 µL/well assay media containing 2.5xEC80 agonist 6-OAU and 2.5xEC90 Forskolin (negative control: 2.5xEC90 Forskolin in assay media) and was continued for 30 minutes at room temperature. The reaction was stopped by addition of 3 µL/well lysis buffer containing cAMP Eu-Cryptate antibody (dilution 1:20) (both supplied with the kit #62AM5PEJ, Cisbio, Condolet, France). To enable complete lysis, plates were incubated for 60 minutes at room temperature before measurement in an HTRF reader, e.g. a PHERAstar (BMG Labtech, Ortenberg, Germany). From the fluorescence emissions at 665 nm (FRET) and at 620 nm (background signal of Eu-cryptate) the ratio (emission at 665 nm divided by emission at 620 nm x 10000) was calculated and the data were normalized (reaction without test compound, only 100% DMSO = 0% inhibition; all other assay components except agonist = 100% inhibition). For dose response testing on the same microtiter plate, compounds were tested at 11 different concentrations in the range of 20 µM to 0.07 nM (20 µM, 5.7 µM, 1.6 µM, 0.47 µM, 0.13 µM, 38 nM, 11 nM, 3.1 nM, 0.89 nM, 0.25 and 0.07 nM; dilution series prepared before the assay at the level of the 100-fold conc. stock solutions by serial 1:3.5 dilutions in 100% DMSO) in duplicate values for each concentration. IC50 values were
calculated by 4-parameter fitting using a commercial software package (Genedata Screener, Basel, Switzerland). Examples were tested in selected biological assays one or more times. When tested more than once, data are reported as either average values or as median values, wherein • the average value, also referred to as the arithmetic mean value, represents the sum of the values obtained divided by the number of times tested, and • the median value represents the middle number of the group of values when ranked in ascending or descending order. If the number of values in the data set is odd, the median is the middle value. If the number of values in the data set is even, the median is the arithmetic mean of the two middle values. Examples were synthesized one or more times. When synthesized more than once, data from biological assays represent average values or median values calculated utilizing data sets obtained from testing of one or more synthetic batch.
Table 6: Potency in GPR84 cAMP HTRF® assay, the potency is given as IC50 [µM]. Example GPR84 IC50 [µM] Example GPR84 IC50 [µM]
Table 6 (continued) Example GPR84 IC50 [µM] Example GPR84 IC50 [µM] 53 0.032 80 0.057
Table 6 (continued) Example GPR84 IC50 [µM] Example GPR84 IC50 [µM] 113 0.091 146 0.047
Table 6 (continued) Example GPR84 IC50 [µM] Example GPR84 IC50 [µM] 179 6.41 216 0.006
Table 6 (continued) Example GPR84 IC50 [µM] Example GPR84 IC50 [µM] 246 0.075 273 0.009
Table 6 (continued) Example GPR84 IC50 [µM] 306 0.027
The suitability of the compounds of general formula (I) for the treatment pain disorders can be demonstrated in the following animal models: In vivo assay 1: GPR84 ligand and antagonist characterization in metabolic PCOS model The efficacy of Example 3-2 in vivo on the treatment of the metabolic disease POCS was measured in the DHT driven rat PCOS model. At 3 weeks of age, Han-Wistar rats were randomly divided into three experimental groups [control (n =10), DHT (n=10), and DHT plus Example 3-2 (n=10)] and implanted s.c. with 60-d continuous-DHT-release pellets (80 µg/d, Bayer AG, Germany). The dose of DHT was chosen to mimic the hyperandrogenic state in women with PCOS. Controls received identical pellets lacking the bioactive DHT molecule. Animal received a standard chow, only for the last week standard show was replaced by a high fat diet. Rats were weighted bi-weekly from 21 d of age. The study was concluded after 26 days of drug administration. Example 3-2
treated animal gained less weight compared to the untreated control. Statistical analysis was performed with one-way analysis of variance, followed by Bonferroni’s multiple comparison test against vehicle control groups using the GraphPad PRISM software, *p<0.05. Table 7: Efficacy of GPR84 antagonist in the rat DHT-PCOS model
In vivo assay 2: Effects of Example 3-2 in the CFA pain model The efficacy of Example 3-2 in vivo on inflammatory pain was measured in inflamed paws after administration of complete Freund’s adjuvant (CFA) (24 h) in the dynamic weight- bearing (DWB) model. The effects of repeated preventive treatment with Example 3-2 on pain following repeated oral administration (3x) in the mouse CFA model of inflammation were investigated using a preventive setting. The GPR84 antagonist Example 3-2 (20 or 60 mg/kg, 3x doses) was administered 2 h before injection of CFA and 6-8 h later at day 0. At 24 h after CFA application, the third dose of Example 3-2 was given 2 h before DWB testing. Statistical analysis was performed with one-way analysis of variance, followed by Bonferroni’s multiple comparison test against vehicle control groups using the GraphPad PRISM software, *p<0.05.
Table 8: Effects of GPR84 antagonist in the CFA pain model Example mg/kg Weight distribution (% weight on injected paw)
In vivo assay 3: Effects in the Oxaliplatin induced pain model The efficacy of example 320 in vivo on chemotherapy (Oxaliplatin; OPNP) induced pain was measured in a rat Oxaliplatin-induced 6 weeks neuropathic pain model. Sprague Dawley male rats at the age of about 9 weeks were used for the experiment. Rats were randomly divided into experimental groups (e.g. n=10). Pain was induced by oxaliplatin application (2 mg/kg) once per day for 5 days. The GPR84 antagonist example 320 was administered with the first application at d1. Rats were habituated to the circumstances for 30 min before starting with behavioral test. Prior to treatment, von Frey test was conducted on all animals for baseline measurement. To assess mechanical allodynia, paw withdrawal thresholds was measured by applying the von Frey filaments (with ascending weights; 0.4, 0.6, 1.4, 2, 4, 6, 8, 15 g) on the center of the right hind paw. Von Frey tests were conducted prior to test article administration (baseline) and once per week, 1 hr, 2 hr and 4 hr post dosing until the end of the experiment. Statistical analysis was performed with one-way analysis of variance, followed by Dunnett multiple comparison test against vehicle control group using the GraphPad PRISM software, *p<0.05. Table 9: Effects of GPR84 antagonist in Oxaliplatin induced pain model Example mg/kg/d Threshold to von Frey Stimulation (g) on day 28
E l 10
In vivo assay 4: Effects in the Streptozotocin (STZ)-induced diabetic neuropathic pain model The efficacy of example 320 in vivo on diabetic neuropathic pain was studied in the Streptozotocin (STZ)-induced neuropathic pain model. Diabetes was induced in Sprague Dawley male rats by dosing of Streptozotocin (STZ, 60 mg/kg) on study day 0. The development of diabetes was confirmed by the measurement of blood glucose levels on study day 3. On study day 10 the sensitivity of all animals to von Frey filaments was tested and diabetic animals (>300 mg/dL) that show a decrease in the withdrawal force threshold (average pain threshold of ≤ 15 g for both hind paws) are included in the study. Animals were treated with the compound example 320 or the vehicle from study day 10 until day 28. Mechanical pain sensitivity was tested using the von Frey test, which measures the withdrawal force threshold of the animals. Statistical analysis is performed with one-way analysis of variance, followed by Dunnett multiple comparison test against vehicle control group using the GraphPad PRISM software, *p<0.05. Table 10: Effects in the Streptozotocin (STZ)-induced diabetic neuropathic pain model Example mg/kg/d Threshold to von Frey Stimulation (g) on day 26 p)
Claims
CLAIMS 1. Use of a compound of general formula (I): in which:
R1 represents hydrogen, C1-C4-alkyl or C1-C4-haloalkyl; R2 represents hydrogen, C1-C4-alkyl or C1-C4-haloalkyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl ring; R3 represents C3-C6-cycloalkyl, 3- to 6-membered heterocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R8, or R3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R8, and additionally R7a and R7b represent deuterium; R4 represents hydrogen, C1-C4-alkyl, C1-C4-haloalkyl or C3-C6-cycloalkyl; R5, R6 represent, independently of each other, hydrogen, C1-C4-alkyl, C2-C4- hydroxyalkyl, (C1-C4-alkoxy)-(C2-C4-alkyl)-, C3-C6-cycloalkyl, C1-C4-haloalkyl, C3-C6-halocycloalkyl, 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, phenyl, heteroaryl, heterocycloalkyl fused with phenyl or heteroaryl, 3- to 6- membered heterocycloalkyl-(C1-C3-alkyl)-, heterospirocycloalkyl-(C1-C3-alkyl)-, (heterocycloalkyl fused with phenyl or heteroaryl)-(C1-C3-alkyl)-, phenyl-(C1-C3-alkyl)- or heteroaryl-(C1-C3-alkyl)-, wherein said 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, heterocycloalkyl fused with phenyl or
heteroaryl, phenyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R9, or R5 and R6 together with the nitrogen atom to which they are attached form a 3- to 6-membered nitrogen containing heterocyclic ring, optionally containing one additional heteroatom or heteroatom containing group selected from O, NH and S, and which may be optionally substituted, one or more times, independently of each other, with R9; R7a represents hydrogen, deuterium, or C1-C4-alkyl; R7b represents hydrogen, deuterium, or C1-C4-alkyl; R8 represents halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkyl-(C1-C3-alkyl)-, R13-(C=O)-, R10-O-(C=O)-, R11-NH-(C=O)-, or R12-(SO2)-; R9 represents halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, H2N-C1-C4-alkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, C3-C6-cycloalkyl, R10-O-(C=O)-, oxo, 5- to 6- membered heterocycloalkyl-, 5- to 6-membered heterocycloalkyl-(C1-C3-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C3-alkoxy, or C1-C3-haloalkoxy; R10 represents hydrogen, C1-C4-alkyl, or phenyl-CH2-; R11 represents hydrogen, C1-C4-alkyl, or 5- to 6-membered heterocycloalkyl-(C1-C3-alkyl)-; R12 represents C1-C4-alkyl or phenyl; R13 represents C1-C4-alkyl, C1-C4-haloalkyl, (C1-C4-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkyl-(C=O)-, C3-C6-cycloalkyl, or phenyl, wherein said C3-C6-cycloalkyl group is optionally substituted with C1-C4-alkyl or hydroxy and said phenyl group is optionally substituted, one or more times, independently of each other, with halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C3-alkoxy, or C1-C3-haloalkoxy; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, for the treatment or prophylaxis of inflammatory-driven pain diseases and/or neuropathic pain diseases.
2. Use of the compound according to claim 1, wherein R1 represents hydrogen, C1-C4-alkyl or C1-C4-haloalkyl; R2 represents hydrogen or C1-C4-alkyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl or heterocycloalkyl ring; R3 represents C3-C6-cycloalkyl, 4- to 6-membered heterocycloalkyl, heterocycloalkyl fused with heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R8, or R3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R8, and additionally R7a and R7b represent deuterium; R4 represents hydrogen, C1-C4-alkyl, C1-C4-haloalkyl or C3-C6-cycloalkyl; R5, R6 represent, independently of each other, hydrogen, C2-C4-hydroxyalkyl, (C1-C4-alkoxy)-(C2-C4-alkyl)-, 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, phenyl, heteroaryl, 4- to 6-membered heterocycloalkyl- (C1-C3-alkyl)-, heterospirocycloalkyl-(C1-C3-alkyl)-, (heterocycloalkyl fused with heteroaryl)-(C1-C3-alkyl)-, or heteroaryl-(C1-C3-alkyl)-, wherein said 3- to 6- membered heterocycloalkyl, phenyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R9, or R5 and R6 together with the nitrogen atom to which they are attached form a 5-membered nitrogen containing heterocyclic ring, which may be optionally substituted, once with R9; R7a represents hydrogen, deuterium, or methyl; R7b represents hydrogen, deuterium, or methyl; R8 represents halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C3-alkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkyl-(C1-C3-alkyl)-, R13-(C=O)-, R10-O-(C=O)-, R11-NH-(C=O)-, or R12-(SO2)-; R9 represents halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, H2N-C1-C4-alkyl, C3-C6-cycloalkyl, R10-O-(C=O)-, oxo, 6-membered heterocycloalkyl-(C1-C3-alkyl)- , phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally
substituted, one or more times, independently of each other, with halogen, C1-C4-haloalkyl, or C1-C3-alkoxy; R10 represents hydrogen, C1-C4-alkyl, or phenyl-CH2-; R11 represents 5- to 6-membered heterocycloalkyl-(C1-C3-alkyl)-; R12 represents C1-C4-alkyl; R13 represents C1-C4-alkyl, (C1-C4-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkyl-(C=O)-, C3-C6-cycloalkyl, or phenyl, wherein said C3-C6-cycloalkyl group is optionally substituted with methyl or hydroxy; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, for the treatment or prophylaxis of diseases. 3. Use of the compound according to claim 1 or 2, wherein: R1 represents hydrogen, methyl or trifluoromethyl; R2 represents hydrogen or methyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; R3 represents cyclopropyl, 4- to 6-membered heterocycloalkyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R8, or R3 represents phenyl, which is optionally substituted, one or more times, independently of each other, with R8, and additionally R7a and R7b represent deuterium; R4 represents hydrogen, methyl, C1-haloalkyl or cyclopropyl; R5 represents hydrogen; R6 represents methoxy-ethyl, 5-membered heteroaryl, 4- to 6-membered heterocycloalkyl-(C1-C2-alkyl)-, heterospirocycloalkyl-methyl, 2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl, or 5- to 6-membered heteroaryl- (C1-C2-alkyl)-, wherein said 4- to 6-membered heterocycloalkyl or heteroaryl
groups are optionally substituted, one or more times, independently of each other, with R9; R7a represents hydrogen, deuterium, or methyl; R7b represents hydrogen, deuterium, or methyl; R8 represents fluoro, chloro, C1-C2-alkyl, trifluoromethyl, C1-C3-alkoxy, cyclopropyl, cyclopropylmethyl, R13-(C=O)-, R10-O-(C=O)-, R11-NH-(C=O)-, or R12-(SO2)-; R9 represents fluoro, chloro, C1-C3-alkyl, trifluoromethyl, cyclopropyl, or oxo; R10 represents C1-C4-alkyl, or phenyl-CH2-; R11 represents 5- to 6-membered heterocycloalkyl-methyl; R12 represents methyl; R13 represents methyl, methoxymethyl, ethyl-(C=O)-, cyclopropyl, or phenyl, wherein said cyclopropyl group is optionally substituted with methyl or hydroxy; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, for the treatment or prophylaxis of diseases. 4. Use of the compound according to claim 1, 2, or 3, wherein: R1 represents hydrogen or methyl; R2 represents hydrogen or methyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; R3 represents cyclopropyl, 2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, oxetan-3-yl, oxolan-3-yl, oxolan-2-yl, 3-methyloxetan-3-yl, 3-fluorooxetan-3-yl, pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, oxan-4-yl, 1,4-dioxan-2-yl, 6-methylpyridin-3-yl, 5- methylpyridin-2-yl, 3-methylpyridin-2-yl, 2-methylpyridin-4-yl, 6-methylpyridin-2- yl, 3-chloropyridin-2-yl, 6-ethylpyridin-3-yl, 1-acetylpiperidin-4-yl, 3-chloro-5- ethoxypyridin-2-yl, 1-benzoylpiperidin-4-yl, or a group selected from:
R3 represents phenyl, and additionally R7a and R7b represent deuterium;
R4 represents methyl, difluoromethyl, trifluoromethyl, or cyclopropyl;
R5 represents hydrogen;
R6 represents (oxolan-2-yl)methyl, (1,3-oxazol-4-yl)methyl, (1,2-oxazol-3-yl)methyl, (4-methyloxolan-2-yl)methyl, (pyrimidin-2-yl)methyl, (pyrazin-2-yl)methyl, (5- methyloxolan-2-yl)methyl, (5-methyloxolan-2-yl)methyl, (1,4-dioxan-2-yl)methyl, (4-methylphenyl)methyl, (5-methylpyrimidin-2-yl)methyl, (5-methylpyrazin-2- yl)methyl, (5-chloropyrazin-2-yl)methyl, (5-cyclopropyl-pyrazin-2-yl)methyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl, 1,3-oxazol-2-ylmethyl, 1,3-thiazol-2- ylmethyl, (1-methyl-1H-pyrazol-3-yl)methyl, (1-methyl-1H-imidazol-4-yl)methyl, (5-isopropyl-1,2-oxazol-3-yl)methyl, (5-cyclopropyl-1,2-oxazol-3-yl)methyl, (5,5- dimethyltetrahydrofuran-2-yl)methyl, (4,4-difluorotetrahydrofuran-2-yl)methyl, (6,6-dimethyl-1,4-dioxan-2-yl)methyl, 5-oxaspiro[2.4]heptan-6-ylmethyl, or 2,6- dioxaspiro[3.4]octan-7-ylmethyl; R7a represents hydrogen; R7b represents hydrogen; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, for the treatment or prophylaxis of diseases. 5. Use of the compound according to claim 1, 2, 3, or 4 which is selected from the group consisting of: 2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N-[(4-methylphenyl)methyl]-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-2-(pyridin-2-ylmethyl)-N-[(2R/S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-(pyridin-2-ylmethyl)-N-[(2R)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[2-(4-methylpiperazin-1-yl)ethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(1,2,4-oxadiazol-3-yl)methyl]-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide
8-methyl-N-(1,2-oxazol-3-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(5-methyl-1,2-oxazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-(pyridin-2- ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-(pyridin-2-ylmethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-(pyridin-2-ylmethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-(2-hydroxy-2-methylpropyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N-{[5-(morpholin-4-ylmethyl)-1,2-oxazol-3-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-(pyridin-2-ylmethyl)-N-(2-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1- yl}ethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-(pyridin-2-ylmethyl)-N-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[5-(3-methoxyphenyl)-1,2-oxazol-3-yl]methyl}-8-methyl-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-4-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide N-{[5-(2-chlorophenyl)-1,2-oxazol-3-yl]methyl}-8-methyl-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(5-isopropyl-1,2-oxazol-3-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide
N-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-(pyridin-2-ylmethyl)-N-(4H-1,2,4-triazol-3-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N,2-bis(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-(1H-pyrazol-3-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-2-(pyridin-2-ylmethyl)-N-(1,3-thiazol-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N-(1,2-oxazol-4-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-2-(pyridin-2-ylmethyl)-N-{[5-(trifluoromethyl)-1,2-oxazol-3-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(4-methyl-1,2-oxazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[2-(3,3-dimethyl-2-oxoazetidin-1-yl)ethyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide N-(2-methoxyethyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxamide [(2R/S)-2-(aminomethyl)pyrrolidin-1-yl][8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazol-7-yl]methanone [(2R)-2-(aminomethyl)pyrrolidin-1-yl][8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazol-7-yl]methanone [(2S)-2-(aminomethyl)pyrrolidin-1-yl][8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazol-7-yl]methanone 3-[({[8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazol-7- yl]carbonyl}amino)methyl]-1,2-oxazole-4-carboxylic acid 8-methyl-N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide
8-methyl-2-(pyridin-2-ylmethyl)-N-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-(pyridin-2-ylmethyl)-N-[(3R)-tetrahydrofuran-3-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(2R/S)-oxetan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N-[(2R)-oxetan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N-[(2S)-oxetan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N-(oxetan-3-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide N-[(3-fluorooxetan-3-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N-{[(2R/S)-4-methylmorpholin-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-{[(2R)-4-methylmorpholin-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-N-{[(2S)-4-methylmorpholin-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-N-{[(2R/S)-5-oxotetrahydrofuran-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-{[(2R)-5-oxotetrahydrofuran-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-{[(2S)-5-oxotetrahydrofuran-2-yl]methyl}-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-(1-methyl-1H-pyrazol-3-yl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N-(pyridin-3-yl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide
8-methyl-N-(2-phenylethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide N-(4-cyanophenyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide 8-methyl-2-(pyridin-3-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyridin-3-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-2-(pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyridin-4-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 2-(cyclopropylmethyl)-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 2-(cyclopropylmethyl)-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3- b]pyridin-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2- ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2- ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2R/S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2R/S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2R/S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(4-methylbenzyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(4-methylbenzyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(4-methylbenzyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[2-(4- methylpiperazin-1-yl)ethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[2-(4- methylpiperazin-1-yl)ethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[2-(4- methylpiperazin-1-yl)ethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(1,2-oxazol-3- ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(1,2-oxazol-3- ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(1,2-oxazol-3- ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-{[6-(trifluoromethyl)pyridin-2-yl]methyl}- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(3-chloro-5-fluoropyridin-2-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(3-chloro-5-ethoxypyridin-2-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(3-chloropyridin-2-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(3-chloropyridin-2-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide
8-methyl-2-[(3-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3-methylpyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(5-methylpyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[(2R/S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[(2R)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[2-(azetidin-1-yl)ethyl]-8-methyl-2-[(6-methylpyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-8-methyl-2-[(6-methylpyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[2-(pyrrolidin-1-yl)ethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R/S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-[(6-methylpyridin- 2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-[(6-methylpyridin-2- yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-[(6-methylpyridin-2- yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-[(6-methylpyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-(1,3-oxazol-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(2-methylpyridin-3-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide
N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2-methylpyridin-3-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-3-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(6-methylpyridin-3-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 2-[(2,6-dimethylpyridin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2,6-dimethylpyridin-3-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(2-methylpyridin-4-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2-methylpyridin-4-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 2-[(2,6-dimethylpyridin-4-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2,6-dimethylpyridin-4-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-(pyrimidin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyrimidin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-(pyrimidin-5-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyrimidin-5-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 2-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N,2-bis[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide 2-[(2S)-1,4-dioxan-2-ylmethyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide
N-[(2R)-1,4-dioxan-2-ylmethyl]-2-[(2S)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-(oxetan-3-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(oxetan-3-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-2-[(3-methyloxetan-3-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3-methyloxetan-3-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 2-[(3-fluorooxetan-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2-[(3-fluorooxetan-3-yl)methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(2R)-oxetan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2R)-oxetan-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(2S)-oxetan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2S)-oxetan-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-{[(2R)-4-methylmorpholin-2-yl]methyl}-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-{[(2R)-4-methylmorpholin-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-{[(2S)-4-methylmorpholin-2-yl]methyl}-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-{[(2S)-4-methylmorpholin-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide
N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N,2-bis[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide tert-butyl 3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5-dihydro-2H- furo[2,3-g]indazol-2-yl)methyl]azetidine-1-carboxylate tert-butyl 3-[(7-{[(2R)-1,4-dioxan-2-ylmethyl]carbamoyl}-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazol-2-yl)methyl]azetidine-1-carboxylate 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-[(3R)-tetrahydrofuran-3-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3R)-tetrahydrofuran-3-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-cyclopropyl-2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-cyclopropyl-N-[(2R)-1,4-dioxan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-cyclopropyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide
8-cyclopropyl-N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8'-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 8'-methyl-N-(1,3-oxazol-2-ylmethyl)-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-(1,3-oxazol-2-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-(cyclopropylmethyl)-8'-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-(cyclopropylmethyl)-N-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-(cyclopropylmethyl)-N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 8'-methyl-2'-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 8-methyl-2-[phenyl(2H2)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[phenyl(2H2)methyl]-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide tert-butyl [2-(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5-dihydro-2H- furo[2,3-g]indazol-2-yl)ethyl]carbamate tert-butyl [2-(7-{[(2R)-1,4-dioxan-2-ylmethyl]carbamoyl}-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazol-2-yl)ethyl]carbamate tert-butyl 4-[2-(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5-dihydro-2H- furo[2,3-g]indazol-2-yl)ethyl]piperazine-1-carboxylate tert-butyl 4-[2-(7-{[(2R)-1,4-dioxan-2-ylmethyl]carbamoyl}-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazol-2-yl)ethyl]piperazine-1-carboxylate 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N,2'-bis[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-2',5'-dihydrospiro[cyclobutane-1,4'- furo[2,3-g]indazole]-7'-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-[(6-{[(2S)-tetrahydrofuran-2- ylmethyl]carbamoyl}pyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2-[(6-{[(2R)-1,4-dioxan-2-ylmethyl]carbamoyl}pyridin-3- yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 4,4,8-trimethyl-2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 8'-methyl-2'-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 8'-methyl-2'-(pyridin-3-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-3-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide
N ,N ,8-trimethyl-N7'-[(2S)-tetrahydrofuran-2-ylmethyl]spiro[cyclopropane-1,4-furo[2,3- g]indazole]-2',7'(5'H)-dicarboxamide N7'-[(2R)-1,4-dioxan-2-ylmethyl]-N2',N2',8'-trimethylspiro[cyclopropane-1,4'-furo[2,3- g]indazole]-2',7'(5'H)-dicarboxamide benzyl 3-fluoro-3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5-dihydro- 2H-furo[2,3-g]indazol-2-yl)methyl]azetidine-1-carboxylate benzyl 3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5-dihydro-2H- furo[2,3-g]indazol-2-yl)methyl]azetidine-1-carboxylate 2-[(3-fluoroazetidin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-(azetidin-3-ylmethyl)-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 2-(azetidin-3-ylmethyl)-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 2-(2-aminoethyl)-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 2-(2-aminoethyl)-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-2-[2-(piperazin-1-yl)ethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[2-(piperazin-1-yl)ethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 2-[(1-acetylazetidin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(1-acetyl-3-fluoroazetidin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[3-fluoro-1-(methylsulfonyl)azetidin-3-yl]methyl}-8-methyl-N-[(2S)-tetrahydrofuran-2- ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide methyl 3-fluoro-3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5-dihydro- 2H-furo[2,3-g]indazol-2-yl)methyl]azetidine-1-carboxylate 2'-[(2S)-1,4-dioxan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluoromethyl)- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide
N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-{[(2±)-5,5-dimethyloxolan-2-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(oxan-4-yl)methyl]-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N-{[(2±)-oxan-2-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-N-{[(2±)-2-methyloxolan-2-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-{[(2±)-4,4-difluorooxolan-2-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-[(4-methyltetrahydrofuran-2-yl)methyl]-2-(2-pyridylmethyl)-4,5- dihydrofuro[2,3-g]indazole-7-carboxamide 8-methyl-N-{[(2±,5±)-5-methyloxolan-2-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 2,5-anhydro-1,3,4-trideoxy-3-methyl-1-({8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carbonyl}amino)-D-threo-pentitol (Racemate) 8-methyl-N-{[(6±)-5-oxaspiro[2.4]heptan-6-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2±)-3,3-dimethyloxolan-2-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide N-{[(6±)-2,5-dioxaspiro[3.4]octan-6-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2±)-6,6-dimethyl-1,4-dioxan-2-yl]methyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(4-fluoropyridin-2-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 2-[(5-fluoropyridin-3-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-2-[(pyridazin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide
N-{[(2R)-1,4-dioxan-2-yl]methyl}-8-methyl-2-[(pyridazin-3-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(1,3-oxazol-2-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 8-methyl-2-{[(2±)-oxan-2-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(6-methylpyridin-3-yl)methyl]-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-cyclopropyl-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-cyclopropyl-2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide N-{[(2±)-5,5-dimethyloxolan-2-yl]methyl}-2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-{[(2±)-6,6-dimethyl-1,4-dioxan-2-yl]methyl}-2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'-methyl- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-{[(2±)-4,4-difluorooxolan-2-yl]methyl}-2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'-methyl-N-{[(2±,5±)-5-methyloxolan-2-yl]methyl}-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2-[[(2S)-1,4-dioxan-2-yl]methyl]-8-methyl-N-[(4-methyltetrahydrofuran-2- yl)methyl]spiro[5H-furo[2,3-g]indazole-4,1'-cyclopropane]-7-carboxamide 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'-methyl-N-{[(6±)-5-oxaspiro[2.4]heptan-6-yl]methyl}- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide
2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(6±)-2,5-dioxaspiro[3.4]octan-6-yl]methyl}-8- methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(6R)-2,5-dioxaspiro[3.4]octan-6-yl]methyl}-8'- methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(6S)-2,5-dioxaspiro[3.4]octan-6-yl]methyl}-8'- methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 8'-Methyl-2'-(pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 8'-Methyl-2'-[(5-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-8'-methyl-2'-[(6-methylpyridin-3-yl)methyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 8'-methyl-2'-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2'-[(6-methylpyridin-3-yl)methyl]-8'-(trifluoromethyl)- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide 2'-[(5-methylpyridin-2-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2'-[(5-methylpyridin-2-yl)methyl]-8'-(trifluoromethyl)- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-4-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclopropan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 2'-(Pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclopropan-1,4'-furo[2,3-g]indazol]-7'-carboxamide N-{[(2S)-oxolan-2-yl]methyl}-2'-[(pyridin-2-yl)methyl]-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-2-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclopropan-1,4'-furo[2,3-g]indazol]-7'-carboxamide N,2-bis{[(2R)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide
2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2±)-4,4-difluorooxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2R)-4,4-difluorooxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2S)-4,4-difluorooxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2±)-5,5-dimethyloxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2R)-5,5-dimethyloxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2S)-5,5-dimethyloxolan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2±, 5±)-5-methyloxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2R, 5R)-5-methyloxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2S, 5R)-5-methyloxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2R, 5S)-5-methyloxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2S, 5S)-5-methyloxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-(1,3-thiazol-2-ylmethyl)-8-(trifluormethyl)-4,5-dihydro- 2H-furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[(5-methylpyrazin-2-yl)methyl]-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-(pyrazin-2-ylmethyl)-8-(trifluormethyl)-4,5-dihydro-2H- furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[(1-methyl-1H-imidazol-4-yl)methyl]-8-(trifluormethyl)- 4,5-dihydro-2H-furo[2,3-g]indazol-7-carboxamide
2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-(1,3-thiazol-5-ylmethyl)-8-(trifluormethyl)-4,5-dihydro- 2H-furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(4-methylpyridin-2-yl)ethyl]-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(pyridin-2-yl)ethyl]-8-(trifluormethyl)-4,5-dihydro-2H- furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(3-methyl-1H-pyrazol-1-yl)ethyl]-8-(trifluormethyl)- 4,5-dihydro-2H-furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(1H-imidazol-4-yl)ethyl]-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(pyridin-3-yl)ethyl]-8-(trifluormethyl)-4,5-dihydro-2H- furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(1,3-thiazol-2-yl)ethyl]-8-(trifluormethyl)-4,5-dihydro- 2H-furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[(6-methylpyridin-2-yl)methyl]-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-g]indazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-(1,3-oxazol-4-ylmethyl)-8-(trifluormethyl)-4,5-dihydro- 2H-furo[2,3-g]indazol-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-[2-(pyrazin-2-yl)ethyl]-8-(trifluoromethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(oxan-4-yl)methyl]-8-(trifluoromethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide 2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-(difluoromethyl)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-(difluoromethyl)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4,8-dimethyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide (4±)-4,8-dimethyl-N-{[(2S)-oxolan-2-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide
(4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4,8-dimethyl-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4±)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4,8-dimethyl-N-{[(2S)-oxolan-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-[(pyridin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4±)-4-methyl-2-[(5-methyl-2-pyridyl)methyl]-N-[[(2S)-tetrahydrofuran-2-yl]methyl]-8- (trifluoromethyl)-4,5-dihydrofuro[2,3-g]indazole-7-carboxamide (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-[(6-methylpyridin-3-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4±)-4-methyl-2-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4±)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-oxazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-oxazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
(4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(5-methylpyrazin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(5-methylpyrazin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-thiazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-thiazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(pyrazin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(pyrazin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-oxazol-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-oxazol-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8-(trifluoromethyl)-N-{[2- (trifluoromethyl)pyrimidin-5-yl]methyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8-(trifluoromethyl)-N-{[2- (trifluoromethyl)pyrimidin-5-yl]methyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-[(oxan-4-yl)methyl]-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-[(oxan-4-yl)methyl]-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-4-methyl-2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-4-methyl-2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4±)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
(4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4±)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-(4R)-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-(4S)-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4,4-dimethyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl]methyl}-4,4-dimethyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 2'-[(2S)-1,4-dioxan-2-ylmethyl]-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-8'-(trifluormethyl)- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 2'-[(2S)-1,4-dioxan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluormethyl)- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-N-[(1,3-oxazol-2-yl)methyl]-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-g]indazole]-7'-carboxamide N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-2-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 2'-(Pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide N-(1,3-Oxazol-2-ylmethyl)-2'-(pyridin-2-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide N-[(1-Methyl-1H-pyrazol-3-yl)methyl]-2'-(pyridin-2-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 2'-[(5-Methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluormethyl)- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide
N-[(2R)-1,4-Dioxan-2-ylmethyl]-2-[(5-methylpyridin-2-yl)methyl]-8-(trifluormethyl)-2,5- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide N-[(1-Methyl-1H-pyrazol-3-yl)methyl]-2'-[(5-methylpyridin-2-yl)methyl]-8'-(trifluormethyl)- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 2'-(Pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-4-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-g]indazol]-7'-carboxamide 2-(cyclopropylmethyl)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro- 2H-furo[2,3-g]indazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[1-(methoxyacetyl)piperidin-4-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[1-(methoxyacetyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-N-{[(2R)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(1-benzoylpiperidin-4-yl)methyl]-N-{[(2R)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(1-benzoylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-2-[2-(pyridin-3-yl)propan-2-yl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide (4R)-2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-4-methyl-N-{[(2S)-oxolan-2- yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-4-methyl-N-{[(2S)-oxolan-2- yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-N-{[(2R)-1,4-dioxan-2- yl]methyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide
(4S)-2-{[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl}-N-{[(2R)-1,4-dioxan-2- yl]methyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide (4R)-2-[(1-acetylpiperidin-4-yl)methyl]-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-[(1-acetylpiperidin-4-yl)methyl]-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[1-(1-hydroxycyclopropane-1-carbonyl)piperidin-4-yl]methyl}-4-methyl-N-{[(2S)- oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide (4S)-2-{[1-(1-hydroxycyclopropane-1-carbonyl)piperidin-4-yl]methyl}-4-methyl-N-{[(2S)- oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide (4R)-2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[1-(1-hydroxycyclopropane-1- carbonyl)piperidin-4-yl]methyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[1-(1-hydroxycyclopropane-1- carbonyl)piperidin-4-yl]methyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4- yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4- yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
(4R)-4-methyl-2-{[1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl]methyl}-N-{[(2S)- oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide (4S)-4-methyl-2-{[1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl]methyl}-N-{[(2S)- oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-{[1-(1-methylcyclopropane-1- carbonyl)piperidin-4-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-{[1-(1-methylcyclopropane-1- carbonyl)piperidin-4-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide N,2-bis{[(2S)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide 2-{[(2R)-1,4-dioxan-2-yl]methyl}-N-{[(2S)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(2-methylpyrimidin-5-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(2-methylpyrimidin-5-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(5-methylpyrimidin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(5-methylpyrimidin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(pyrimidin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(pyrimidin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2R)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide
2-{[1-(cyclopropylmethyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(1-methylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(1-methylpiperidin-4-yl)methyl]-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-{[1-(cyclopropylmethyl)piperidin-4-yl]methyl}-N-{[(2R)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(1-ethylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(1-ethylpiperidin-4-yl)methyl]-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2,5-anhydro-1,3,4-trideoxy-1-{[(4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carbonyl]amino}-4-methylpentitol 2,5-anhydro-1,3,4-trideoxy-1-{[(4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carbonyl]amino}-4-methylpentitol (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1-methyl-1H-imidazol-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1-methyl-1H-imidazol-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(6-methylpyridin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(6-methylpyridin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-thiazol-5-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1,3-thiazol-5-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-2-[(1±)-1-(pyridin-2-yl)ethyl]-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-N-[(3R)-oxolan-3-yl]-4,5-dihydro-2H-furo[2,3- g]indazole-7-carboxamide
2-[(5-cyanopyridin-2-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-yl]methyl}-4,5-dihydro-2H- furo[2,3-g]indazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(5-cyclopropylpyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-N-[(5-cyclopropylpyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4S)-N-[(5-cyclopropylpyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide (4R)-N-[(5-chloropyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,
3-g]indazole-7-carboxamide (4S)-N-[(5-chloropyrazin-2-yl)methyl]-2-{[(2S)-1,
4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,
5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, for the treatment or prophylaxis of diseases.
6. Use of a compound of formula (I) according to claims 1-5 for the treatment or prophylaxis of diabetic neuropathic pain.
7. Use of a compound of formula (I) according to claims 1-5 for the treatment or prophylaxis of chemotherapy induced neuropathic pain.
8. Use of a compound of formula (I) according to claims 1-5 for the treatment or prophylaxis of post-breast surgery pain.
9. Use of a compound of formula (I) according to claims 1-5 for the treatment or prophylaxis of cancer bone pain.
10. Use of a compound of formula (I) according to claims 1-5 for the treatment or prophylaxis of trigeminal neuralgia.
11. Use of a compound of formula (I) according to claims 1-5 for the treatment or prophylaxis of post-mastectomy pain.
12. Use of a compound of formula (I) according to claims 1-5 for the treatment or prophylaxis of fibromyalgia.
13. Use of a compound of formula (I) according to claims 1-5 for the treatment or prophylaxis of multiple sclerosis pain diseases.
14. Use of a compound of formula (I) according to claims 1-5 for the treatment or prophylaxis of post-herpetic neuralgia.
15. Use of a compound of formula (I) according to claims 1-5 for the treatment or prophylaxis of Fabry, gout, or bladder pain syndrome.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22202234.5 | 2022-10-18 | ||
EP22202234 | 2022-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024083705A1 true WO2024083705A1 (en) | 2024-04-25 |
Family
ID=83903248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/078602 WO2024083705A1 (en) | 2022-10-18 | 2023-10-16 | Furoindazole derivatives for the treatment of pain |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024083705A1 (en) |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245796B1 (en) | 1997-06-13 | 2001-06-12 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrrole or pyrazole derivative |
WO2001083487A1 (en) | 2000-04-28 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Froindazole derivative |
WO2005050225A2 (en) * | 2003-10-31 | 2005-06-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) |
WO2009023773A2 (en) | 2007-08-15 | 2009-02-19 | University Of Miami | Galactokinase inhibitors |
US20090163545A1 (en) | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
WO2011071136A1 (en) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | Therapeutic agent for fibromyalgia |
WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
WO2013092791A1 (en) | 2011-12-22 | 2013-06-27 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2014095798A1 (en) | 2012-12-20 | 2014-06-26 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
WO2015197550A1 (en) | 2014-06-25 | 2015-12-30 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2016085990A1 (en) | 2014-11-24 | 2016-06-02 | The Regents Of The University Of Michigan | Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity |
WO2016169911A1 (en) | 2015-04-23 | 2016-10-27 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2018161831A1 (en) | 2017-03-06 | 2018-09-13 | 中国科学院上海药物研究所 | Gpr84 receptor antagonist and use thereof |
WO2019084271A1 (en) | 2017-10-25 | 2019-05-02 | Children's Medical Center Corporation | Papd5 inhibitors and methods of use thereof |
WO2021122415A1 (en) | 2019-12-19 | 2021-06-24 | Bayer Aktiengesellschaft | Furoindazole derivatives |
WO2022179940A1 (en) * | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
WO2022229061A1 (en) * | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
-
2023
- 2023-10-16 WO PCT/EP2023/078602 patent/WO2024083705A1/en unknown
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245796B1 (en) | 1997-06-13 | 2001-06-12 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrrole or pyrazole derivative |
WO2001083487A1 (en) | 2000-04-28 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Froindazole derivative |
WO2005050225A2 (en) * | 2003-10-31 | 2005-06-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) |
WO2009023773A2 (en) | 2007-08-15 | 2009-02-19 | University Of Miami | Galactokinase inhibitors |
US20090163545A1 (en) | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
WO2011071136A1 (en) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | Therapeutic agent for fibromyalgia |
WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
WO2013092791A1 (en) | 2011-12-22 | 2013-06-27 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2014095798A1 (en) | 2012-12-20 | 2014-06-26 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
WO2015197550A1 (en) | 2014-06-25 | 2015-12-30 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2016085990A1 (en) | 2014-11-24 | 2016-06-02 | The Regents Of The University Of Michigan | Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity |
WO2016169911A1 (en) | 2015-04-23 | 2016-10-27 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2018161831A1 (en) | 2017-03-06 | 2018-09-13 | 中国科学院上海药物研究所 | Gpr84 receptor antagonist and use thereof |
WO2019084271A1 (en) | 2017-10-25 | 2019-05-02 | Children's Medical Center Corporation | Papd5 inhibitors and methods of use thereof |
WO2021122415A1 (en) | 2019-12-19 | 2021-06-24 | Bayer Aktiengesellschaft | Furoindazole derivatives |
WO2022179940A1 (en) * | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
WO2022229061A1 (en) * | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
Non-Patent Citations (29)
Title |
---|
"Isotopic Compositions of the Elements 1997", PURE APPL. CHEM., vol. 70, no. 1, 1998, pages 217 - 235 |
"IUPAC Rules Section E", PURE APPL CHEM, vol. 45, 1976, pages 11 - 30 |
A. E. MUTLIB ET AL., TOXICOL. APPL. PHARMACOL., vol. 169, 2000, pages 102 |
A. M. SHARMA ET AL., CHEM. RES. TOXICOL., vol. 26, 2013, pages 410 |
B. TESTA ET AL., INT. J. PHARM., vol. 19, no. 3, 1984, pages 271 |
BOUCHARD C. ET AL., GLIA, vol. 55, no. 8, June 2007 (2007-06-01), pages 790 - 800 |
C. J. WENTHUR ET AL., J. MED. CHEM., vol. 56, 2013, pages 5208 |
C. L. PERRIN ET AL., J. AM. CHEM. SOC., vol. 127, 2005, pages 9641 |
C. L. PERRIN ET AL., J. AM. CHEM. SOC., vol. 129, 2007, pages 4490 |
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1 March 2018 (2018-03-01), SACHER F ET AL: "The medium-chain free fatty acid receptor GPR84 in endometriosis associated pain", XP002808817, Database accession no. EMB-621267647 * |
F. MALTAIS ET AL., J. MED. CHEM., vol. 52, 2009, pages 7993 |
F. SCHNEIDER ET AL., ARZNEIM. FORSCH. / DRUG. RES., vol. 56, 2006, pages 295 |
GAGNON L. ET AL., AM. J. PATHOL., vol. 188, no. 5, May 2018 (2018-05-01), pages 1132 - 1148 |
HUANG Q. ET AL., DEV. COMP. IMMUNOL., vol. 45, no. 2, 2014, pages 252 - 258 |
LATTIN J.E. ET AL., IMMUNOME RES, vol. 4, 29 April 2008 (2008-04-29), pages 5 |
MUREDDA ET AL., ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, vol. 4, no. 2, 12 August 2017 (2017-08-12), pages 1 - 12 |
MUREDDA L. ET AL., ARCH. PHYSIOL. BIOCHEM., vol. 4, no. 2, 12 May 2018 (2018-05-12), pages 97 - 108 |
NAGASAKI H. ET AL., FEBS LETT., vol. 586, no. 4, 17 February 2012 (2012-02-17), pages 368 - 72 |
NGUYEN ET AL., ANNUAL CONGRESS SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION (AHA 2018, 2018 |
NICOL L. S. C. ET AL: "The Role of G-Protein Receptor 84 in Experimental Neuropathic Pain", THE JOURNAL OF NEUROSCIENCE, vol. 35, no. 23, 10 June 2015 (2015-06-10), US, pages 8959 - 8969, XP093031266, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.3558-14.2015 * |
PUENGEL ET AL., 2018 INTERNATIONAL LIVER CONGRESS (ILC) OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (EASL, 2018 |
ROMAN ET AL., 7TH FORUM OF EUROPEAN NEUROSCIENCE (FENS, 2010 |
S. M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104 |
SACHER F ET AL: "The medium-chain free fatty acid receptor GPR84 in endometriosis associated pain", REPRODUCTIVE SCIENCES 20180301 SAGE PUBLICATIONS INC. NLD, vol. 25, no. 1, 1 March 2018 (2018-03-01), pages 290A CONF 20180306 to 20180310 San Diego, CA - 65th Annu, ISSN: 1933-7205 * |
SACHER F. ET AL., CONFERENCE ABSTRACT SRI, 2018 |
SANIERE L ET AL., 2019 INTERNATIONAL CONFERENCE OF THE AMERICAN THORACIC SOCIETY (ATS, 2019 |
SMITHTASI, NAT. PROD. REP., no. 5, 24 October 2007 (2007-10-24), pages 1041 - 72 |
SOTO-VACA A. ET AL., J. AGRIC. FOOD CHEM., vol. 61, no. 42, 23 October 2013 (2013-10-23), pages 10074 - 9 |
WANG J ET AL., J. BIOL. CHEM., vol. 281, no. 45, 10 November 2006 (2006-11-10), pages 34457 - 64 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201840567A (en) | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | |
US20230227441A1 (en) | 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors | |
KR20170106452A (en) | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives | |
JP7357617B2 (en) | Modulators of beta-3 adrenergic receptors useful in the treatment or prevention of heart failure and related disorders | |
EA017952B1 (en) | PYRROLO[2,3-d]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | |
EA024123B1 (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
US20230112499A1 (en) | Furoindazole derivatives | |
WO2011149874A2 (en) | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | |
US11319324B2 (en) | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | |
WO2020260463A1 (en) | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide | |
JP2022539208A (en) | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | |
BR112021008995A2 (en) | heterocyclic derivatives like nav1.7 and nav1.8 blockers | |
US10196383B2 (en) | Substituted quinazoline compounds and preparation and uses thereof | |
WO2022229061A1 (en) | Furoindazole derivatives as antagonists or inhibitors of gpr84 | |
WO2024083705A1 (en) | Furoindazole derivatives for the treatment of pain | |
JP2022130716A (en) | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVE AS IRAK4 INHIBITOR | |
CA3211437A1 (en) | Furoindazole derivatives as gpr84 antagonists | |
WO2023118092A1 (en) | Pyrazolo[1,5-a]pyrido[3,2-e]pyrimidines and pyrazolo[1,5-a][1,3]thiazolo[5,4-e]pyrimidines as p2x3 inhibitors for the treatment of neurogenic disorders | |
CN117624187A (en) | Efficient HPK1 degradation agent compound and preparation method and application thereof | |
WO2023239846A1 (en) | Heterocyclic compounds as pi3kα inhibitors | |
JP2023519605A (en) | Compounds active against nuclear receptors | |
EP4017858A1 (en) | Organic compounds | |
EP3782997A1 (en) | Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases |